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General introduction and scope of the thesis
Cancer is the second leading cause of death worldwide, after cardiovascular disease, 
accounting for 7.9 million deaths; ∼ 13% of all deaths in 2007. Additionally the incidence of 
cancer is increasing. The five most mortal types of cancer are; lung, stomach, liver, colorectal 
and esophageal cancer. Over 30% of cancer can be prevented by not using tobacco, having 
a healthy diet, being physically active and by preventing infections that may cause cancer1. 
Once diagnosed, there are several different types of treatment ranging from resection 
(surgery), to radiation (radiotherapy), to systemic therapy used as adjuvant or palliative 
therapy. The conventional cytotoxic chemotherapeutic agents have a generic working profile 
that interact non-specifically with cellular DNA and/ or tubulin resulting in growth arrest of 
all fast growing cells. With the increased understanding of cancer biology, rational design of 
targeted drugs has started. Targeted drugs have antitumor activity in selected subgroups of 
tumors expressing proteins that are specific for the malignant phenotype2. The clinical use of 
targeted therapy started with the development of monoclonal antibodies3. Five years later, 
the first tyrosine kinase inhibitor was approved for cancer treatment. Tyrosine kinase inhibitors 
are a class of targeted therapy that is designed to compete with adenosine-5’-triphosphate 
(ATP) for the ATP-binding pocket within the intracellular domain of wild type and/or mutated 
tyrosine kinase receptor and thereby blocks downstream signaling important for tumor 
growth. Imatinib is the first rationally designed tyrosine kinase inhibitor approved in 2001 for 
the treatment of three Philadelphia chromosome positive leukemia subtypes4. Since 2001, 
seven additional tyrosine kinase inhibitors have been approved, all rationally designed to be 
active against specific tyrosine kinases. These targeted drugs tend to have a better toxicity 
profile than traditional cytotoxic chemotherapy that interacts non-specifically resulting in 
more collateral, transient damage in healthy tissues5. With the introduction of tyrosine kinase 
inhibitors a new era of treating tumors has started6. 
All tyrosine kinase inhibitors exhibit rather similar pharmacokinetic characteristics. They are 
all highly protein bound, have a long half life and a large volume of distribution, they are 
all primarily metabolized by cytochrome P450 (CYP) 3A, and predominantly excreted with 
the feces7-14. However, several pharmacokinetic aspects of these drugs are also unknown. 
For example, the absolute bioavailability for most tyrosine kinase inhibitors is unknown as 
is the clinical relevance of their interactions with (substrates for and/or inhibitors of) drug 
transporters on intestinal cells, hepatocytes, cancer cells and renal cells. Since these drugs 
are both substrates and inhibitors of their own metabolic pathways, the metabolism of these 
drugs at steady-state exposure is complex and unpredictable. 
Therefore, the aim of this thesis is to further explore clinical pharmacological aspects of 
two tyrosine kinase inhibitors; imatinib and sunitinib, to better understand steady-state 
 pharmacokinetics, clinical relevant interactions and genetic determinants that may 


















The suggested effect of grapefruit juice on steady-state sunitinib exposure will be determined 
(chapter 8). A drug-drug interaction in two patients treated with mitotane and sunitinib will 
be presented in chapter 9. In chapter 10 a possible explanation will be presented for the 
pronounced effect of grapefruit juice on intestinal but absent effect on hepatic CYP3A4 in 
healthy volunteers. 
Finally the results from these studies will be put into perspective in the general discussion 
(chapter 11).
Most information of the pharmacokinetic behavior of the tyrosine kinase inhibitors originates 
from preclinical studies. In addition, clinical studies have revealed important pharmacoki-
netic data of these drugs. An overview of the current knowledge on absorption, distribution, 
metabolism, elimination, drug transporter affinity and drug-drug interactions of all approved 
tyrosine kinase inhibitors as well as their similarities and differences will be presented in 
chapter 2.
Little information is available on the relevance of drug interactions at steady-state pharma-
cokinetics. According to the drug label of imatinib, CYP3A4 is the most important enzyme 
responsible for the metabolism. Since many clinically used drugs are known to inhibit or 
induce CYP3A4, imatinib is prone for drug-drug interactions. In chapter 3 we will determine 
the effect of ritonavir, a potent CYP3A4 inhibitor, on the steady-state imatinib exposure 
(AUC). Multiple CYP enzymes, such as CYP3A4, 3A5, 2D6, 2C9, 2C19, 1A2, 1A1, are capable of 
metabolizing imatinib in in vitro experiments; however there are no data available on the 
influence of these minor enzymes on imatinib exposure15. Since we know that smoking has a 
pronounced effect on CYP mediated metabolism and hereby on erlotinib exposure a similar 
effect is hypothesized for imatinib. In chapter 4, the effect cigarette smoking on imatinib 
exposure will be studied16. 
The exact absorption-site of imatinib in the intestines is unknown. Some patients with 
gastrointestinal stromal tumor (GIST) may not be able to take imatinib orally, due to tumor 
related gastro-intestinal obstruction. Therefore, in chapter 5 we will study imatinib pharma-
cokinetics in a patient after using the rectal route of administration. 
Sunitinib, like all tyrosine kinase inhibitors, shows large interpatient variability in drug 
exposure which might affect the clinical outcome with respect to both toxicity and efficacy. 
In clinical practice ∼ 33% of the patients need a dose interruption or a dose reduction due to 
drug related toxicities17-19. We will explore the use of a noninvasive and harmless phenotypic 
probe (midazolam) to determine CYP3A4 activity and thereby predict the exposure to 
sunitinib before starting sunitinib therapy. The results of this study will be described in 
chapter 6. Most interaction studies are performed with a single dose of the drug of interest, 
whereas the metabolism at steady-state can be distinctively different due to auto-inhibition 
of the primary metabolic pathway20. Some tyrosine kinase inhibitors (imatinib, dasatinib and 
nilotinib) appear to be both substrates and inhibitors of CYP3A412, 21, 22. The effect of steady-state 
sunitinib exposure on CYP3A4 activity is also described in chapter 6. Additionally, we will 
study the association between genetic variants in genes encoding enzymes, transporters 
and sunitinib targets and sunitinib induced toxicities (chapter 7). 
Since the absolute bioavailability of sunitinib is unknown, the influence of intestinal CYP3A4 
activity on sunitinib exposure is unpredictable. However, in the drug label of sunitinib there 
is a warning for co-administration of CYP3A4 inhibitors, such as ketoconazole, clarithromycin 
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In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer 
treatment and numerous are under investigation. These drugs are rationally designed to 
target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues. 
Post marketing study commitments have been made upon (accelerated) approval such 
as additional pharmacokinetic studies in patients with renal- or hepatic impairment, in 
children, additional interactions studies and studies on the relative or absolute bioavailability. 
Therefore, much information will emerge on the pharmacokinetic behavior of these drugs 
after their approval. 
In the present manuscript, the pharmacokinetic characteristics; absorption, distribution, 
metabolism and excretion (ADME), of the available TKIs are reviewed. Results from 
additional studies on the effect of drug transporters and drug-drug interactions have been 
incorporated. In general, TKIs reach their maximum plasma levels relatively fast; have an 
unknown absolute bioavailability, are extensively distributed and highly protein bound. 
The drugs are primarily metabolized by cytochrome P450 (CYP) 3A4 with other CYP- 
enzymes playing a secondare role. They are predominantly excreted with the feces and 
only a minor fraction is eliminated with the urine. All TKIs appear to be transported by the 
efflux ATP binding cassette transports (ABC) B1 and G2. Additionally these drugs can inhibit 
some of their own metabolizing enzymes and transporters making steady-state metabolism 
and drug-drug interactions both complex and unpredictable. 
By understanding the pharmacokinetic profile of these drugs and their similarities, factors 
that influence drug exposure will be better recognized and this knowledge may be used to 
limit sub- or supra-therapeutic drug exposure.  
Introduction
In 1960, a minute chromosome, later known as the Philadelphia chromosome, was discovered 
in human chronic granulocytic leukemia and a causal relationship was suggested between 
this abnormal chromosome and the disease1-3. Later, a translocation between the long arm 
of the 22 and the long arm of the 9 chromosome was found and which was associated 
with an altered heavier human c-abl protein with tyrosine kinase activity and assumingly a 
growth stimulating effect4-6. The group of Heisterkamp et al. discovered the linkage between 
c-abl, positioned at chromosome 9 and the breakpoint cluster region (bcr) on chromosome 
22 resulting in the bcr-abl oncogene and corresponding protein supposedly important for 
the generation and/ or maintenance of the disease7-10. Ninety-five percent of all chronic 
myelogenous leukemia (CML) was suggested to be the result of the altered tyrosine kinase 
that, under physiological conditions, is under tight control but in fusion is deregulated and 
expressed constitutively resulting in indefinite proliferation11. The involvement of protein 
tyrosine kinase activity in the development of tumors made them interesting targets for 
selective chemotherapy and thus for rational drug design. As a result the first series of low 
molecular weight compounds (tyrphostins) that display specificity for individual tyrosine 
kinase receptors were synthesized12. 
Also a novel compound (CGP57148, STI571, imatinib) was synthesized that specifically inhibits 
Bcr-Abl cell proliferation. It competes with ATP for the ATP binding site of the tyrosine kinases. 
In in vitro tests imatinib inhibits Bcr-Abl, c-Abl and platelet-derived growth factor receptor 
(PDGFR) tyrosine kinase13, 14. Only five years after the presentation of the in vitro and animal 
study data, the results of the phase I studies were presented15-17. Based on the results from three 
additional phase II studies, the drug that was rationally designed to inhibit the Bcr-Abl protein 
appeared substantially active and received accelerated approval by the FDA on the 5th of May 
2001 for the treatment of three Philadelphia chromosome positive leukemia subtypes18-20. 
Additionally imatinib potentially inhibits the kinase activity of the mutated and wild-type 
c-kit receptor in vitro and an effect on malignancies that is completely or partly dependent 
on c-kit activity was hypothesized and confirmed21, 22. The phase I study, presented in 2001, 
showed imatinib activity in c-kit receptor positive gastrointestinal stromal tumor (GIST)23. 
On the 18th of April 2003 the registration of imatinib was extended to treatment of patients 
with c-KIT receptor positive unresectable and/or metastatic GISTs and was reassigned to the 
first line treatment of patients with CML in the chronic phase24. With the introduction of 
imatinib a whole new era of tumor treatment started, with therapy that is rationally designed 
and given orally on a daily basis. Since the introduction of imatinib seven additional TKIs 
have been approved (Table I). All TKIs are designed to compete with ATP for the ATP binding 








































longer part of the gastrointestinal tract32.  Another case report describes the absorption from 
the rectum; the exposure (AUC) was approximately 40% of the orally achieved exposure 
indicating that absorption of the drug in the rectum takes place33. The interpatient variability 
in imatinib clearance is large ∼ 40% and mainly unexplained34.
Gefitinib
The peak plasma levels of gefitinib occur within 3-7 hrs35. The absolute bioavailability is ∼ 
60% in healthy volunteers and cancer patients36. Administration of a granular formulation, 
a dispersion of the classic tablets or administration by nasogastric tube did not significantly 
influence the bioavailability37, 38. Food has only a moderate and clinical non-significant effect 
on gefitinib exposure. Data of a study with 50 mg gefitinib showed a 14% decrease in AUC, 
another study with 250 mg of the drug showed a 37% increase in AUC after co-administration 
with food; this combined with the large interpatient variability (45-70%) makes the effect of 
food negligible35, 36, 39. 
Erlotinib
The peak plasma levels of erlotinib occur 4 hrs after dosing40. The bioavailability following 
a 150 mg dose is 100% when applying a noncompartimental approach and ∼ 60% using 
a 2-compartiment nonlinear model41. The assumed nonlinearity in the compartmental 
approach is not confirmed by the data from the phase I dose escalation study42. Food 
increases the bioavailability to almost 100%40. Since the effect of food on erlotinib exposure is 
highly variable, the drug should be taken without food41. Erlotinib shows a large interpatient 
variability (∼60%) which is unexplained yet43.  
Sorafenib
The peak plasma levels of sorafenib occurs ∼3 hrs after dosing44. The absolute  bioavailability 
is unknown. The relative bioavailability of tablets compared to oral solution is 38-49%45. 
Conflicting data are published on the effect of food on the pharmacokinetics of sorafenib. In 
the phase I studies no major effect of food was observed46. However, the FDA approval reports 
a reduction of the bioavailability of 29% when taken with food and advices to take sorafenib 
without food 47. Sorafenib pharmacokinetics show a large interpatient variability44. The large 
interpatient variability is supposed to be the result of slow dissolution in the  gastrointestinal 
tract and enterohepatic circulation46. The drug shows a less than proportional increase in 
exposure with dose escalation. The underlying reason for this nonlinearity is not known yet46.
Sunitinib
The maximum plasma concentration of sunitinib is achieved within 6-12 hrs and the absolute 
bioavailability is unknown. The drug may be taken with or without food since food only has 
Absorption
Imatinib
Imatinib is rapidly absorbed after oral 
administration with a peak plasma 
concentration  at 2 hrs25. For imatinib, 
the bioavailability is surprisingly 
well investigated for a drug with no 
intravenously registered formulation. 
The exposure after intravenous 
infusion and after intake of oral capsule 
or solution was measured to determine 
the absolute bio availability26. The 
intravenous formulation was specially 
made for investigational purposes 
and the capsule was used at the 
time the study was performed. The 
later registered tablet formulation 
was compared to the capsules to 
determine the relative bioavailability27. 
The bioavailability of imatinib is ∼ 98% 
which is irrespective of oral formuation 
(solution, capsule or tablet) or dosage 
(100mg or 400mg)26-28. Imatinib 
absorption is not influenced by food or 
concomitant antacid use29. Long-term 
exposure might influence the bioavail-
ability since imatinib inhibits efflux 
transporters (ABCB1 and ABCG2) 
and enzymes (CYP3A4 and CYP3A5) 
present at the intestinal wall, but 
conflicting data are reported on this 
matter30, 31. The exact gastro intestinal 
site of absorption is not known yet. In 
a case of a woman with short bowel 
syndrome only 20% of the imatinib 
exposure was measured indicating 




































































































































































































































































































































































































is only known for the three 
earliest registered TKIs (imatinib, 
gefitinib and erlotinib). It is 
remarkable that the bio-
availability is not mandatory 
for registration since this 
information is used in the 
clinical practice to treat patients 
with altered gastro intestinal 
anatomy/physiology. TKIs are 
generally well soluble in acidic 
environment and the solubility 
rapidly declines above pH 4-6. 
A pronounced effect of food 
was expected for all TKIs since 
food can rapidly buffer gastric 
acid and thereby negatively 
influence the drug’s solubility. 
However, food has an effect on 
only a few TKIs and even then 
in the opposite direction, 
in dicating that other possible 
factors such as micelle formation 
or a hydrophobic vehicle (fat) 
are more important for the 
absorption of TKIs than the 
drug’s solubility is. 
The bioavailability of lapatinib 
and nilotinib was pronouncedly 
increased by food, the bio -
availability of erlotinib was 
marginally increased, the bio-
availability of gefitinib, sorafenib 
and dasatinib is not clinically 
significant increased by food 
and food has no effect on the 
bioavailability of imatinib and 
sunitinib. Only sorafenib and 
a marginal effect on the exposure48.  The interpatient variability is large ∼40%49. A recent 
case report describes a significant decrease in sunitinib exposure (AUC) in an obese patient, 
which might indicate that body mass index has a pronounced effect on drug exposure and 
might thereby explain partly the large interpatient variability50.  
Dasatinib
The maximum plasma concentration of dasatinib is achieved within 3-5 hrs and the 
 bioavailability in humans is unknown. A 14% AUC increase may occur in patients taking the 
drug with a high-fat meal, however, this effect is not supposed to be clinically significant51. 
The interpatient and inter-occasion variability is large and ranges from 32-118%. A substantial 
proportion of the inter-occasion variability is supposed be explained by the bioavailability52. 
The origin of the interpatient variability has not been elucidated yet.  
Lapatinib
The maximum plasma concentration of lapatinib is achieved within 3-4 hrs53. The absolute 
bioavailability has not been studied. However, the bioavailability of the drug must be low 
since food has such an extraordinary effect on the bioavailability. The largest effect is seen 
with a high-fat meal, which increased the exposure of lapatinib by 325% while a low-fat meal 
increased the exposure by 167%54. Possible explanations for this pronounced effect are: 1] 
A delayed gastric emptying induced by food allows more time for the tablets to dissolve and/
or 2]  Food increases the formation of micelles by bile salts of hydrophobic substances such 
as lapatinib which might be of great influence on the bioavailability. Food does not influence 
the half life which suggests that the increased exposure is mainly caused pre systemically54. 
The interpatient variability is large (68%) and not significantly reduced by the co-administra-
tion of food (52%)54.  
Nilotinib
The maximum plasma concentration of nilotinib is reached 3 hrs after oral  administration55. 
The absolute bioavailability is unknown but again cannot be high since the systemic exposure 
is increased by 82% when the drug is given with a high fat meal compared to fasted state56. 
The interpatient variability in exposure is 32-64% and unexplained yet57. In the phase I dose 
escalation study a saturation of serum levels was observed with doses ranging from 400 – 
1200mg daily. A possible explanation might be that the uptake of nilotinib is saturated at 
doses exceeding 400mg since a modified dose schedule to a twice-daily regimen results in 
an increased exposure55.  
Absorption: In summary most TKIs reach the maximum plasma concentration relatively fast 









































































































































































































































































































































































































































































































































Erlotinib and gefitinib have a common chemical backbone structure and are distributed 
very similarly in the human body. Erlotinib is also extensively protein bound, predominantly 
to albumin and AGP, has a long half life of 36.2 hrs and an accompanying large volume 
of  distribution of 232 L40.  AGP concentration and steady state exposure (AUC) are tightly 
linked43. AGP together with total bilirubin and smoking status were the most important 
factors affecting the drug clearance75. The penetration of erlotinib in the CNS is poor, with 
CNS levels that represent ∼7% of the plasma exposure76.  
Sorafenib
The volume of distribution of sorafenib is not reported. However, since the drug is highly protein 
bound (∼99.5%) and has a long half life of 25-48hrs, a large volume of distribution is expected47. 
Sunitinib
Sunitinib has a large volume of distribution of 2230 L and is highly (95%) protein bound. 
The half life of the drug is 40-60 hrs49.
Dasatinib
Dasatinib is extensively distributed in the extravascular space and is highly protein bound 
(∼94%) which results in a large volume of distribution of 2505 L and a half life of 3-5 hrs77. 
The distribution between plasma and blood cells was equal in in vitro experiments77. 
The brain penetration is poor. In three patients the CSF: plasma ratios ranged from 0.05-0.28. 
However, dasatinib appears to be more potent against CNS tumors than imatinib which 
might be the result of a much greater potency (325-fold) along with the low amount of 
proteins in the CNS resulting in a relatively large fraction of unbound drug78.
Lapatinib
The volume of distribution of the terminal phase of lapatinib is >2200 L and the half life is 
24 hrs. The drug is highly protein bound (> 99%) to albumin and AGP79. Rat and mouse studies 
demonstrated a very limited penetration of the drug in the CNS which was increased with 
40-fold in ABCB1/ ABCG2 knockout mice though single transporter knockout mice have only 
limited effect on the CNS penetration80, 81. The translation of the results of these animal studies 
to human remains difficult and therefore additional studies in humans are warranted.
Nilotinib
The volume of distribution of nilotinib is not reported. Although the high level of protein 
binding (98%) and the long half life (∼17 hrs) suggest that the volume of distribution is 
presumably large.  
nilotinib showed a less than proportional increase in exposure with dose escalation which 
could be result of multiple mechanisms e.g. saturation at the absorption site, solubility 
aspects and transporter interactions. This non-proportionality distinguishes them from the 
other TKIs and might be addressed in future research. Also the large and unexplained inter-




Imatinib is extensively distributed into tissues and highly protein bound, predominantly to 
albumin and α1-glycoprotein (AGP), which is translated into a large volume of distribution of 
435 L and a long half life of 18 hrs26, 58-60. Changes in the unbound drug fraction had a large 
effect on the intracellular drug concentration in in vitro experiments61. The role of AGP on the 
pharmacokinetics is underscored in in vivo studies, and a possible relation was suggested 
between imatinib-free plasma levels and the treatment efficacy62-65.  Imatinib only penetrates 
in the cerebrospinal fluid (CSF) to a limited extent;  ∼100-fold lower levels were measured 
in the central nervous system (CNS) compared to plasma61, 66-70. This limited penetration in 
the CNS was confirmed in a non-human primate model. The drug appears to concentrate 
in the sinuses and tissues surrounding the brain58, 71. ABCB1 and to a lesser extent ABCG2 
are suggested to strongly regulate the uptake in the CNS and malignant cells. Inhibition of 
ABCB1 in in vitro and animal studies resulted in a 2-10 fold increase in CNS penetration66, 
67, 69, 70. However, the clinical relevance of the efflux transporters has to be investigated in 
humans. In in vivo and in vitro studies a 5-8 cell/plasma ratio was observed which indicates 
that imatinib is actively transported into the leukemia cells and a possible role for the organic 
cation transporter (OCT) 1 is hypothesized61, 62.
Gefitinib
Gefitinib is extensively distributed into the tissues and highly protein bound (to albumin and 
AGP) which results in a large volume of distribution of 1400L and a long half life of 48hrs72, 
73. The blood to plasma ratio of 0.76 suggests that the drug mainly binds to plasma proteins, 
with a preference for AGP, and to a lesser degree to blood cells72. The penetration in the CNS 
is poor, probably as a result of ABCB1 mediated efflux at the blood-brain barrier73. The drug 
preferably distributes into highly perfused tissues (lung, liver, kidney and gastrointestinal 
tract) including tumor tissues73. In mice bearing human tumor xenografts the tumor cell/
plasma ratio was 11-fold as was the skin/plasma ratio which points into the direction of active 








































The overall metabolism of erlotinib, and formation of O-desmethyl-erlotinib (OSI-420), 
is predominantly through CYP3A4 and CYP3A5 and to a lesser extent by CYP1A2 and the 
extrahepatic isoform CYP1A1 and CYP1B1, with only a minor role for CYP2D6 and CYP2C840, 
75, 87, 91. However, induction of the enzymes CYP1A2 and CYP1A1 has a pronounced effect 
on the drug exposure, indicating that both enzymes might have a more prominent role in 
the in vivo erlotinib metabolism as suggested by the in vitro results91. Erlotinib is a moderate 
pregnane X receptor (PXR) inducer and strongly induces CYP3A4 mRNA levels, although the 
formation of 1-hydroxymidazolam is decreased in in vitro experiment showing the potency 
of erlotinib to inhibit CYP3A4 metabolism92. Conflicting data are published on the effect the 
drug has on CYP3A4 metabolism87.  
Sorafenib
Oxidative metabolism of sorafenib is mediated by CYP3A4, additionally the drug is 
glucuronidated by UDP glucuronosyltransferase (UGT) 1A947. Around 50% is eliminated in 
the unchanged form which is either the result of poor metabolism capacity or the result of a 
low fraction of the drug that is absorbed from the intestines.  
Sunitinib 
Sunitinib is primarily metabolized by CYP3A4 to produce its primary active metabolite 
SU12662 which is further metabolized by CYP3A4 into inactive metabolites93. Data on 
additional enzymes involved in the metabolism are lacking. 
Dasatinib
Dasatinib is extensively metabolized and thus relatively small amount of unchanged drug is 
excreted94. Dasatinib is primarily metabolized by CYP3A4 to produce its  pharmacologically 
active metabolites; M4, M5, M6, M20 and M24 that represent around 5% of the parent 
compound AUC. Flavin-containing mono-oxygenase 3 (FMO-3) and UGT are also involved 
in the formation drug metabolites51.  In vitro data demonstrate that multiple CYP isoforms 
(e.g. CYP1A1, 1B1  and 3A5) are capable of metabolizing dasatinib, however the relevance of 
these other CYP-enzymes in vivo requires further investigation95. 
Lapatinib
In vitro studies indicate that lapatinib is primarily metabolized to oxidation products by 
CYP3A4, 3A5, 2C19 and 2C879. The major enzyme is CYP3A4 which accounts for approximately 
70% of the metabolism. One metabolite GW690006 remains active against EGFR however it 
has lost activity against HER2, whereas other metabolites appear to be inactive79. Lapatinib 
is an inhibitor of CYP3A4 and CYP2C8 and may therefore interact with substrates of these 
Distribution: In summary TKIs are extensively distributed into tissues and are highly protein 
bound, resulting in a large volume of distribution and a long terminal half life (Table II). 
The volume of distribution, the affinity for specific plasma proteins and the CNS penetration 
is not reported for all TKIs yet. However, since the TKIs share multiple pharmacokinetic 
 characteristics, parallels might be drawn between the TKIs. Especially, the influence of AGP 
on the pharmacokinetics and efficacy of TKIs might be interesting, since TKIs are preferably 
bound to this plasma protein and AGP is often elevated in cancer patients and could 
therefore interfere with an effective treatment.  
Metabolism
Imatinib
Imatinib is primarily metabolized through CYP3A4 and CYP3A5 with CYP2D6, CYP2C9, 
CYP2C19 and CYP1A2 playing a minor role28, 82-84 . A recent study identified two extra hepatic 
enzymes (CYP1A1 and CYP1B1) and the flavin-containing monooxygenase 3 (FMO3) enzyme 
as being capable of extensively metabolizing the drug83. Additionally, imatinib can inhibit 
CYP3A4 and CYP2D6 metabolism34, 84, 85. Patients carrying a polymorphism in CYP2D6 
(*4 allele) show a reduced apparent clearance indicating that CYP2D6 appears to be 
important in vivo in the metabolism of imatinib86. The clinical relevance of these enzymes 
at steady-state pharmacokinetics, under auto inhibition of metabolic pathways, is mainly 
unsolved and needs to be addressed in additional studies. The main metabolite is CGP74588 
which represents approximately 10% of the imatinib AUC and has similar potency in vitro25.  
Gefitinib
In vitro studies indicate that gefitinib is metabolized by CYP3A4, CYP3A5, CYP2D6 and by 
the extrahepatic enzyme CYP1A139, 87. The drug inhibits CYP2C19 and CYP2D6 although 
the clinical relevance is questioned88. The main metabolite is the O-desmethyl derivate 
(M523595) which is present at concentrations similar to gefitinib and is formed through 
CYP2D6 metabolism87, 89. M523595 and gefitinib have similar potency against epithelial 
growth factor receptor (EGFR) tyrosine kinase activity in isolated enzyme assays. However, 
the metabolite has lower activity in a cell based assay due to the poor penetration into the 
cell and is therefore unlikely to contribute significantly to the therapeutic activity74. In CYP2D6 
poor metabolizers a higher exposure to gefitinib was observed compared to the extensive 
metabolizers. Additionally, M523595 was undetectable in poor metabolizers. CYP3A4 activity 
and CYP3A5 polymorphisms did not explain the large interindividual variability89. In vitro 
studies claim that CYP3A4 is the most prominent enzyme in gefitinib metabolism though 
conflicting data are presented73, 87, 88. However in vivo data suggests that besides CYP3A4 also 







































enzymes; additional studies to investigate this effect are ongoing79.
Nilotinib
Nilotinib is mainly metabolized through CYP3A4. In vitro data demonstrate that the drug 
is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6 and UGT1A1. Additional in 
vitro data show that nilotinib may induce CYP2B6, CYP2C8 and CYP2C957. In vivo data have 
been presented on the clinical relevance of CYP3A4 inhibition in an interaction study with 
midazolam and for UGT1A1 in a genetic polymorphism study describing an increased risk of 
nilotinib induced hyperbilirubinemia for the UGT1A1 *28 genotype56, 96.  
Metabolism: In summary all TKIs are metabolized in a very similar way (Table III, Figure I). 
All TKIs are primarily metabolized by CYP3A4, with other CYP-enzymes and for some TKIs 
(sorafenib, dasatinib) UGT playing only a minor role. The enzymes that show affinity are 
mostly identified in in vitro experiments, whereas the clinical effects of the major enzymes is 
typically investigated in in vivo interaction studies in healthy volunteers. The clinical relevance 
of the involvement of minor enzymes is largely unsolved at the time of registration and 
needs to be addressed in additional studies after registration. Several TKIs (imatinib, gefitinib, 
lapatinib and nilotinib) are inhibitors of enzymes by which they are primarily metabolized 
themselves, this could alter their metabolism substantially upon multidose use at steady-
state. There is little insight in the steady-state metabolism at this point, which is surprising 
since these drugs are used on a daily basis. Some TKIs (erlotinib, sorafenib, sunitinib and 
dasatinib) are thought to have no effect on CYP-enzyme activity which might be the result 
of a lack of data rather than an absent effect. Additional research to investigate the effect of 
these drugs on CYP-enzyme activity is needed.  
Excretion
Imatinib
Imatinib is mainly eliminated trough the liver. The kidneys only excrete a minimal amount 
of the drug and its metabolites. At this point there is still a discussion ongoing whether the 
apparent clearance increases, decreases or remains the same at steady-state97-100. However, 
a decrease in clearance seems more plausible since imatinib is capable of inhibiting its own 
metabolic pathways. Of a single dose imatinib in healthy volunteers 81% of the dose was 
recovered in urine (13.2%; 5% as unchanged imatinib) and feces (67.8%; 23% as unchanged 
imatinib) in 7 days25. This suggests that the drug clearance will more likely be affected by 
hepatic impairment than by renal dysfunction61. Surprisingly, two independent groups found 








































































































































































































































































































































































































































































a case study in an end-stage renal function patient claims no effect on the pharma cokinetics, 
however the clearance in this patient was significantly reduced compared to patients with 
normal renal function102. Two possible explanations for this apparent discrepancy were put 
forward: a correlation between renal failure and AGP levels and an effect of elevated levels of 
uremic toxins in renal failure on the organic anion transporting polypeptide (OATP) 1B3 and 
hereby influencing the hepatic elimination101, 103, 104. Moreover, there was no effect observed of 
mild and moderate liver dysfunction on the pharmacokinetics of imatinib and CGP74588  in 
three independent studies105-107. Severe liver dysfunction resulted in elevated drug exposure 
levels106. Renal and hepatic impairment is no reason for abstaining patients from imatinib 
treatment though patients with moderate renal failure should start at a 50% decreased dose 
and patients  with severe liver dysfunction are advised to start with a 25% dose reduction24.  
Gefitinib
About 90% of gefitinib is recovered in feces (86%) and urine (0.5%) over 10 days indicating that 
renal excretion is not a major route of elimination35. Surprisingly, in patients with moderate 
and severe elevated liver tests the pharmacokinetics was not altered. No data are available 
on the influence of renal impairment on the pharmacokinetics39.











Major: CYP3A4,  CYP3A5
Minor: CYP2D6, CYP1A1, CYP1A2
OSI-420 (active metabolite)
BAY 67 3472 (active metabolite)
M4 (BMS 528691) M5 (BMS 606181)
M6 (BMS 573188)











None of the metabolites contribute





The tyrosine kinase inhibitors with only their active metabolites are demonstrated. The enzymes involved according 








































Lapitinib is primarily eliminated hepatically, with 27% of the oral dose recovered in the feces 
and <2% recovered in the urine79. It is suggested that a large part of the oral dose remains 
in the intestines and is not absorbed which may contribute to the most prevalent dose 
limiting toxicity diarrhea. Indeed, diarrhea showed no relation to serum levels of lapatinib113. 
In patients with severe hepatic impairment the AUC of lapatinib was increased by > 60% and 
the half life was ∼3-fold increased compared to patients with normal hepatic function79. No 
data are available on the influence of severe renal impairment.
Nilotinib
Nilotinib recovery was assessed over 7 days after a single dose and showed 4.4% of the drug 
being recovered in urine and 93.5% in feces (69% unchanged nilotinib). A large amount (31%) 
of unchanged nilotinib excreted via the feces was suggested to be the result of unabsorbed 
drug114. Nilotinib pharmacokinetics has not been studied in patients with hepatic or renal 
impairment, however the drug label warns for the possible risk of giving nilotinib to patients 
with hepatic impairment57. 
Excretion: In summary all TKIs are predominantly excreted via the feces and only a minor 
fraction is eliminated with the urine. The fraction of unchanged drug in the feces can vary 
widely among the TKIs. Large fraction of unchanged drug in the feces can either be the 
result of a relatively large fraction that is not absorbed and directly eliminated or by a low 
efficient metabolism. Without data on the absolute bioavailability or the time frame of the 
fecal elimination it is difficult to distinguish between both mechanisms. Data on the effects 
of mild, moderate or severe renal and hepatic impairment on the pharmacokinetics of TKIs 
are mainly absent. For the few TKIs where the effect is studied some unexpected results 
are observed. Mild to moderate hepatic impairment did not affect the pharmacokinetics of 
imatinib and gefitinib whereas severe hepatic impairment did affect the pharmacokinetics of 
imatinib and lapatinib and did not affect the pharmacokinetics of gefitinib. Surprisingly, mild 
to moderate renal impairment did affect the pharmacokinetics of imatinib pharmacokinetics. 
Since the patients treated with these drugs are at risk to develop renal or hepatic impairment 
at any stage of their disease it is necessary that more data become available on the possible 
influence of these impairments on the pharmacokinetics of these drugs.
Drug transporters 
The ABCB1 (P-glycoprotein; P-gp), ABCC1 (multidrug resistance-associated protein; MRP1) 
and ABCG2 (breast cancer resistance protein; MXR) are efflux transporters and are now 
Erlotinib
Following a 100 mg oral dose of erlotinib, 91% of the dose was recovered over 11 days: 83% 
in feces and 8% in urine of which 1% and 0.3% as parent drug respectively108. No data are 
available regarding the influence of hepatic dysfunction and/or hepatic metastases and 
renal dysfunction on the drug pharmacokinetics40. 
Sorafenib
Sorafenib is eliminated primarily through the liver. Of a 100mg dose 77% is excreted with 
the feces and 19% is excreted as glucuronidated metabolites in the urine47. Approximately 
50% of an oral dose is recovered as unchanged drug in the feces, due to either inefficient 
metabolism or lack of absorption47. Mild to moderate hepatic impairment does not 
 significantly alter the exposure. Sorafenib pharmacokinetics has only recently been studied 
in patients with severe hepatic and renal impairment109. After a single dose of 400mg no 
significant alterations were observed in drug and metabolite AUC regardless of the severity 
of renal or hepatic impairment. However, only patients with normal or mild hepatic and renal 
dysfunction tolerated (without experiencing dose limiting toxicities) a dose of 400mg twice 
daily at steady state. Patients with moderate renal en hepatic dysfunction needed a dose 
reduction of 50%, while patients with severe hepatic impairment did not tolerate sorafenib. 
Patients with very severe hepatic and renal dysfunction only tolerated 200mg once daily, no 
explanation for the discrepancy between the tolerance in severe and very severe hepatic 
impairment is provided109. This recent study provides valuable information since sorafenib is 
used for the treatment of patients with hepatocellular carcinoma that is often accompanied 
by severe hepatic impairment. 
Sunitinib
Sunitinib is primarily eliminated with the feces (61%), with renal elimination accounting for 
only 16% of the administered dose. There are no studies on the pharmacokinetics in patients 
with serious hepatic or renal insufficiency. However, in pharmacokinetic studies where also 
the creatinine clearance was assessed, there appeared to be no pharmacokinetic alterations 
in volunteers with a wide range of creatinine clearances110. Additionally in a case report 
describing two hemodialyzed patients on sunitinib therapy the plasma concentration of the 
drug and its major metabolite at steady-state were comparable to patients with normal renal 
function111. 
Dasatinib
Dasatinib is mainly excreted via feces, 85% of which 19% as intact drug. Urine excretion is 
around 4% of which <1% as unchanged dasatinib51, 112. No data are available on the effect of 








































In in vitro experiments erlotinib was shown to be a substrate for ABCB1 and ABCG2 but 
not for ABCC2. In mice studies the absence of ABCB1 and ABCG2 significantly affected the 
oral  bioavailability127. Erlotinib also inhibits the ABCB1 and ABCG2 drug efflux function128. 
In a recent study in humans the ABCG2 -15622C/T and 1143C/T polymorphisms, resulting in a 
reduced expression of the transporter, were associated with increased AUC and Cmax129. 
Sorafenib
The role of transporters on the disposition of sorafenib is yet unknown.  
Sunitinib
Recently, an in vitro study demonstrated that sunitinib is a high affinity inhibitor of ABCG2 
and inhibits ABCB1, albeit more weakly. Moreover, the drug is also a substrate of both 
 transporters130. The bioavailability might therefore be affected by polymorphisms in the 
genes encoding for these transporters but this needs to be addressed in clinical studies130. 
Dasatinib
In vitro data demonstrated that dasatinib is a substrate of ABCB1 and ABCG2 but not a 
potent inhibitor of these transporters77, 131, 132. Additional in vitro studies suggested that the 
drug is also a substrate for hOCT1 however the uptake is much less hOCT1 dependent 
compared to imatinib. Inhibitors of hOCT1 did not interfere with the uptake of dasatanib 
and it is hypothesized that the uptake in vivo is more likely driven by diffusion than by active 
transport131, 132.
Lapatinib
Results from in vitro studies indicated that lapatinib is a substrate and an inhibitor of the 
efflux transporters ABCB1, ABCG2 and solely an inhibitor of OATP1B180. It has the potency 
to reverse the ABCB1 and ABCG2 driven resistance on multi drug resistant cells in vitro133. 
In addition, lapatinib did not inhibit nor was a substrate of OAT, OCT and uric acid transporter 
(URAT) transporters which is in line with the marginal renal clearance of the drug80. Further 
studies in humans are warranted to further clarify the role of transporters on the efficacy, 
disposition, toxicity and drug interactions80. 
Nilotinib
Nilotinib appears to be a substrate and an inhibitor of ABCB1 and ABCG2, however the clinical 
relevance of these in vitro assessments need to be addressed57, 134.  
recognized to have an important role in the absorption, distribution, excretion and toxicity of 
xenobiotics115. Also the solute carrier family (SLC) transporters, which are influx transporters, 
are receiving more attention although their effect on drug kinetics is less well established 
at this point116. Members of the SLC family are the solute carrier OATP, solute carrier peptide 
transporter family (PepT1), and organic zwitterion/cation transporters (OCTNs)116. Also for the 
disposition of TKIs efflux and influx transporters are gaining interest.
Imatinib
The high bioavailability of imatinib, a substrate for multiple CYP enzymes (especially CYP3A4 
and CYP3A5), and also for ABCB1, ABCG2 with ambiguous affinity for SLC transporters, 
is remarkable and can only be explained by a low hepatic extraction and low efficient 
transport of imatinib by the efflux transporters115, 117-119. Although conflicting results have 
been published, imatinib is most likely a substrate and an inhibitor of ABCB1 and ABCG2120. 
The ABCG2 421C/A  polymorphism is associated with a reduced clearance in humans65. A 
recent study in 90 CML patients showed a pronounced effect of ABCB1 1236C/T and 2677G/T 
polymorphisms on trough drug levels and an corresponding clinical effect (major molecular 
response)121. However, additional studies are necessary to conclusively determine the role of 
ABC-transporters on imatinib pharmacokinetics and efficacy. There appears to be a modest 
role for the organic cation transporter 1 (OCT1) as observed in in vitro experiments. OAT1, 
OAT3 and OCT2 do not transport imatinib in vitro which is consistent with their presence 
on the kidneys and the relative low renal clearance117, 122. OATP1B3 and OCTN2 appeared to 
have affinity for the drug, however the in vivo relevance is not yet studied [Oostendorp RL 
The role of Organic Cation Transporter 1 and 2 in the in vivo pharmacokinetics of imatinib 
Submitted]. Since the precise role of the transporters on imatinib disposition and the effect 
of transporter inhibition by the drug is not completely understood, no additional warnings 
have been added to the drug label. However, alertness is necessary for possible drug interac-
tions on drug transporter level. Moreover, the highly polymorphic transporters might explain 
at least in part the large interpatient variability.    
Gefitinib
Gefitinib also interacts with ABCG2 and to a lesser extend with ABCB1123. In in vitro experiments 
the drug appeared to reverse ABCG2 mediated resistance by inhibiting ABCG2 at relatively 
high drug concentrations123-125. It is a substrate of ABCG2 in in vitro experiments at clinically 
relevant drug concentration. Additionally patients carrying the ABCG2 421C/A polymorphism 
have higher gefitinib exposure and more diarrhea compared to those carrying the wild-type 








































with 83%88. In in vitro experiments gefitinib stimulates midazolam metabolism through 
CYP3A4. An explanation for this observation is not provided yet87. High doses of ranitidine, 
inducing a gastric pH > 5.0, resulted in a decreased gefitinib AUC143. Gefitinib co-administra-
tion resulted in a 35% increase in metoprolol exposure indicating that the drug is a CYP2D6 
inhibitor at therapeutic levels88. In a case report the possible interaction between herbal 
medicines (e.g. ginseng) and gefitinib is suggested since interruption of the herbal medicine 
treatment turned the patient from a non-responder into a responder. Unfortunately, in this 
case the gefitinib plasma levels were not measured144. Surprisingly, sorafenib reduced the 
AUC of gefitinib by 38%, where gefitinib has no effect on sorafenib exposure145. There is no 
explanation for this observation.
Erlotinib
Inhibitors and inducers of CYP3A4 interfere with erlotinib exposure. Co-administration of 
rifampicin results in a 67% decreased drug exposure (AUC)146. Ketoconazole increases the 
drug exposure (AUC0-∞) and Cmax with 86% and 102% respectively147.
Co-administration of BAS 100, a substance in grapefruit juice, resulted in a 2.1 fold increase in 
the AUC of erlotinib in mice, most likely due to an increased uptake by inhibiting CYP3A4 or 
ABCB1148. Smoking results in a decreased erlotinib AUC (35.9%) possibly by inducing CYP1A1 
and CYP1A2 metabolism91. The maximum tolerated dose in smokers was 300 mg compared 
to 150 mg in non-smokers. Additionally the steady-state trough levels and incidence of rash 
and diarrhea in smokers at 300mg were similar as the data for non smokers receiving 150mg 
erlotinib149.
Sorafenib
Since sorafenib is metabolized by CYP3A4, an interaction with CYP3A4 inhibitors was 
expected. In a drug interaction study with ketoconazole and sorafenib, ketoconazole did not 
alter the exposure. However it did decrease the plasma concentration of sorafenib-N-oxide 
which is formed through CYP3A4. This finding is consistent with an earlier mass-balance study 
showing that 15% of the administered dose was eliminated by glucuronidation where only 
5% was eliminated as oxidative metabolites150.  Co-administration of sorafenib with gefitinib 
causes an decrease in gefitinib exposure of 38%. The interaction can not be mediated through 
CYP3A4 inhibition since sorafenib does not influence the exposure of midazolam which is 
suggested to be solely metabolized through CYP3A4145. In vitro data demonstrated that 
sorafenib is a competitive inhibitor of CYP2C19, CYP2D6 and CYP3A4 although the inhibitory 
potency does not appear in clinical studies where the drug was given concomitantly 
with midazolam (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate) or omeprazol 
(CYP2C19 substrate)45, 47. Sorafenib is also a competitive inhibitor of CYP2B6 and CYP2C8 
though the clinical relevance of this inhibition is not studied yet151. The hypothetical effect 
Drug transporters:  In summary all TKIs are substrates and inhibitors of ABCB1 and ABCG2, 
except for dasatinib which appears to be no inhibitor of these transporters and for sorafenib 
of which no data are available. Additionally, imatinib and dasatinib might interact with OCT1. 
No data are available on the affinity of the other TKIs for the SLC transporter family. Multiple 
in vitro studies have been published on the effect TKIs have on drug transporters and visa 
versa. At this point the clinical significance of polymorphic transporters and interactions 
between drugs on transporters are mainly undefined.
Drug-drug interactions
Imatinib
The drug label of imatinib warns for co-administration of potent CYP3A4 inhibitors and for 
co-administration of substrates of CYP3A4 with a narrow therapeutic window. This warning 
makes the clinical practice difficult since a large group of drugs is either a substrate or an 
inhibitor of CYP3A4. The inhibitory effect of the drug on CYP3A4 was investigated by an 
interaction study with simvastatin. Simvastatin clearance was reduced by 70% indicating 
a clinically relevant strong CYP3A4 inhibitory effect85.  Contrary results are presented in 
interaction studies with CYP3A4 inhibitors after a single dose (ketoconazole) and at steady-
state (ritonavir)84, 135.  CYP3A4 inducers (rifampicin, St. John’s wort, phenytoin and enzyme 
inducing anti-epileptic drugs (EIAED’s)) very constantly show a decrease in imatinib 
exposure15, 100, 136-139. Administration of the drug together with metoprolol, a CYP2D6 substrate, 
resulted in an increase in metoprolol exposure of 23% with moderate differences between 
the intermediate and extensive metabolizers140. Smoking does not alter imatinib exposure, 
indicating no major contribution of CYP1A2 in the metabolism of the drug141. An interaction 
between imatinib and warfarin is hypothesized since both increases and decreases in INR 
have been reported after starting therapy. Warfarin is a substrate of CYP2C9 and CYP3A4 and 
both enzymes are involved in the metabolism of imatinib28.  Interactions through the other 
enzymes are hypothesized and warned for in the drug label but not yet investigated. Also 
the effect of drug transporter inhibitors (e.g. pantoprazol, cyclosporine) on the disposition of 
the drug in humans is not evolved yet and neither is the influence of imatinib on drugs that 
are transported by ABCB1 (e.g. digoxine) or ABCG2 (e.g. nitrofurantoin). The cellular uptake of 
nilotinib is enhanced by the co-administration of imatinib due to ABCB1 and possibly ABCG2 
inhibition in in vitro studies142. The drug label does not include warnings with regard to risks 
related to drug transporter interactions though alertness is on its place.  
Gefitinib
Inhibitors and inducers of CYP3A4 interfere with gefitinib exposure. Itraconazole elevated 







































one or all mechanisms are responsible for this in vivo interaction152. In the combination of 
lapatinib with paclitaxel the exposure of lapatinib as well as paclitaxel was increased with 21% 
and 23% respectively79. The mechanism behind the described interactions is yet unknown. 
Since in vitro data suggest that lapatinib is an inhibitor of ABCB1, alertness may be warranted 
when the drug is co-administered with ABCB1 substrates79. However, no clinical studies are 
available to confirm this interaction. 
Nilotinib
Nilotinib is mainly metabolized through CYP3A4. The concomitant administration of 
ketoconazole with nilotinib produces a 3-fold increase in systemic exposure. Nilotinib itself 
appears to be a weak inhibitor of CYP3A456. The co-administration of midazolam with the drug 
in healthy volunteers resulted in a 30% increase in the systemic exposure of midazolam56.
Drug-drug interactions: In summary most clinical interaction studies investigate interactions 
in healthy volunteers with a single dose of the TKI given together with a CYP3A4 inhibitor 
(e.g. ketoconazole, itraconazole) or a single dose of the TKI given after a few days of CYP3A4 
inducing therapy (e.g. rifampicin, carbamazepine) (Table IV, V). This study design might not 
represent the metabolism at steady-state pharmacokinetics, since most TKIs are capable of 
inhibiting at least partly the enzymes by which they are metabolized. Auto-inhibition could 
result in the shunting of the metabolism through less prominent metabolic pathways at 
steady-state. Therefore, interaction studies performed at steady-state pharmacokinetics are 
more informative and representative for the clinical relevance of the investigated enzymes. 
Fortunately, the FDA is becoming stricter and demands additional research at steady-state for 
the newer TKIs (lapatinib, nilotinib) that have potency to inhibit enzymes and transporters.  
on CYP2C9 was indirectly measured by the effect on warfarin therapy. The INR in sorafenib 
treated patients was similar in placebo treated patients. The effect of CYP3A4 inducers (e.g. 
rifampicin) is not studied, however a warning is included in the drug label of sorafenib47. The 
drug does interfere with the pharmacokinetics of concomitantly administered antineoplastic 
agents doxorubicin and irinotecan. The exposure of doxorubicin was increased by 21%. The 
increase in SN-38 exposure was 67-120% most likely through competition or inhibition of 
UGT1A1 and additionally the irinotecan exposure increased with 26-41%47.  
Sunitinib
Since sunitinib is primarily metabolized through CYP3A4, the influence of ketoconazole 
and rifampicin was investigated in healthy volunteers. Co-administration of ketoconazole 
increased the cumulative exposure of sunitinib and SU12662 with ∼ 50%. Rifampicin 
 coadministration resulted in a 50% decrease in combined systemic exposure110. It is suggested 
that sunitinib has no influence on other co-administered drugs.
Dasatinib
The exposure of dasatinib is increased five fold on the co-ingestion of ketoconazole in 
healthy volunteers. Rifampicin decreased the exposure by 82%. In vitro data demonstrated 
that the drug does not induce human CYP-enzymes. It however does appear to be a time 
dependent CYP3A4 inhibitor. As a result, the co-ingestion of dasatinib with simvastatin 
(a CYP3A4 substrate) resulted in a 20% increased exposure to simvastatin. The solubility 
of dasatinib appears to be pH dependent. Famotidine reduced the exposure by 61%, the 
co-administration of agents that provide prolonged gastric acid suppression is therefore not 
recommended51.  
Lapatinib
Lapatinib is a substrate and an inhibitor of CYP3A4 and an inhibitor of CYP2C8. A single 
dose of a CYP3A4 inhibitor (ketoconazole) increases the exposure by 3.6-fold. In contrast 
carbamazepine, a CYP3A4 inducer, decreases the exposure by ∼75%79. An extrapolation is 
made to other CYP3A4 inhibitors and inducers although no clinical data are available on 
these interactions. Dose adjustment advices are given in the package insert when combining 
lapatinib with an inducer or an inhibitor. These advices are not tested in clinical setting and/
or on steady-state lapatinib exposure. 
In the combination of lapatinib with folinic acid, 5-fluorouracil and irinotecan the AUC 
of SN-38, the active metabolite of irinotecan, was increased by 41%. There are multiple 
suggested explanations for this interaction. Lapatinib showed inhibition of CYP3A4, OATP1B1, 
ABCB1 and ABCG2 in vitro which are enzymes and transporters important in the metabolism 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TKIs are a relatively new and fast growing group of anticancer drugs developed as oral 
formulations and administered on a daily basis. In general, these TKIs are substrates of several 
drug transporters and metabolizing enzymes. Some of them are also capable to inhibit 
drug transporters and enzymes making their disposition and metabolism at steady-state 
pharmacokinetics rather complex and unpredictable. Most of the available pharma cokinetic 
information is based on information obtained from in vitro experiments, animal studies, 
drug-drug interaction studies and mass balance studies in healthy volunteers with a single 
dose of the aimed TKI. However, it is difficult to translate the results of these studies to the 
clinical oncology practice where these drugs are administered on a daily basis with possible 
auto-inhibiting mechanisms significantly altering the pharmacokinetics outcomes as well as 
the relevance of claimed drug interactions. Most information is available for the TKIs that are 
used for the longest time in clinical practice. A question that arises is whether the knowledge 
obtained for one TKI should not be used for the rational design of studies with the other 
TKIs and whether translations between these drugs are possible when confronted with 
unexpected low or high drug exposure. 
In this review the current knowledge on the pharmacokinetic aspects; ADME, drug 
 transporters and drug-drug interactions of the individual TKIs are described. Similarities 
and differences between the TKIs are summarized. It appears that several pharmacokinetic 
aspects are unfortunately not investigated yet for these drugs. While awaiting the results 
the only way to anticipate on clinical features and drug interaction potential in the clinical 
practice is by translating the knowledge obtained from the other TKIs as described in this 
review.   
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Purpose:  To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-
state pharmacokinetics of imatinib.
Experimental Design:  Imatinib pharmacokinetics were evaluated in cancer patients 
receiving the drug for at least 2 months, after which ritonavir (600 mg) was administered 
daily for 3 days.  Samples were obtained on the day before ritonavir (day 1) and on the third 
day (day 4). The in vitro metabolism of imatinib with or without ritonavir and the effect of 
imatinib on 1-OH-midazolam formation rate, a probe for CYP3A4 activity, were evaluated 
with human CYP3A4 and pooled liver microsomes.
Results:  In 11 evaluable patients, the geometric mean (95% confidence interval) area under 
the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) μg·h/mL and 41.2 (32.1-53.1) μg·h/
mL, respectively (P = 0.65).  A population analysis performed in NONMEM with a time- 
dependent covariate confirmed that ritonavir did not influence the clearance or bio availability 
of imatinib.  In vitro, imatinib was metabolized to the active metabolite CGP74588 by CYP3A4 
and CYP3A5 and, to a lesser extent, by CYP2D6.  Ritonavir (1 μmol/L) completely inhibited 
CYP3A4-mediated metabolism of imatinib to CGP74588, but inhibited metabolism in 
microsomes by only 50%. Imatinib significantly inhibited CYP3A4 activity in vitro.
Conclusion: At steady-state, imatinib is insensitive to potent CYP3A4 inhibition and relies on 
alternate elimination pathways.  For agents with complex elimination pathways that involve
autoinhibition, interaction studies that are done after a single dose may not be applicable 
when drugs are administered chronically.
Introduction
The first rationally designed inhibitor of a signal transduction pathway, imatinib, is a 
competitive inhibitor of Bcr-Abl, platelet-derived growth factor receptors (α and β), and 
c-KIT receptor tyrosine kinases1-4.  It was first approved for the treatment of Philadelphia 
 chromosome-positive chronic myelogenous leukemia and, shortly thereafter, for c-KIT 
positive metastatic and unresectable gastrointestinal stromal tumor5, 6.
The pharmacokinetic properties of imatinib have been investigated in healthy volunteers 
and in patients with chronic myelogenous leukemia, gastrointestinal stromal tumor, and 
other tumors7, 8.  Imatinib is well absorbed after oral administration with a bioavailability 
exceeding 90%9.  It is extensively metabolized, with up to 80% of the administered dose 
being recovered in feces, predominantly as metabolites10.  Imatinib is metabolized in vitro 
principally by cytochrome P450 (CYP) 3A4 and CYP3A5 with CYP1A2, CYP2C9, CYP2C19, and 
CYP2D6 playing a minor role8.  The main circulating metabolite of imatinib is an N-desmethyl 
derivative, CGP74588, which has in vitro activity similar to that of imatinib, and the systemic 
exposure represents approximately 10% to15% of that for imatinib10.  The pharmacokinetic 
profile of a single dose of imatinib is sensitive to CYP3A4 modulation, with a 74% and 30% 
reduction in imatinib area under the curve (AUC) observed with coadministration of the 
CYP3A4 inducers rifampin11 or St. John’s wort12, respectively, and a 40% increase in imatinib 
AUC observed with coadministration of the CYP3A4 inhibitor ketoconazole8. Interestingly, 
imatinib itself is known to decreased the clearance of simvastatin, a CYP3A4 substrate, by 
70% in patients with chronic myelogenous leukemia13.
Because imatinib is a substrate for CYP3A4, there is great potential for drug interactions with 
co-administered drugs, food, and herbal and nutritional supplements potentially leading 
to subtherapeutic exposure or concentrations associated with greater than acceptable 
toxicity for imatinib14, 15.  The prescribing information for imatinib mesylate indicates a need 
for caution when imatinib is administered with inhibitors and inducers of CYP3A4, based 
on drug interaction studies involving single-dose administration of imatinibi.  However, it is 
unknown if similar drug interactions occur when imatinib concentrations are at steady-state. 
The purpose of this study was to evaluate the effect of acute administration of ritonavir, a 
potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib.
i  Novartis Pharma Stein AG, Gleevec (imatinib mesylate): prescribing information [accessed 2007 July 31]. 




















































mL.  Analytes were extracted from plasma by protein precipitation with 10% perchloric acid. 
Separation was achieved on a column (4 × 125 mm internal diameter) packed with 5-µm 
particle size Nucleosil C18.  The mobile phase consisted of a mixture of acetonitrile-water 
(20:80, v/v) containing 0.05% trifluoroacetic acid and was delivered isocratically at a flow rate 
of 1 mL/min.  Imatinib eluted at 5.5 ± 0.2 minutes, and CGP74588 eluted at 4.4 ± 0.1 minutes. 
The metabolite CGP74588 was quantitated indirectly using the imatinib calibration curve at a 
wavelength of 270 nm.  A small amount of CGP74588 was available to confirm the retention 
time and to ensure the peak areas of imatinib and CGP74588 were similar (within 90-110% 
of each other) at a concentration of 10 µmol/L.  Over 4 days of validation, the within- and 
between-day precision was always < 10%.
Ritonavir plasma concentrations were measured using a validated method based on high-
performance liquid chromatography with UV detection as described previously, with minor 
modifications18.
Non-compartmental analysis.  Individual plasma concentrations of imatinib, CGP74588, 
and ritonavir were analyzed by noncompartmental methods using WinNonlin version 5.0 
(Pharsight, Inc., CA, USA).  Pharmacokinetic variables assessed included peak concentration 
(Cmax), AUC during the dosing interval (0-24 h), and apparent oral clearance (CL/F), calculated 
as dose/AUC.  To account for the 50% reduction in imatinib dose between days 1 and 4, Cmax 
and AUC for imatinib and CGP74588 on both days 1 and 4 were normalized to an imatinib 
dose of 400 mg.  The relative extent of conversion of imatinib to CPG74588 was calculated as 
the AUC ratio of CPG74588 to imatinib and expressed as a percentage.
Modeling conditions.  To more accurately account for variations in drug doses and to apply 
a more formal method for estimating CL/F values, additional analyses were done with 
the first-order conditional estimation method in the NONMEM program, version VI (Icon 
Development Solutions).  Exponential variable distributions were used with exploration of 
off-diagonal elements (covariances). An additive residual error model following log transfor-
mation of imatinib concentrations was used. Identification of a structural model was initially 
done using the imatinib data obtained on day 1.   The same model was then applied to 
all imatinib data (days 1 and 4), and the variables were reestimated.  Next, a dichotomous 
covariate was introduced (RITA), which was given the value zero before the first ritonavir 
dose and the value one thereafter.  The basic model using all data was compared to a model 
where CL and/or bioavailability (F) were allowed to change with the value of RITA.  A change 
in CL would affect CL/F only, whereas a change in F would affect both CL/F and the apparent 
volume of distribution (V/F).  Based on anticipated changes in imatinib pharmacokinetic 
variables, the effect of RITA was constrained to potentially decrease CL and/or an increase 
F.  The basic model was then refined by introducing interoccasion variability, where each 
Methods
Patients.  Eligibility for study entry included a histologically or cytologically confirmed 
diagnosis of gastrointestinal stromal tumor.  Patients had to be on single-agent imatinib 
treatment for at least 2 months and receive a daily dose of at least 400 mg.  Patients were ≥ 18 
years old, HIV negative, and had a WHO performance status ≤ 2.  Patients were not allowed 
to have been in surgery within four weeks before entering the study protocol nor experience 
gastrointestinal toxicity on imatinib treatment during the last 2 weeks before enrollment. 
Concurrent use of substances known or likely to interfere with the pharmacokinetics of 
imatinib was not allowed.  All patients had adequate clinical functional reserves as defined 
by absolute neutrophil count > 1.5 × 109/L, platelets > 100 × 109/L, creatinine clearance 
> 65 mL/min, and bilirubin < 1.75 × the upper limit of institutional normal.  The study was 
approved by the institutional ethics committee (Leiden University Medical Center, Leiden, 
The Netherlands), and all patients gave written inform consent before entering the study. 
Study design. The study was designed to evaluate the effect of ritonavir on imatinib 
 pharmacokinetics at steady-state.  All patients were treated daily, for at least 2 months, with 
commercially available imatinib mesylate film-coated tablets (Novartis International AG) at an 
oral dose ranging between 400 and 800 mg.  The study was done over 5 consecutive days. 
Ritonavir at a dose of 600 mg (6 capsules of 100 mg; Abbott Laboratories) was coadministered 
on days 2, 3 and 4 of the study, ∼ 30 min before the planned administration of imatinib.  The 
selected dose and schedule of ritonavir are associated with significant inhibition of CYP3A416, 
17.  On days 2 to 4 during coadministration of ritonavir, the dose of imatinib was reduced 
by 50% for safety reasons.  On the 5th day of the study, patients returned to receiving the 
imatinib dose they were taking before entering the study. 
Pharmacokinetic sampling and analytical assays.  Blood samples were collected on the 
1st and 4th day of the study for assessment of imatinib and ritonavir pharmacokinetics.  Blood 
was collected into heparin-containing tubes at the following time points: before treatment 
and after imatinib administration at 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours.  Blood samples were 
centrifuged at 3,000 x g for 10 min and plasma was divided into two tubes, one each for 
imatinib and ritonavir pharmacokinetics, and stored at –20˚C until the day of analysis.
Imatinib and CGP74588 concentrations in plasma were measured using a validated method 
based on reversed-phase high-performance liquid chromatography with UV detection at 
a wavelength of 270 nm using a Water 2690 Alliance Separation Module and 2487 UV/Vis 
Dual Wavelength Detector (Waters Corp.).  Each analytical run included a calibration curve 
of imatinib spiked in plasma over the concentration range of 0.2 to 10 µg/mL and quality 




















































to be statically significant.  Calculations were done using the software package Number 
Cruncher Statistical Systems, version 2005 (NCSS, J. Hintze).
Results
Patients.  Twelve patients with a diagnosis of gastrointestinal stromal tumor were enrolled 
on the study, and 11 were evaluable for pharmacokinetic analysis (Table 1).  One patient did 
not take the ritonavir dose on days 2, 3 and 4 and was excluded from analysis.  No severe or 
unexpected side effects were observed during the concurrent administration of imatinib 
and ritonavir for 3 days. 
Imatinib pharmacokinetics.  Ritonavir did not significantly alter the steady-state exposure 
to imatinib with dose-normalized geometric mean AUC values (95% confidence interval) 
on days 1 and 4 of 42.6 (33.0 – 54.9) μg·h/mL and 41.2 (32.1 – 53.1) μg·h/mL, respectively 
(P = 0.65; Table 2; Fig. 1).  Imatinib dose-normalized Cmax and CL/F values were also 
unchanged after 3 days of ritonavir administration. However, ritonavir administration 
resulted in a > 40% increase in plasma exposure to CGP74588, with mean values for 
CGP74588 to imatinib AUC ratio on days 1 and 4 of 16.8% (14.6 – 19.4%) and 24.0% 
(19.9 – 29.0%), respectively (P < 0.0001; Table 2; Fig. 1).
Population analysis.  A one-compartment model with linear elimination and first-order 
absorption adequately described the imatinib concentration-time data, and a two-compart-
dosing interval was treated as a new occasion.  This model was further refined by allowing 
the morning trough samples to have a different (higher) residual variability magnitude 
compared with other samples.  As an alternative to the dichotomous RITA covariate, the 
predicted ritonavir concentration was evaluated.  This was based on individual predictions 
from a linear one-compartment model with first-order absorption and an absorption lag time 
(not shown).  It was hypothesized that ritonavir potentially could increase F and/or decrease 
CL, this time via maximum-effect models.  Identification of the best structural model and 
subsequent improvement of the model was based on differences in the objective function 
value (∆OFV) from the NONMEM output and on interpretation of diagnostic plots using the 
Xpose program, version 4 (Uppsala University, Uppsala, Sweden).
In vitro metabolism studies.  The in vitro metabolism of imatinib and CGP74588 (50 µmol/L 
each) was determined using human CYP3A4, CYP3A5, CYP1A2, CYP1A1, CYP2D6, CYP2C9 and 
CYP2C19 Supersomes (10 – 160 pmol/mL) and pooled human liver microsomes (1.6 mg/mL; 
Gentest, BD Biosciences).  The effect of 30 min coincubation of ritonavir (0.1 – 20 µmol/L) 
with imatinib on the formation of CGP74588 from imatinib (50 µmol/L), as well as the effect 
of imatinib (1 – 20 µmol/L) on the formation rate of 1-OH-midazolam from midazolam 
(10 µmol/L) was assessed in CYP3A4 Supersomes and pooled human liver microsomes. 
Reaction mixtures were made in duplicate and consisted of 1.3 mmol/L NADP+, 3.3 mmol/L 
glucose-6-phosphate, 0.4 units/mL glucose-6-phosphate dehydrogenase, 3.3 mmol/L 
magnesium chloride, 50 µmol/L sodium citrate, and 100 mmol/L potassium phosphate 
buffer in a total volume of 0.2 mL (pH 7.4).  Reaction mixtures were incubated for 30 min at 
37˚C and terminated by adding 100 µL of acetonitrile and centrifugation at 14,000 rpm at 4°C 
for 10 min.  The supernatant was analyzed for imatinib, CGP74588 and any other unknown 
metabolites absorbing at 270 nm as described above with minor modifications.  Using 
this modified assay, imatinib and CGP74588 eluted at approximately 12.0 and 9.5 minutes, 
respectively.  Like CGP74588, concentrations of unknown metabolites were quantitated by 
interpolation on the imatinib calibration curve.  Column effluents containing suspected 
unknown metabolites were subjected to high-performance liquid chromatography analysis 
with tandem mass spectrometric detection in the scan mode using a Micromass Quattro 
LC triple-quadrupole mass spectrometer (Waters) to obtain initial structural information. 
Midazolam and 1-OH-midazolam were analyzed in supernatant using a previously described 
method based on high-performance liquid chromatography with tandem mass spectro-
metric detection19.  
Statistical considerations.  Data are presented as a geometric mean along with 95% 
confidence intervals, unless stated otherwise.  Statistical analysis was based on a two-tailed 
paired t-test of logarithmically transformed data, and P values of < 0.05 were considered 
Table 1  Patient characteristics 
Characteristic Value
Number of patients 11
 Sex (female / male)  6 / 5
 Age, years a 62 (51 – 79)
Baseline renal and liver function parameters a 
 Creatinine, μM 86 (70 – 95)
 Total bilirubin, μM 7 (6 – 24)
 ALT, units/L 20 (9 – 27)
 AST, units/L 32 (22 – 45)
 Gamma-glutamyltransferase, units/L 16 (9 – 38)
 Alkaline phosphatase, units/L 85 (61 – 112)
 




















































Ritonavir pharmacokinetics.  On day 4, the mean Cmax and AUC values of ritonavir were 
14.7 ± 6.3 µg/mL and 85.3 ± 23 μg·h/mL, respectively, which are similar to those previously 
published for ritonavir in drug interaction studies to inhibit CYP3A4 when it was adminis-
tered to enhance the oral absorption of antiretroviral agents20, 21.
In vitro metabolism studies.  Imatinib was metabolized to CGP74588 by CYP3A4 and 
CYP3A5, and to a lesser extent by CYP2D6, with CYP1A1 having minor involvement (Fig. 2A 
and B).  Imatinib was also converted to a metabolite with a retention time of 5.5 min by 
CYP3A4 and CYP1A1, with a minor fraction formed by CYP3A5 and CYP2D6 (Fig. 2C).  The UV 
ment model did not significantly improve the fit (ΔOFV = 7.3; P > 0.05).  For the one-compart-
ment model, CL/F (percent interindividual variability) was estimated to 9.18 ± 0.95 L/h (33%), 
the apparent volume of distribution to 225 ± 31 L (38%), and absorption rate constant to 
1.64 ± 0.39 h-1 (38%).  The estimate of CL/F obtained when applying the same model to all 
imatinib data was 9.99 ± 1.05 L/h.  Introduction of the dichotomous covariate RITA did not 
offer an improvement of the model compared with the basic model (ΔOFV = 0.0; P > 0.05). 
Introducing interoccasion variability into the basic model resulted in a significant decrease in 
ΔOFV of 121.1 (P < 0.001) and provided an estimate for CL/F of 9.40 ± 1.16 L/h.  This model was 
further refined by allowing the morning trough samples to have a higher residual variability 
magnitude compared to other samples (ΔOFV = 34.7; P < 0.001), with an error magnitude of 
42.3% for morning trough samples and 10.2% for all other samples.  To this refined model, 
the influence of RITA on CL and/or F was again tested, but the improvement in the model 
fit was negligible (ΔOFV = 0.3; P > 0.05).  Similarly, a model that incorporated a predicted 
ritonavir concentration offered no improvement in the description of imatinib data (ΔOFV 
= 0.0; P > 0.05).
Table 2  Pharmacokinetic parameters obtained with non-compartmental analysis 
Parameter a,b Day 1 Day 4 Day 4 / Day 1 ratio P
  (imatinib alone) (imatinib with ritonavir) 
Imatinib    
Cmax, μg/mL
 2.88 2.50 0.869 .072
  (2.27 – 3.65) (1.93 – 3.24) (0.744 – 1.02) 
AUC, µg·h/mL
 42.6 41.2 0.969 .65
  (33.0 – 54.9) (32.1 – 53.1) (0.835 – 1.125)
CL/F, L/h
 9.40 9.69 1.032 .65
  (7.29 – 12.1) (7.53 – 12.5) (0.889 – 1.198) 
CGP74588    
Cmax, μg/mL
 0.467 0.521 1.050 .52
  (0.356 – 0.612) (0.411 – 0.661) (0.893 – 1.235)
AUC, µg·h/mL 7.16 9.92 1.385 .0023
  (5.74 – 8.93) (7.85 – 12.5) (1.159 – 1.656)
CGP74588/imatinib  16.8 24.0 1.429 <.0001
AUC ratio, % (14.6 – 19.4) (19.9 – 29.0) (1.317 – 1.551)
a Values are geometric mean with 95% confidence interval in parenthesis; P-values were obtained from a paired 
t-test. b Cmax and AUC values are normalized to an imatinib dose of 400 mg.  















































Days of measurement 
Imatinib dose normalized area under the concentration-time curve (AUC) (A) and CGP74588 to imatinib AUC ratio 




















































spectrum of this unknown compound indicated the presence of at least two metabolites. 
Analysis by mass spectrometry suggested that one of the metabolites formed from imatinib 
is AFN911, whereas the other could be CGP72383 or CGP71422 or a combination of both, as 
described previously10.  No biotransformation of imatinib was observed by CYP1A2, CYP2C9 
and CYP2C19 (Fig. 2A-C).  CGP74588 was less sensitive to CYP-mediated metabolism, but 
an unknown metabolite at a retention time of 4.3 min was observed in the presence of 
CYP3A4 and CYP1A1 (Fig. 2D).  The UV spectrum of this unknown metabolite also indicated 
the presence of two or more compounds, and mass-spectral analysis suggested that these 































































































































































































































































































































































































In vitro metabolism of imatinib (A-C) and CGP74588 (D-E) by different cytochrome P450 (CYP) isoforms.  





















































This study shows that acute inhibition of CYP3A4 by the potent enzyme inhibitor ritonavir 
does not result in a substantial pharmacokinetic interaction with imatinib at steady state. 
These data not only emphasize the need to consider appropriate trial designs to evaluate 
the plausibility of pharmacokinetic interactions in the development of anticancer drugs that 
require daily chronic dosing but also have direct clinical relevance for chemotherapeutic 
treatment with imatinib.
It was previously established that the most prominent pathway of imatinib elimination 
consists of CYP3A4-mediated metabolism leading to the formation of CGP74588 and 
several other metabolites8.  This suggested that imatinib was potentially subject to a host of 
enzyme-mediated drug interactions with commonly prescribed medications14.  Indeed, the 
prototypical CYP3A4 inhibitor ketoconazole has been shown to inhibit the CL/F of imatinib 
by 40% in healthy volunteers after single-dose imatinib administration8.  This led to the 
concern that some degree of interaction is to be expected with simultaneous administration 
of other potent CYP3A4 inhibitors with imatinib and that concurrent administration should 
be avoided or that dose adjustments for imatinib should be consideredi.
In consideration of prior knowledge8, the current observation that acute inhibition of CYP3A4-
mediated metabolism by ritonavir does not lead to substantially altered imatinib steady-state 
exposure was somewhat unexpected.  In particular, ritonavir is generally considered to have 
similar CYP3A4-inhibitory potency as compared with ketoconazole22, and hence, it is unlikely 
Ritonavir concentrations of 1 µmol/L and higher completely inhibited the metabolism of 
imatinib to CGP74588 by CYP3A4 (Fig. 3A).  However, in pooled human liver microsomes only 
50% inhibition of imatinib metabolism by ritonavir was noted at 1 µmol/L, and ∼ 80% inhibition 
at the highest ritonavir concentration tested (Fig. 3B).  This suggests the involvement of other 
CYPs in imatinib metabolism when CYP3A4 function is inhibited.  Finally, imatinib concentra-
tions of 1 µmol/L and higher inhibited the metabolism of midazolam to 1-OH-midazolam 
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Influence of ritonavir on the in vitro metabolism of imatinib by human liver microsomes (A) and cytochrome P-450 
(CYP) 3A4 (B).  Experimental details are provided in the Methods section.
Table 3  Effect of imatinib on 1-OH-midazolam formation rate
 in human liver microsomes and by CYP3A4a
 
Imatinib Concentration (μM) 1-OH-midazolam formation rate (% control) b
CYP3A4 
 1 μM 92.3
 5 μM 86.4
 20 μM 57.1
Liver microsomes 
 1 μM 64.7
 5 μM 60.9
 20 μM 56.8
a Midazolam concentration used was 10 μM.  Experimental details are provided in the Methods section.




















































decreasing the amount of drug absorbed after oral intake due to their localization on the 
apical surface of intestinal epithelial cells31, 32.  Furthermore, these efflux transporters may 
alter systemic drug elimination, as they are expressed in proximal renal tubular cells and on 
the biliary surface of hepatocytes32.  Indeed, inhibitors of ABCB1 and ABCG2 function, such as 
elacridar and pantoprazol, have been shown to significantly reduce the systemic clearance of 
imatinib in mice33.  Because ritonavir is a known inhibitor of both ABCB1 and ABCG234, 35, the 
current data suggest that modulation of the activity of these transporters in humans would 
not result in substantially altered exposure to imatinib under steady-state conditions.
In conclusion, this study suggests that acute inhibition of CYP3A4 by ritonavir does not result 
in increased steady-state plasma concentrations of imatinib.  The current findings suggest 
that the warning in the prescribing information for imatinib related to the concomitant use 
of substrates or inhibitors of CYP3A4 should be reconsidered.  Furthermore, the design of 
drug interaction studies with novel agents that require continuous administration should 
consider additional evaluation at steady-state.
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that the degree of interaction between imatinib at steady-state and inhibitors of CYP3A4 
other than ritonavir would be more substantial than that observed in the current study.
To reconcile the apparent inconsistencies with reported studies on the drug interaction 
potential of CYP3A4 inhibitors given in combination with imatinib, several additional in vitro 
experiments were done.  We found that ritonavir completely inhibited the metabolism of 
imatinib in CYP3A4 expression system but had only a limited effect on imatinib biotrans-
formation in human liver microsomes.  This suggests that the lack of pharmacokinetic 
interference with ritonavir might be the result of inhibition of only one of multiple enzymes 
involved in the hepatic metabolism of imatinib, which results in shunting of parent drug 
to alternative elimination pathways.  The present study also showed that imatinib itself is a 
potent inhibitor of CYP3A4 in vitro, and it is plausible that, at steady state, continuous admin-
istration of imatinib causes auto-inhibition of the primary metabolic pathway (CYP3A4) and 
that the presence of another modulator of this route does not result in additional changes in 
systemic exposure to imatinib.
It should be pointed out that the effect of ritonavir on CYP3A4 activity may be time 
dependent.  Although acute exposure to ritonavir inhibits CYP3A4, extended daily adminis-
tration of ritonavir may induce CYP3A4.  For example, exposure to ritonavir for 7 days or more 
increased the clearance of the CYP3A4 substrate drugs methadone, alprazolam, mefloquine, 
dapsone, and cortisol20, 23-25.  Several recent trials have evaluated the effects of acute and 
extended exposure to ritonavir on CYP3A activity in the same individuals.  In contrast to 
previous studies, 200 mg ritonavir given twice daily for three doses (acute exposure) and 
for 10 days (extended exposure) increased the AUC of triazolam, a CYP3A4 probe drug, by 
50-fold and 20-fold, respectively16.  Likewise, acute and extended exposure to 200 mg ritonavir 
twice daily increased exposure to midazolam, a CYP3A4 substrate probe, by up to 50-fold17. 
If induction does occur, it is likely that ritonavir exposure for more than 10 days is required 
for this phenomenon.  Therefore, the present observations may not be extrapolated to the 
situation where imatinib is coadministered with ritonavir for an extended period of time.
Interestingly, ritonavir may also affect CYP2C9 and CYP2C19 activity20, but this may not be of 
concern clinically, because CYP2C9 and CYP2C19 seem to play only a minor role in imatinib 
metabolism (Fig. 2).  Compared with imatinib, the in vitro experiments indicated that the 
catalytic activity and the relative affinity of CGP74588 for CYP3A4 were substantially weaker. 
However, subsequent elimination of CGP74588 seem to be highly dependent on the activity 
of CYP3A4, and therefore, this metabolite is likely to be more sensitive to an acute interaction 
with ritonavir.  This hypothesis is consistent with the current observation that the systemic 
exposure to CGP74588 was increased by ritonavir (Table 2).
It is noteworthy that imatinib is also both a substrate and an inhibitor for the ATP-binding 
cassette transporters ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)26-
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Effect of cigarette smoking on 
pharmacokinetics, safety and efficacy of 
imatinib: a study based on data of the Soft Tissue 


































































































Purpose:  Smoking is a potent inducer of cytochrome  P450 (CYP) 1A2 and may affect 
the pharmacokinetics of CYP1A2 metabolized drugs. The effect of smoking on the 
pharmacokinetics of imatinib, which is metabolized by CYP3A4 and partly by CYP1A2, 
is unknown. We studied the effect of smoking on imatinib pharmacokinetics, safety, and 
efficacy.
Experimental Design:  Imatinib pharmacokinetics, safety, and efficacy were analyzed in 45 
patients with gastrointestinal stromal tumors (GIST) or soft-tissue sarcoma included in two 
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma 
Group trials, including 15 smokers and 30 nonsmokers. Apparent oral clearance, distribution 
volume, elimination half-life, and dose-standardized area under the concentration curve 
(AUC) were assessed in 34 patients using nonlinear mixed-effect modeling.
Results:  Mean ± SD pharmacokinetic variables in smokers (n  = 9) versus nonsmokers 
 (n = 25) groups were 9.6 ± 5.5 versus 9.2 ± 4.6L/h (apparent oral clearance), 216.5 ± 114.3 
versus 207.0 ± 116.9 L (distribution volume), 16.1 ± 6.0 versus 16.5 ± 6.0 h (elimination half-
life), and 133.6 ± 71.0 versus 142.3 ± 84.0 ng·h/mL·mg area under the concentration curve; 
P > 0.05. Smokers experienced more grade 2/3 anemia (P = 0.010) and fatigue (P = 0.011) and 
those with GIST had a significantly shorter overall survival (P = 0.037) and time to progression 
(P = 0.052).
Conclusions: This retrospective study suggests that the pharmacokinetics of imatinib is 
not affected by smoking. However, smokers have an increased risk of anemia and fatigue. 
Smokers with GIST have a shorter overall survival and time to progression.
Introduction
Tobacco smoking is a major problem for public healthi. Despite all the attention paid to the 
negative effects of smoking cigarettes by the medical profession and media, its prevalence 
remains highii. Between 2002 and 2005, ∼ 34% and 23% of men and women,  respectively, 
smoked in the European Unioniii. The smoking prevalence in the United States is similar, 
with estimates of 24% to 32% of men and 18% to 21% of women smoking1. Among the 
various biological effects, tobacco smoke induces several drug-metabolizing enzymes. 
One of the constituents in tobacco smoke known to be involved in the induction of 
 cytochrome P450 (CYP) 1A1, 1A2, 2E1 and UDP-glucuronosyltransferases are the polycyclic 
aromatic hydrocarbons, a product of incomplete combustion of organic matter2. CYP1A1 
and CYP1A2 are involved in the metabolism of a variety of drugs. By inducing these CYPs, 
 smoking can interfere with the pharmacokinetics of many drugs. The most extensively 
 described  pharmacokinetic interaction between smoking and drug clearance is that 
of  clozapine, which is primarily metabolized by CYP1A23-5. However, in addition, the 
metabolism of drugs that are not predominantly metabolized by CYP1A2 can be influenced 
by smoking. For example, erlotinib is principally metabolized by CYP3A4 and to a minor ex-
tent, by CYP1A2. Smoking has been shown to increase the clearance of erlotinib by 23.5% 
and may therefore reduce the efficacy of the drug in patients with non-small-cell lung 
cancer6. Likewise, imatinib, also a receptor tyrosine kinase inhibitor, is principally 
metabolized by CYP3A4 and CYP3A5 with CYP1A1, CYP1A2, CYP2C9, CYP2C19, and CYP2D6 
playing a secondary role7, 8. However, the role of CYP3A4 in imatinib metabolism is under 
discussion since acute inhibition of CYP3A4, by the potent CYP3A4 inhibitor ritonavir, did 
not result in a substantial change in the PK of imatinib at steady-state exposure levels 8. 
This might be a result of the activity of other CYP enzymes, which while playing only a 
secondary role in in vitro experiments become the principal catabolic enzymes when the 
main metabolic route is blocked. Induction of an enzyme that only plays a secondary role 
in the metabolism of imatininb might likewise result in a shift in importance of the individual 
CYPs.   
Therefore, we aimed to explore the effect of smoking on the pharmacokinetics of imatinib 
as a primary endpoint and the effect of smoking on adverse events and treatment outcome 
as secondary endpoints.
i  European Commission. Tobacco and Health in the European Union. Visited Sept 2007  
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/tobacco_fr_en.pdf
ii  Lopez AD, Collishaw N.E., Piha T.A. Tobacco Control Country Profiles. Visited Sept 2007  
http://www.who.int/tobacco/statistics/country_profiles/en/Introduction.pdf



































































































Blood samples were taken for pharmacokinetic analysis as described in the phase I and II 
studies. On day 1 blood samples were taken pre-dose, and 1, 2, 3, 4, 8, 12, 14 and 24 h after 
dosing for patients receiving one daily dose. For patients being dosed twice daily, the 12 h 
sample was taken after the first dose, just before the second dose, and the 14 h sample 2 h 
after the second dose. In both groups of patients, the 24 h sample was before the second and 
the third dose of imatinib respectively9, 11.
The plasma imatinib concentrations were determined in the Novartis USA bioanalytical 
laboratory using a validated liquid chromatography-tandem mass spectrometry assay14.
The pharmacokinetic variables were estimated with a one-compartment model with 
zero-order absorption and first-order elimination. The model was developed with non linear 
mixed-effect modeling in the study of Judson et al. The following pharmacokinetic variables 
were estimated: volume of distribution (Vd), apparent oral clearance (Cl/F), elimination half 
life (t1/2), and absolute and dose-standardized area under the concentration time curve 
(AUC). Details on the model can be found in the original article12. 
Statistics
The estimated pharmacokinetics variables were compared between the smoker and non-
smoker populations using the Student’s t-test. The maximum grades of observed toxicities 
were compared between those populations using a Cochrane-Armitage χ2 test for trend; if 
this test was significant, the probability of undergoing a grade ≥ 2 toxicity was analyzed in 
a logistic model including the initial imatinib daily dose and the smoking status; if this test 
was significant, the probability of undergoing a grade ≥ 2 toxicity was analyzed in a logistic 
model stratified by imatinib daily dose. The time to progression and overall survival were 
compared between smokers and non-smokers using the log-rank test. All statistical tests were 
done two-sided with rejection of the null hypothesis at P < 0.05. All statistical analyses were 
performed using SAS, version 9.1 for Windows (SAS Institute). The sample size was based 
on the available data. A retrospective power computation shows that the study had a 69% 
power to detect a 50% elevation of the Cl/F calculated with a two-sided t-test and a 62% 
power to detect a 50% decrease of the dose-standardized AUC.
Results
Smoking data were available for 45 patients and pharmacokinetic data for 34 of these. 
Therefore, correlation of the smoking status with pharmacokinetics, the primary endpoint, 
is based on the analysis of 34 cases, whereas the correlation of the smoking status with 
treatment outcome, the secondary endpoint, is based on 45 patients. In the group of 
Materials and methods
Patients and treatment
A total of 91 patients were included in 2 European Organisation for Research and Treatment 
of Cancer Soft Tissue and Bone Sarcoma Group phase I and II trials of imatinib in patients 
with gastrointestinal stromal tumors (GIST) and other soft-tissue sarcomas9-11.  Smoking 
data were only available for 45 patients; pharmacokinetic data were available for 34 of these 
patients. The patients from three centers (Leuven, Belgium; London, United Kingdom; and 
Rotterdam, The Netherlands) were included in this retrospective analysis9-12. Eligible patients 
had histologically proven soft-tissue sarcomas, and those with GISTs were required to be 
KIT positive by CD117 expression on immunohistochemical staining. Patients had to have 
a measurable lesion with evidence of progression of < 6 weeks before treatment. Previous 
chemotherapy was allowed, but had to be discontinued for at least 4 weeks. Additional s 
elected eligibility criteria for inclusion were WHO performance status of ≤ 2; adequate 
haematological, renal, and hepatic function; no other severe illness; and no concomitant use 
of coumarin, other investigational drugs, or systemic corticosteroid therapy; before patient 
registration, written informed consent was given according to the International Conference 
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use/European Union-Good Clinical Practice and national-local regulations. 
Patients were treated with imatinib 400 mg once daily (7 patients), 300 mg twice daily 
(7 patients), 400 mg twice daily (25 patients), or 500 mg twice daily (6 patients). All toxicities 
were graded using the National Cancer Institute Common Toxicity Criteria version 2.0.  
Smoking status
Patients were categorized as smokers or non-smokers based on information collected and 
 recorded before study entry. If the smoking behavior was not clearly described in the 
medical record, the patients were excluded from analyses. In the de novo analysis, we divided 
the patients in two groups: ever versus never smokers. The rationale for this is that it is unclear 
for how long after cessation smoking could influence the toxicity profiles and overall survival 
as well as other clinical endpoints such as time to progression. In contrast, with regard to 
 alteration of pharmacokinetic variables by smoking, the a priori hypothesis is that smoking 
 induces CYP1A2. In that case, it is clear that the influence of smoking will last for a  maximum 
of 9 days, because the half life of CYP1A2 is estimated to be ∼ 38.6 h after smoking cessation13. 
In the sensitivity analysis, we have studied the possible effect of the two different ways of 
 categorization and repeated the analysis with the criterion of current smokers. In fact, two 
patients who were classified as ever smokers stopped smoking >1 year before imatinib 
 therapy started. This analysis showed that the two different ways of categorization did not 

































































































Smoking and imatinib toxicity
The maximum grade of the principal toxicities observed in the study has been tabulated for 
non-smokers and smokers (Table 4). Grade 2/3 fatigue and anemia were more frequently 
observed in smokers (P = 0.0493 and P = 0.0258, respectively). The probability of grade 2/3 
fatigue and anemia remained higher in smokers after adjustment for the imatinib dose 
(logistic model adjusted by dose, P=0.011 and 0.010, respectively).
Smoking and time to progression and overall survival
In the entire population (n = 45), non-smoking patients showed a favorable but non 
 significant difference in the overall survival analysis (P = 0.12) but not in the time to 
progression (P = 0.36). However, in GIST patients, nonsmokers showed a favorable time 
to progression (P = 0.052) and overall survival (P = 0.037; Figs. 1 and 2)
45 patients with smoking data 15 patients were categorized as smokers and 30 were 
 categorized as non-smokers. The patient characteristics and the distribution of the smokers 
and the non-smokers over the different treatment arms are listed in Tables 1 and 2.
Smoking and imatinib pharmacokinetics
The imatinib exposure in smokers versus non smokers was not significantly different; the 
mean ± SD dose-standardized AUC was 133.6 ± 71.0 ng·h/mL·mg in smokers versus 142.3 
± 84.0 ng·h/mL·mg in non-smokers (P = 0.78); the mean Cl/F was 9.6 ± 5.5 L/hr in smokers 
versus 9.2 ± 4.6 L/hr in non-smokers (P = 0.84); the volume of distribution (Vd) was 216.5 
± 114.3 L in smokers versus 207.0 ± 116.9 L in non-smokers (P = 0.84) and the half life (t1/2) 
was 16.1 ± 6 h in smokers versus 16.5 ± 6 h in non-smokers (P = 0.87; Table 3).  
Table 1  Patient characteristics 
  Smokers (n=15) Non-smokers (n=30) Total (n=45)
Sex    
 Male 10 18  28 
 Female 5  12 17 
Age group    
 <40 3  5 8
 40-50 2 9 11
 50-60 7 9 16
 60-70 3 7 10
Weight   
 Median (range) 77.0 (46.2 - 104.7) 70.3 (30.6 – 102.2) 70.4 (30.6 – 104.7)
Prior chemotherapy   
 No 6 15 21
 Yes 9 15 24
GIST   
 No 2 9 11
 Yes 13 21 34
Age   
 Median (range) 55.1 (35.9 – 67.7) 50.7 (21.0 – 69.9) 51.3 (21.0 – 69.9)
Time since diagnosis   
 Median (range) 430 (9.0 – 5694.0) 476 (28.0 – 1933.0) 430 (9.0 – 5694.0)
Haemoglobin   
 Median (range) 7.8 (5.7 – 10.4) 8.0 (5.7 – 9.8) 7.9 (5.7 – 10.4)
White Blood cell Counts   
 Median (range) 7.4 (4.5 – 11.3) 6.1 (4.0 – 17.1) 6.4 (4.0 – 17.1)
Creatinine clearance    
 Median (range) 79.3 (26.4 – 140.8) 82.2 (41.2 – 146.7) 81.7 (26.4 – 146.7)
Table 2  Distribution of smokers and non-smokers in the different treatment groups 
  Smokers  Non-smokers
400 mg od
 1 6
  6.7% 20%
300 mg bid
 3 4
  20% 13.3%
400 mg bid
 7 18
  47.7% 60%
500 mg bid
 4 2


































































































Table 4  Effect of smoking on imatinib induced toxicities  
   Smokers  Non-smokers P value
Variables  (n = 15) (n = 30)
Edema Grade 0 1 3 0.1106
  Grade 1 5 19 
  Grade 2 9 7 
  Grade 3 0 1 
Fatigue Grade 0 1 6 0.0493
  Grade 1 2 13 
  Grade 2 11 8 
  Grade 3 1 3 
Dyspnea Grade 0 9 24 0.2251
  Grade 1 1 0 
  Grade 2 4 5 
  Grade 3 1 1 
Rash Grade 0 3 3 0.0628
  Grade 1 10 16 
  Grade 2 2 7 
  Grade 3 0 4 
Infection Grade 0 10 16 0.4071
  Grade 1 2 6 
  Grade 2 3 7 
  Grade 3 0 1 
Leukopenia Grade 0 5 7 0.4125
  Grade 1 5 9 
  Grade 2 3 9 
  Grade 3 2 5 
Neutropenia Grade 0 7 9 0.3581
  Grade 1 5 6 
  Grade 2 0 9 
  Grade 3 1 5 
  Grade 4 2 1 
Thrombocytopenia Grade 0 12 19 0.0346
  Grade 1 1 1 
  Grade 2 0 0 
  Grade 3 1 0 
  Grade4 1 0 
Anemia Grade 0 1 3 0.0258
  Grade 1 2 15 
  Grade 2 7 6 
  Grade 3 5 4
Figure 1 Time to progression in smokers versus non-smokers in GIST patients
Figure 2 Overall survival in smokers versus non-smokers in GIST patients
(years)
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olanzapine, flecainide and propranolol)2, 4, 20-23. Because our data do not show any effect of 
smoking on the pharmacokinetics of imatinib, we decided not to expand the study with 
additional patients.
The absence of an interaction between cigarette smoke and imatinib will most likely be 
explained by at best a minor role of CYP1A1 and CYP1A2 in imatinib pharmacokinetics in 
vivo. The pharmacokinetic data analyzed in this study were obtained after the first dose of 
imatinib. Because imatinib is a potent inhibitor of CYP3A4, one may hypothesize that at steady-
state pharmacokinetics, imatinib inhibits its own primary metabolizing CYP3A4 pathway and 
its metabolism is shunted to CYP1A1 and CYP1A224. We can only conclude from our data 
that metabolism through CYP1A1 and CYP1A2 is not important immediately after starting 
imatinib therapy, but we cannot exclude an effect of smoking at steady-state pharmo-
cokinetics. Also, other factors that are known to influence the apparent clearance of imatinib 
should be considered (α1-acid glycoprotein , albumin, body weight, hemoglobin and WBC 
counts)25-27. Elevated α1-acid glycoprotein levels are often seen in cancer patients and with 
increasing age12, 28. However, smoking does not significantly influence the α1-acid glycoprotein 
levels29. In our study, age, body weight, albumin, hemoglobin and WBC counts seems to be 
equally distributed between the two groups. α1-Acid glycoprotein was not measured, but we 
have no reason to believe that these factors are unequally distributed between the smoking 
and non-smoking groups. We studied the most prevalent imatinib toxicities: edema, fatigue, 
nausea, skin rash, anemia, infection, leucopenia, neutropenia and thrombocytopenia. 
Except for neutropenia, all toxicities have been shown to be highly dose dependent30. In our 
study, smokers received a higher mean dose of imatinib compared with nonsmokers, which 
could explain the higher incidence of toxicities in the former group. However, on adjustment 
for the imatinib dose using multivariate analysis, the increased risk of toxicity in smokers 
remained significant. Therefore, it is more plausible that the relation of smoking with toxicity 
is causal31.  
Interestingly, in patients treated for GIST with imatinib, smokers had a significant shorter 
time to progression and overall survival, which is obviously not explained by differences in 
imatinib exposure. A possible explanation may be that smokers harbor unfavorable somatic 
mutations that make the tumor less sensitive to the tyrosine kinase inhibitor and hence are 
related to a worse outcome. However, in 19 nonsmokers and 11 smokers, we detected a 
limited set of somatic mutations in cKIT exons 11, 9, 13 and PDGFRA exon 18 in the GIST 
tumors and found no differences between smokers and non-smokers (data not shown). 
In this study, we explored multiple outcomes that might introduce the risk for chance 
findings. The outcomes of this study are highly correlated (e.g., anemia and fatigue and time 
to progression and overall survival); however, they should be interpreted as hypothesis-
 generating and need confirmation. 
Currently, little is known of the effect of smoking on the metabolism of most anticancer 
Discussion
This study suggests that smoking does not affect the pharmacokinetics of imatinib. 
However, smoking did increase the risk of some toxicities such as grade ≥ 2 anemia and 
fatigue. Interestingly, in patients treated with imatinib for GIST, nonsmokers showed a 
favorable outcome with respect to both time to progression and overall survival.
To date, all interaction studies with imatinib have focused on its primary metabolizing 
enzyme, CYP3A4 (e.g., the description of the interactions with ketoconazole, rifampicin 
and St. John’s wort)15-17.  There is one study describing the relationship between genotypes 
encoding for CYP450 enzymes and ATP-binding cassette transporters thought to play a role 
in imatinib metabolism and transport, indicating that they do not appear to influence the 
pharmacokinetics of imatinib significantly in humans. However, the study did show that the 
Cl/F of orally administered imatinib was slightly reduced in carriers of at least one CYP2D6*4 
allele compared with individuals carrying two wild-type CYP2D6 alleles 18. This might indicate 
that CYP2D6 plays a more important role in imatinib metabolism in vivo than that observed 
in vitro. Imatinib can inhibit certain CYP450 enzymes; hence, although a substrate for CYP3A4 
and CYP3A5, it may also inhibit their action, directing metabolism towards other enzymes 
for which it is a less preferred substrate, such as CYP2D6 and CYP1A2. This emphasizes the 
importance of exploring the influence of enzymes in vivo that appear to only play a minor 
role in in vitro experiments.  
In the current retrospective study, smoking habits were retrieved from the medical 
record and were originally recorded following direct questions about smoking habits before 
 entering the study. We could not validate the smoking status of the patients by measuring 
the plasma cotinine levels because the plasma samples were not available anymore in this 
retrospective study. Because ∼10% of the patients report not to smoke while smoking, there 
is a chance of potentially misclassified patients19. However this would dilute the outcome of 
our study because their toxicity profile would be less favorable than the correctly classified 
patients and they also would negatively influence the time to progression and overall survival. 
Therefore, 10% misclassification would not influence the conclusion of our study. 
The specified smoking attitudes of the patients were not noted (e.g., how many tobacco-
containing units were consumed what type of tobacco product was used). Therefore, we 
defined smoking regardless of the quantity of cigarettes smoked per day. We excluded all 
patients from the analysis for whom the smoking status was not clearly noted, either 
positively or negatively, in the patients’ medical records. 
This study is marginally powered (69%) to detect a 50% elevation of the Cl/F of imatinib. 
Obviously, it could be suggested that a 50% decrease in exposure to a drug is a large effect. 
However, there are several interactions with cigarette smoking described, which resulted in 

































































































drugs. Since imatinib is a substrate for CYP1A2 and CYP1A1 in vitro7, 8, it was anticipated that 
smoking might have an effect on imatinib exposure comparable to erlotinib6. Recently, a 
significant effect of smoking was observed in irinotecan exposure, a chemotherapeutic drug 
not primarily metabolized by CYP1A1 and CYP1A232. This result emphasizes the importance 
of studying the effect of smoking on the pharmacokinetics of anticancer drugs, including 
those for which clearance by CYP1A1 and CYP1A2 is a minor metabolic route, given that ∼ 
30% of both female and male cancer patients smoke33. 
In conclusion, this exploratory study suggests that smoking is not associated with altered 
pharmacokinetics of imatinib and more specifically with reduced systemic drug exposure. 
However, it does show that smokers have an increased risk for grade ≥ 2 anemia and fatigue. 
GIST patients who smoke may experience a shorter overall survival and a shorter time to 
progression on treatment with imatinib, but this observation is hypothesis generating and 
warrants further exploration.
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A 52 year old woman with metastatic gastro-intestinal stromal tumor (GIST) presented herself 
in March 2006 with tumor-related intra-abdominal obstructions and diffuse intra-abdominal 
bleeding. Priorly, the metastatic GIST was successfully treated with 400mg imatinib since 
2002 but now appeared to be progressive again. The patient underwent palliative resection 
of multiple bleeding peritoneal tumor deposits. When confronted with GIST progression, as 
seen in this patient, the dose of imatinib should be elevated from 400 mg /day to 800 mg /
day 1. However, a major limitation for treatment in this patient was that, due to the gastro-
intestinal obstructions, she was unable to take anything orally, including the imatinib tablets 
for 8 days prior to surgery. Unfortunately, imatinib is available as a tablet formulation only. 
Therefore, in this patient we tested the rectal route of administration as an alternative way to 
administer the drug. 
The day following surgery, the patient received imatinib 400 mg b.i.d. with the imatinib 
oral tablets being administered rectally. After the fourth dose of imatinib given rectally we 
collected blood samples at t = 0, 1, 2, 3, 4, 5, 6, 8 and 10 hours. The patient volunteered 
in a pharmacokinetic study a year before 2. In the study, after informed consent, we 
collected steady state blood levels of imatinib at the same time points as described above, 
but after an oral dose of 400 mg imatinib. This enabled us to compare the area under the 
 concentration-time (AUC) curve following oral and rectal administration of imatinib in this 
patient. Plasma  concentrations of imatinib were analyzed at The Netherlands Cancer Institute 
by a validated HPLC-UV assay with a variation coefficient within the generally accepted 15% 
range and a lower limit of  quantification of 10ng/ml. AUC0-10hr after the oral  administration 
of 400 mg imatinib was 35,508 and it was 14,243 ng/ml *h after rectal administration 
(Figure 1) calculated by the trapezoidal method. Assuming relatively small intraindividual 
variation in pharmacokinetics, comparison of the AUCs indicates that at least 40% of 
the oral imatinib levels are reached by rectal administration. About 40% will be a slight 
 underestimation because steady-state conditions were not fully reached. The AUC after the 
fourth rectal dose was estimated at 80-90% of the steady-state AUC. 
The t1/2 of imatinib is ∼18 hours 3. In the 9 days before rectal administration of imatinib the 
body is cleared from imatinib. Therefore, the AUC measured after the fourth rectal dose of 
imatinib is solely produced by absorbance of imatinib from the rectum and is not influenced 
by the oral dose used before. 
The lack of alternative dosing forms of imatinib sometimes causes problems in clinical practice. 
Patients with GIST may show obstruction or narrowing of the gastro-intestinal tract causing 
problems to take food and drugs orally. These patients are unable to take imatinib treatment. 













































of imatinib could be a good alternative. Imatinib mesylate is a highly water soluble drug 
with a bioavailability of nearly 100% when taken orally 4. This characteristic readily predicts 
absorption from the rectal mucosa. Indeed, in the patient presented here, we demonstrated 
by plasma level measurement that imatinib could be administered rectally resulting in a 40% 
drug exposure. Therefore, doubling the dose is anticipated to reach a similar drug exposure 
compared to when given orally.
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Purpose: The objective of this study was to explore the feasibility of CYP3A4 phenotyping 
for dose  individualization of sunitinib. The relationship between CYP3A4 activity and 
sunitinib  exposure was assessed. Moreover, the impact of sunitinib exposure on CYP3A4 
activity was evaluated.
Patients and Methods: Sunitinib and midazolam pharmacokinetics were evaluated in 
cancer patients receiving sunitinib monotherapy in a “four weeks on - 2 weeks off” regimen. 
Serial blood samples for pharmacokinetic analysis of midazolam and sunitinib were collected 
on two separate days. On both PK days the patients received a single oral dose of 7.5 mg 
midazolam as a CYP3A4 phenotyping probe. The first PK day was at steady-state sunitinib 
pharmacokinetics (between day 14-20), the second PK day was after two weeks wash out 
of sunitinib (day 42). The influence of sunitinib on midazolam exposure was assessed by 
comparing midazolam exposure on the both PK days. For the phenotyping study, midazolam 
exposure at the second PK day, after the wash out of sunitinib, and sunitinib exposure at the 
first PK day were associated. 
Results: A linear correlation between midazolam exposure and 1] steady-state sunitinib 
exposure (R2= 0.56; P = .021) and 2] steady state sunitinib plasma trough levels (R2= 0.51; P = 
.030) were found. Additionally a strong linear relation was found between sunitinib plasma 
trough  levels and sunitinib exposure (R2= 0.90; P < .0001). Co-administration of sunitinib 
reduced the exposure to midazolam. However this reduction was not significant (P = .113). 
Conclusion: Steady-state sunitinib exposure and sunitinib trough levels are strongly related 
to CYP3A4 activity. Therefore, CYP3A4 phenotyping could be useful for individualization of 
the sunitinib starting dose. In addition, sunitinib exposure relates well to sunitinib plasma 
trough levels and sunitinib appears to be a mild inducer of CYP3A4.
Introduction
Sunitinib malate (Sutent®; SU11248) is an oral, multi-targeted tyrosine kinase inhibitor that 
specifically inhibits vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1, -2 and -3, 
respectively), platelet derived growth factor receptor alpha and beta (PDGFR-α and -β), KIT, 
Fms-like tyrosine kinase-3 receptor (FLT3), colony stimulating factor receptor type 1 (CSF-1R) 
and the receptor encoded by the ret proto-oncogene (RET)1, 2. Sunitinib is approved for first 
line treatment of metastatic renal cell carcinoma (mRCC) and imatinib-resistant metastatic 
gastrointestinal stromal tumors (GIST)3-5. Sunitinib is metabolized by cytochrome P450 
(CYP) 3A4 to an equally active metabolite SU12662, which is further metabolized to inactive 
moieties by CYP3A46. 
Clinical pharmacokinetics of sunitinib show high interpatient variability (∼ 40%) which is 
mainly unexplained5. This could result in supra- or sub-therapeutic sunitinib levels leading 
to toxicity or inefficacy, respectively. Since sunitinib is predominantly metabolized by 
CYP3A4, variability in the activity of this enzyme may explain a considerable proportion 
of the observed interpatient variability in sunitinib pharmacokinetics. A noninvasive 
and inexpensive phenotypic probe to measure the CYP3A4 activity might be useful for 
therapeutic optimization of the dosage of sunitinib. The probe could also be used to evaluate 
the potential impact of sunitinib on CYP3A4 activity. In this study, midazolam was used for 
CYP3A4 phenotyping. The design of the study was not only suitable to assess the activity 
of CYP3A4, but also to evaluate the potential impact of sunitinib on the pharmacokinetics 
of midazolam in cancer patients. It is thought that sunitinib is neither an inhibitor nor an 
inducer of CYP-enzymes and therefore the drug is considered not prone to drug-drug and 
drug-food interactions, while other tyrosine kinase inhibitors (e.g. imatinib, erlotinib, gefitinib) 
appear to be substrates and/or inhibitors of several CYP-enzymes in vivo and in vitro7-12.  For 
sunitinib, in vivo confirmatory studies to define an effect of sunitinib on CYP-enzymes are 
lacking. Moreover, recently it was shown in an in vitro study that sunitinib is a substrate for 
and an inhibitor of the transporter proteins ABCG2 and to some extent ABCB1, which may 
also lead to drug-drug interactions13. 
Therefore, in this study the relationship is determined between CYP3A4 activity and sunitinib 
exposure in cancer patients, using the phenotypic probe midazolam. In addition, the 
relationship between sunitinib plasma trough levels and sunitinib exposure is investigated 






















































Blood samples were collected on the first PK day of the study for assessing sunitinib pharma-
cokinetics at steady-state. The samples were collected into heparin-containing tubes at 0, 10, 
20, 40 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hours after the sunitinib dose.  Blood samples were 
centrifuged at 3,000 rpm for 10 minutes and plasma was divided into two aliquots and stored 
at –80˚C until the day of analysis. Total sunitinib plasma concentrations were determined in 
plasma using a validated liquid chromatographic tandem mass spectrometric (LC/MS/MS) 
assay, as described previously14.  
Midazolam Pharmacokinetics
Blood samples to assess midazolam pharmacokinetics were collected on the first and 
second PK day after a single dose of midazolam. The samples were collected into heparin-
containing tubes at the following time points: 0, 10, 20, 40 minutes; 1, 2, 3, 4, 5, 7 hours after 
the midazolam dose. Blood samples were centrifuged at 3,000 rpm for 10 minutes and 
plasma was stored at –80˚C until the day of analysis. Midazolam was measured using a 
validated liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay. Briefly, 200 
µl plasma was extracted by adding 500 µl of acetonitrile containing midazolam D4 (4µg/L) 
as the internal standard, followed by vortex mixing and centrifugation at 13,000 rpm for 5 
minutes at ambient temperature. The supernatant was collected and 10 µL was separated 
on an Atlantis T3 C18 analytical column (2.1 x 50 mm, i.d 3 µm) and eluted with the following 
Methods
Patients
Eligibility for study entry included adult cancer patients that were on sunitinib treatment 
for palliative treatment of various tumors, mainly mRCC and GIST, at a dose level of 25 – 50 
mg once daily in a “four weeks on – two weeks off” schedule. Patients were ≥ 18 years old, 
had a WHO performance status ≤ 2 and a life expectancy of at least 12 weeks.  Cytotoxic 
chemotherapy or radiation therapy within four weeks before entering the study was not 
allowed. Concurrent use of substances known or likely to interfere with the pharmacokinetics 
of sunitinib or with CYP3A4 activity, such as ketoconazole, fluconazole, rifampicin, St. John’s 
wort etc., were not allowed within 14 days before study entry. All patients had adequate 
clinical functional reserves as defined by hemoglobin ≥ 6.0 mmol/L, WBC ≥ 3.0 × 109/L, ANC 
≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, creatinine clearance ≥ 60 mL/min, bilirubin ≤ 1.75 × the 
upper limit of institutional normal value.  The study was approved by the institutional ethics 
committee (Leiden University Medical Center, The Netherlands), and all patients gave written 
informed consent before entering the study.  
Study design
In this study, midazolam was used as a probe to assess CYP3A4 activity. The study was 
designed to determine the relationship between CYP3A4 activity and sunitinib exposure 
in cancer patients and additionally to evaluate the effect of sunitinib on CYP3A4 activity by 
studying its effect on midazolam pharmacokinetics.
All patients were treated in a “four weeks on – two weeks off” dosing schedule, with 
commercially available sunitinib malate hard capsules (Pfizer, Kent, United Kingdom) at an 
oral once daily dose ranging between 25 and 50 mg. The study was performed during 
one sunitinib treatment cycle of six weeks.  Patients were admitted to the hospital on two 
separate days. The first PK day was at steady-state sunitinib pharmacokinetics (between day 
14 - 20), the second PK day was on day 42, the last day of the two weeks “off period” after the 
wash out of sunitinib. On both PK days the patients were given one midazolam 7.5 mg tablet 
of a single batch (Roche, Woerden, The Netherlands) either with (first PK day) or without 
sunitinib (second PK day). 
CYP3A4 phenotyping for dose individualization of sunitinib would be performed prior 
to treatment with sunitinib in clinical practice. Hence, exposure to midazolam without 
concomitant exposure to sunitinib (midazolam, second PK day) was related to sunitinib 
exposure at steady-state (suntinib, first PK day) to explore the feasibility of CYP3A4 
phenotyping for dose individualization of sunitinib. Additionally midazolam exposures on 
the first and second PK day were compared to assess the effect of sunitinib on CYP3A4 
activity (Figure 1).
First PK day: 
 
 
Assessment of steady-state sunitinib PK   
 
 Assessment of midazolam PK  





Assessment of midazolam PK 
Day 1 Day 14 Day 28 Day 42 
Sunitinib od 25 – 50 mg per day  Sunitinib wash-out period  
Day 20  
Eect of sunitinib on CYP3A4 
activity determined by 
comparing midazolam 
exposure on both PK days
Phenotying of CYP3A4 
activity by relating sunitinib 
exposure on the rst PK day 
with midazolam exposure on 
the second PK day
For assessment of the 
relation between sunitinib 
trough levels and exposure, 
sunitinib PK on the rst day 
were used
Figure 1 Study design






















































Dose normalized sunitinib exposure (AUC0-24hr) and trough levels (Css,min) at steady-state 
pharmacokinetics varied 8 to 9.5-fold (geometric mean = 1,105 ng⋅hr/mL, range 267 – 
2,119 ng⋅hr/mL and geometric mean = 43.6 ng/mL, range 7.2 – 68.7 ng/mL, respectively) 
(Table 2). The interpatient variabilities (defined as  the coefficient of variation (CV%)) in 
sunitinib exposure and sunitinib trough levels were large: 51% and 56%, respectively 
(Figure 2). Pharmacokinetic parameters of sunitinib are listed in Table 2. Sunitinib trough 
levels (Css,min) and sunitinib exposure (AUC0-24hr) were found highly related (R2 = .90, 
P < 0.0001) (Figure 3A).
Midazolam pharmacokinetics related to sunitinib exposure
Midazolam exposure (AUC0-7hr), Cmax and Tmax are listed in Table 2. Midazolam exposure 
(AUC0-7hr) was highly correlated to sunitinib trough levels (Css,min) (R2 = .51, P = .030) 
and sunitinib exposure (AUC0-24hr) (R2 = .56, P = .021) and could thereby reduce both 
the interpatient variability in sunitinib trough levels and sunitinib exposure to 29% 
(Figure 3B, 3C). 
Midazolam pharmacokinetics to evaluate the effect of sunitinib on CYP3A4 
The mean midazolam exposure (AUC0-7hr) with and without sunitinib were 91.0 µg*hr/L and 
130.4 µg*hr/L, respectively (P = .113; Table 3). 
gradient [flow rate (ml/min)/ time (minutes)/ percentage of solvent A (formic acid 0.1% in 
water)/ percentage of solvent B (formic acid 0.1% in acetonitril)]: 0.3/0.5/85/15/, 0.3/1/10/90, 
0.3/4.3/10/90, 0.5/0.01/10/90, 0.5/0.39/85/15, 0.5/3.3/85/15, 0.3/0.05/85/15, 0.3/0.05/85/15. 
The effluent was monitored with a Micromass Quattro LC triple-quadrupole  mass- 
spectrometric detector (Waters, Milford, MA, USA) using the electrospray positive ionization 
mode. The calibration curve of midazolam was linear over the range of 1 – 100 ng/mL. 
The within day and between day precision and accuracy were less than 5%. The lower limit 
of quantification (LLQ) of midazolam was 0.3 ng/mL.
Pharmacokinetic analysis
Sunitinib and midazolam plasma concentrations were analyzed by non-compartmental 
methods using WinNonlin (version 5.2.1) (Pharsight Corporation, Mountain View, CA, USA). 
Pharmacokinetic parameters assessed for midazolam were: AUC over the sampling period 
(0-7h), AUC0-∞ over an extrapolated time interval calculated as: AUC0-∞ = AUC(0-7hr) + C(last)/
λz, peak plasma concentration (Cl,max), time to reach peak concentration (Tl,max). 
For sunitinib the following pharmacokinetic variables were assessed: AUC over the dosing 
interval (0-24h); apparent oral clearance (CL/F), calculated as dose/AUC0-24; Css,min = average 
trough plasma concentration; Tl,max = time to reach peak plasma concentration; Cl,max = 
peak plasma concentration. To account for the sunitinib dose differences (37.5mg and 50mg) 
between the patients, the Css,min, Cl,max, and AUC0-24hr were normalized to a sunitinib dose 
of 50 mg.  
Statistical analyses
The relationship between midazolam exposure and sunitinib exposure was studied by 
linear regression analysis. The Pearson R square (R2) was used to asses the percentage of 
the variability in sunitinib exposure that could be explained by CYP3A4 activity. Midazolam 
exposures on the first and second PK day were compared by a two-tailed paired Student’s 
t-test. For all tests P values < .05 were considered to be statically significant. Statistical 
calculations were performed using SPSS 16.0 (SPSS Inc., Chicago, Illinois, USA). 
Results
Patients
Nine patients were included in this pharmacokinetic study; 7 patients were treated with 50 
mg and 2 patients were treated with 37.5 mg sunitinib once daily. Patient characteristics are 
summarized in Table 1. No unexpected side effects were observed on the day of midazolam 
administration or during sunitinib treatment.  
Table 1  Patient characteristics 
Characteristic Value
Number of patients 9
    Sex (female / male)  2/7
    Age, years* 56 (41 - 78)
Baseline renal and liver function parameters 
    Creatinine, µM* 76 (56 - 122)
    Total bilirubin, µM* 8 (6 - 15)
    ALT, units/L*  33 (14 - 68)
Baseline bone marrow function parameters 
    Hb, mM* 8.7 (7 - 9.4)
    WBC, x 109/L* 5.5 (3.5 - 38.2)
    Thrombocytes, x 109/L* 193 (122 - 318)





















































Table 2  Pharmacokinetic parameters for evaluation of the relation between 
sunitinib and midazolam  
Parametera Sunitinib at steady-state
AUC0-24hr (ng·hr/mL) 1105 ± 189
Cl/F (L/hr) 71.8 ± 21.8
Css,min (ng/mL) 43.6 ± 8.1
Tl,max (hr) 6.1 ± 1.1
Cl,max (ng/mL) 57.6 ± 8.6
   Midazolam after a single dose
   without sunitinib
AUC0-7hr (ng·hr/mL) 130.4 ± 22.9
AUC0-∞  (ng·hr/mL) 162.1 ± 34.7
Tl,max (hr) 1.0 ± 0.3
Cl,max (ng/mL) 51.9 ± 5.8
Results are presented as mean values ± the standard error of the mean (SEM). 
a Sunitinib Css,min, Cl,max and AUC0-24hr values are normalized to a sunitinib dose of 50 mg. 
Abbreviations: AUC0-24hr = area under the plasma concentration-time curve at steady-state over a dose interval 
of sunitinib; AUC0-7hr = area under the plasma concentration-time curve over the observed interval after a single 
midazolam dose; AUC0-∞ = area under the plasma concentration-time curve over a time interval 0 - infinity; CL/F 
= apparent oral clearance; Css,min = average trough plasma concentration; Tl,max = time to reach peak plasma 
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Midazolam AUC(0-7hr) (ng*hr/mL) 
y = 6,1577x + 301,89 


























Figure 2 Individual observed sunitinib plasma concentrations versus time profiles
Figure 3  Correlation between A: sunitinib trough levels (Css,min) and sunitinib exposure 
(AUC0-24hr), B: Midazolam exposure (AUC0-7hr) and sunitinib trough levels 
(Css,min) C: Midazolam exposure (AUC0-7hr) and sunitinib exposure (AUC0-24hr)






















































in sunitinib exposure23. In fact, CYP3A4 activity explained a large part (51%) of the total 
interpatient variability in sunitinib exposure and might therefore help to identify patients 
predisposed to relatively high sunitinib exposure or those that are potentially underdosed. 
When plasma drug concentrations are monitored to guide individual therapy, drug exposure 
is typically assessed by estimating the area under the plasma concentration time curve after 
taking blood samples at different time points. However, this strategy is difficult and time 
consuming in clinical practice and the use of surrogate parameters, such as drug trough 
levels, are favorable to determine drug exposure. To our knowledge, this is the first study 
that shows that sunitinib trough levels are highly correlated to sunitinib exposure. Therefore, 
through drug level measurement could be interesting especially since for imatinib, another 
tyrosine kinase inhibitor, a relation between elevated drug exposure and toxicities as well 
as minimal exposure levels and efficacy has been demonstrated24, 25. Our finding implicates 
that a relationship between sunitinib exposure and efficacy or toxicity could be studied by 
measuring sunitinib trough levels instead of sunitinib exposure, which is a more feasible 
approach than monitoring total exposure curves in treated patients. Before therapeutic drug 
monitoring is considered in clinical practice additional information on concentration-effect 
relationship of sunitinib for the different tumor subtypes is warranted1, 26, 27.  
Sunitinib shows a trend towards induction of CYP3A4 metabolism resulting in a reduced 
midazolam exposure while co-administered. Only gefitinib showed a similar interaction 
with midazolam in an in vitro study, however this effect has not been confirmed in vivo yet10. 
All other tyrosine kinase inhibitors are either CYP3A4 inhibitors (imatinib, dasatinib, and 
nilotinib) or show no influence on CYP3A4 metabolism, however caution with concomitant 
administered CYP3A4 substrates is still warranted8, 9, 28.
The relatively small number of patients in this study may be considered as a limitation 
especially for regarding accurate estimation of interpatient variability in sunitinib PK and 
assessment of relationships. However, the dense sampling results in a reliable determination 
of the exposure to sunitinib and midazolam. Moreover, the interpatient variability in our 
study is consistent with the interpatient variability of ∼ 40% reported so far5, 23. 
In conclusion, variability in sunitinib PK is strongly related to CYP3A4 activity and therefore 
CYP3A4 phenotyping could be useful for individualizing the sunitinib starting dose. Sunitinib 
trough levels relate well to sunitinib exposure, making this more assessable approach suitable 
for studying the exposure-efficacy and exposure-toxicity relations. 
Discussion
This study shows that sunitinib exposure is highly related to CYP3A4 activity. Also a strong 
relationship between sunitinib trough levels and sunitinib exposure is observed. Moreover, 
sunitinib appears to show a trend towards CYP3A4 induction, however this was not found 
significant.
Sunitinib is metabolized by cytochrome P450 3A4 (CYP3A4)5. No other enzymes are known 
to be involved in sunitinib metabolism5, 6. In addition, sunitinib appears to be an in vitro 
substrate and inhibitor for the ATP-binding cassette transporters ABCG2 and ABCB1 and 
these transporters may, therefore, also contribute to sunitinib disposition in vivo13. Similarly, 
midazolam is extensively metabolized by CYP3A4 with less affinity for CYP3A515. It, however, 
appears to be a poor substrate of ABCB1 (P-glycoprotein; MDR1) and ABCG2 (BCRP; MXR)16, 17. 
Oral midazolam is widely accepted and used as a probe for evaluating (hepatic and intestinal) 
CYP3A4 activity, without influencing the activity of this enzyme18-21.
Former studies have shown that sunitinib pharmacokinetics comprises high interpatient 
variability (∼ 40%) with respect to drug exposure. Until now, this high interpatient variability 
was only marginally explained by the studied variables; tumor type, race, sex, body weight, 
and Eastern Cooperative Oncology Group score22, 23. The relationship between sunitinib 
exposure and clinical efficacy or toxicity has not yet been elucidated but substantial pharma-
cokinetic variability is likely to impact treatment outcome. Phenotyping patients for CYP3A4 
activity may not only help to understand variability in sunitinib pharmacokinetics but it may 
also be a future clinical tool to individualize and optimize sunitinib treatment.   
In the presented study the interindividual variability in the sunitinib exposure was large (51%) 
and partially explained by midazolam exposure. Therefore, CYP3A4 activity as assessed by 
oral midazolam phenotyping adds to the variables identified in explaining the variability 
Table 3  Midazolam pharmacokinetics with and without sunitinib   
Parameters Midazolam alone Midazolam with sunitinib P value
AUC0-7hr (ng·hr/mL) 130.4 ± 22.9 91.0 ± 21.3 .113
AUC0-∞  (ng·hr/mL) 162.1 ± 34.7 118.8 ± 28.4 .092
Tl,max (hr) 1.0 ± 0.3 1.0 ± 0.5 .895
Cl,max (ng/mL) 51.9 ± 5.8 50.6 ± 12.2 .926
Results are presented as mean values ± the standard error of the mean (SEM)
Abbreviations: AUC0-7hr = area under the plasma concentration-time curve over the observed interval after  
a single midazolam dose; AUC0-∞ = area under the plasma concentration-time curve over a time interval  
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Purpose: To identify genetic markers in the pharmacokinetic and pharmacodynamic 
pathways of sunitinib that predispose for development of toxicities; thrombocytopenia, 
leukopenia, mucosal inflammation, hand-foot syndrome and any toxicity according to 
National Cancer Institute Common Toxicity Criteria higher than grade 2.
Patients and Methods: A multicenter pharmacogenetic association study was performed 
in 219 patients treated with single-agent sunitinib. A total of 31 single nucleotide 
polymorphisms in 12 candidate genes, together with several nongenetic variants, were 
analyzed for a possible association with toxicity. In addition, genetic haplotypes were 
developed and related to toxicity.
Results: The risk for leukopenia was increased when the G-allele in CYP1A1 2455A/G (odds 
ratio [OR], 6.24; P = .029) or the T-allele in FLT3 738T/C (OR, 2.8; P = .008) were present or CAG in 
the NR1I3 (5719C/T, 7738A/C, 7837T/G) haplotype (OR, 1.74; P = .041) was absent. Any toxicity 
higher than grade 2 prevalence was increased when the T-allele of VEGFR-2 1191C/T (OR, 2.39; 
P = .046) or a copy of TT in the ABCG2 (-15622C/T, 1143C/T) haplotype (OR, 2.63; P = .016) were 
present. The risk for mucosal inflammation was increased in the presence of the G-allele in 
CYP1A1 2455A/G (OR, 4.03; P = .021) and the prevalence of hand-foot syndrome was increased 
when a copy of TTT in the ABCB1 (3435C/T, 1236C/T, 2677G/T) haplotype (OR, 2.56; P = .035) 
was present.
Conclusion: This exploratory study suggests that polymorphisms in specific genes 
encoding for metabolizing enzymes, efflux transporters, and drug targets are associated with 
 sunitinib-related toxicities. A better understanding of genetic and nongenetic determinants 
of sunitinib toxicity should help to optimize drug treatment in individual patients.
Introduction
The oral, multitargeted tyrosine kinase inhibitor sunitinib (sunitinib malate; Sutent; Pfizer 
Pharmaceuticals Group, New York, NY) is known to inhibit vascular endothelial growth factor 
receptors (VEGFRs) 1, 2, and 3, platelet-derived growth factor receptor (PDGFR) α and β, KIT, 
Fms-like tyrosine kinase 3 receptor (FLT3), and the receptor encoded by the ret proto-onco-
gene (RET).1-4 Sunitinib is approved for first-line treatment of metastatic renal cell carcinoma 
(mRCC) and imatinib-resistant metastatic gastrointestinal stromal tumors (GIST).4-6 Targeted 
cancer therapies are generally considered to be less toxic than conventional chemotherapy 
since they specifically inhibit tyrosine kinase receptors that are frequently overexpressed or 
mutated in various types of tumor cells.7 Tyrosine kinases, however, are also present in normal 
tissues and toxic effects are therefore difficult to eliminate. The 4 weeks on 2 weeks off 
dosing schedule of sunitinib was selected for the first phase I study on request of the health 
authorities to allow patients to recover from potential bone marrow and adrenal toxicity 
observed in animal models, indicating that toxicity was regarded as a serious problem.3, 8 
Although the proportion of patients with grade 3 to 4 adverse events was relatively low in 
the recent phase III studies, a dose interruption appeared to be necessary in 38% of patients 
with mRCC and in 28% of patients with GIST whereas a dose reduction was required in 32% 
and 11%, respectively. Similar percentages were reported in other studies.2, 4, 9 Disease- and 
sunitinib-related toxicities can be distinguished based on results of a phase III trial in which 
the toxicity profile of sunitinib-treated patients has been compared with events in the 
placebo-treated patients.2 Adverse events that preferentially occurred in the group treated 
with sunitinib were diarrhea, hand-foot syndrome, mucositis, vomiting, hypertension, 
leukopenia, neutropenia, and thrombocytopenia.2-4, 9-13 Less common, but specific toxicities 
related to sunitinib were cardiotoxicity and hypothyroidism.5, 14, 15
Sunitinib is used as palliative therapy with no standard therapeutic options available after 
failure of the therapy. It is therefore relevant for patients to adhere to sunitinib therapy while 
their quality of life is not unnecessarily reduced by drug toxicity. To date, it is not completely 
clear which patient characteristics render an individual patient at risk for sunitinib-induced 
toxicity. The aim of the present study is to identify genetic markers in sunitinib disposition, 
metabolism, and mechanism of action that predispose for development of common 
sunitinib related toxicities: thrombocytopenia, leukopenia, mucosal inflammation, hand-foot 
syndrome and any higher than grade 2 National Cancer Institute Common Toxicity Criteria 






















































in the drug label of sunitinib. Moreover, mucosal inflammation and hand-foot syndrome are 
frequently reported and poorly manageable and therefore dose reduction is relatively soon 
considered. In addition, dose reduction of at least 25% according to the drug label (data 
complete for 187 patients) which is applied because of safety or tolerability issues, after cycle 
1 to 3 was related to the toxicity outcomes.
Genetic Polymorphisms
Nineteen polymorphisms in seven genes involved in the pharmacokinetics and 12 
polymorphisms in five genes involved in the pharmacodynamics of sunitinib were selected. 
Selection criteria for the polymorphisms were an allelic frequency higher than 0.2 in 
whites and an assumed clinical relevance based on previously reported associations or the 
assumption that nonsynonymous amino acid change leads to changed protein functionality. 
The selected polymorphisms are listed in Table 1. 
Genotyping of selected polymorphisms
Germline DNA was isolated from 1 ml of serum or EDTA-blood with the Magnapure LC 
(Roche Diagnostics, Almere, The Netherlands). DNA concentrations were quantified on the 
nanodrop (Isogen, IJsselstein, The Netherlands). Taqman assays were obtained from Applied 
Biosystems (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). All Single 
Nucleotide Polymorphisms (SNPs) were initially determined on the Biomark 48.48 Dynamic 
Array (Fluidigm, San Fransisco, CA, USA) according to the manufacturer’s protocol. Failed 
samples were repeated on the TaqMan 7500 (Applied Biosystems), according to standard 
procedures. For serum samples, a pre-amplification step was necessary. Briefly, a dilution of 
all TaqMan assays in a total volume of 1.25 µL and 2.5 µL of pre-amplification mastermix 
(Applied Biosystems) was added to 1.25 µL of serum-DNA, and subsequently amplified by 
polymerase chain reaction. This mixture was 20 times diluted and 2.5 µL was used in the 
Biomark array according to the protocol. 
Genotyping assay validity
The overall average success rate of the assays and the individual samples was 98%. The lowest 
success rate in our study was 93.5%. As a quality control, all DNA samples were genotyped 
in duplicate for 12 of 31 SNPs, and three DNA samples were genotyped in duplicate for all 
31 SNPs. No inconsistencies were observed. In addition negative controls (water) were used. 
The allelic frequencies of the 31 single nucleotide polymorphisms were tested for Hardy-
Weinberg equilibrium (HWE). Six genotype assay results did not meet HWE. However, of four 
of these, frequencies were compared with allelic frequencies as reported on the National 
Center for Biotechnology Information website (NCBI) for white population and found similar 
to the reported frequencies. Of the two remaining SNPs no frequencies were available on the 
Patients and methods
A total of 219 patients from five Dutch medical centers were analyzed in this study. The study 
was approved by the medical ethics review board. Patients were treated at the Erasmus 
University Medical Center (n=74), the Netherlands Cancer Institute (n=51), Leiden University 
Medical Center (n=37), VU University Medical Center (n=36), and the University Medical 
Center Groningen (n=21). The collection of DNA and patient data was performed between 
June 2004 and May 2008. A total number of 159 mRCC, 50 GIST, and 10 patients with other 
tumors were included in this study. Of them, 77 patients with mRCC and 26 patients with 
GIST were treated according to an expanded access programme of sunitinib. Eligible patients 
were those treated with single agent sunitinib for at least one treatment cycle (4 consecutive 
weeks of 50 mg per day followed by a two-week period of rest). 
Study design
Sunitinib toxicity was evaluated during the first treatment cycle by CTCAE version 3.0.16 
Toxicity scores were assessed by analysis of adverse events, physical examination and 
laboratory assessments carried out at baseline (before starting sunitinib), after 4 weeks of 
sunitinib therapy, and after 6 weeks (just before starting the second cycle). Demographic 
and clinical data of patients were reported on case record forms designed for data collection 
in this study. Patient characteristics considered relevant for experiencing toxicity were: age, 
gender, ethnicity, body-surface area (BSA), Eastern Cooperative Oncology Group (ECOG) 
performance status, tumor type, renal, liver and bone marrow function (serum creatinine, 
total bilirubin, albumin, ALT, AST, hemoglobin, leukocytes and thrombocytes). Residual 
blood or serum samples taken for routine patient care were stored at -20ºC at the local 
hospital laboratory. Of each patient one whole blood or serum sample was collected from 
the participating centers. All samples were anonymized by a third party, according to the 
instructions stated in the Codes for Proper Use and Proper Conduct in the Self-Regulatory 
Codes of Conduct (www.federa.org). 
Definition of toxicity
All adverse events were graded by independent physicians of the participating medical 
centers. Four- and 6-week reported toxicities were compared to baseline conditions. 
The primary outcome measures of this study were thrombocytopenia, leukopenia, mucosal 
inflammation, hand-foot syndrome and any toxicity higher than grade 2. Toxicities were 
selected based on objectivity, clinical relevance and manageability of the symptoms. 
Thrombocytopenia and leukopenia were scored from blood cell counts and are thus 
objective endpoints. In case of any toxicity higher than grade 2, a dose interruption and, 






















































measure Rh2 was calculated.  Rh2 gives us information on the uncertainty in the prediction of 
common haplotypes from unphased SNP genotypes 17. A haplotype was considered to be 
present if the haplotype uncertainty measure Rh2 was greater than 0.98 as tested with the 
software program CHAPLIN 18. Haplotypes with an uncertainty measure Rh2 ≤ 0.7 in CHAPLIN 
were not considered for further analysis since the data provided no information on haplotypes 
in our population. All  haplotypes with uncertainty (0.7 < Rh2 ≤ 0.98 ) and without uncertainty 
(Rh2 > 0.98) were computed and assigned per individual using gPLINK 19.  Rare haplotypes 
(< 2%) were combined into one group of other haplotypes in the association analysis. The 
haplotypes used in this study had no phase uncertainty (Rh2 > 0.98). The VEGFR-2 gene had a 
large phase uncertainty (Rh2 ≤ 0.7) indicating that in our population VEGFR-2 polymorphisms 
could not be defined as a haplotype. The following SNPs were combined for further analysis: 
ABCG2; 1143C/T and -15622C/T; PDGFRα; -573G/T, -1171C/G, -735G/A, 1580T/C; NR1I3; 5719C/T, 
7738A/C, 7837T/G; NR1I2 ; 10620C/T, 10799G/A and ABCB1; 3435C/T, 1236C/T, 2677G/T. 
Statistical design and data analysis
For the analysis of toxicity, we used dichotomous end points expressed as increased toxicity 
(yes or no) or any toxicity higher than grade 2 (yes or no). All demographic and clinical 
variables were tested univariately against the selected primary outcomes using t test, the 
Mann-Whitney U test or the χ2 test, depending on the tested variables. A χ2 test was also used 
to detect linkage disequilibrium (LD). The polymorphisms were initially tested with 2 df. If the 
initial 2 df tests resulted in P ≤ .1, the polymorphisms were fitted and the most appropriate 
model (multiplicative, dominant, or recessive) was selected. The number of copies of each 
haplotype was used as parameter in the analysis. The polymorphisms and haplotypes 
were tested univariately against the selected primary outcomes using a χ2 test. Candidate 
variables with P ≤ .1 were selected for the multiple logistic regression analysis with toxicity 
as depending variable. All multivariate logistic regression analyses were corrected for age, 
gender and ECOG performance status. Additional patient characteristics were introduced in 
the multivariate analyses based on univariate tested results if P ≤ .1. Missing data were kept as 
missing data except for BSA and ECOG performance status. Missing BSA values (n=15) were 
replaced for the median BSA (1.93m2) and missing ECOG performance status (n=7) were 
replaced for the median ECOG performance status (1). To test this action, the multivariate 
analyses were performed with and without the replacement of the patients with missing 
BSA and ECOG performance status. Similar results were generated, indicating that the 
replacement was legitimate. All statistical analyses were performed using SPSS 16.0 software 
(SPSS, Chicago, IL, USA). With the sample size of our study, an increase in toxicity of 17% could 
be measured between two groups with a power of 80% and a confidence interval of 99%. All 
results from the multivariate analyses with P less than .05 were considered significant. Since 
this was an exploratory study, no correction for multiple testing was done.  
NCBI website (www.ncbi.nlm.nih.gov). The homozygotic wildtype frequencies of both SNPs 
exceed the HWE and were therefore allowed for the analysis. 
Haplotype estimation 
Polymorphisms within a gene were tested to detect linkage disequilibrium (LD). If LD between 
SNPs was present, haploblocks (with several haplotypes) were determined. The uncertainty 
Table 1  Polymorphisms genotyped in the pharmacokinetic and  
pharmacodynamic pathway of sunitinib    
   Gene Polymorphism  rs-number
Pharmacokinetic pathway NR1I2 -25385C/T  rs3814055
    -24113G/A  rs2276706
    7635A/G  rs6785049
    8055C/T  rs2276707
    10620C/T  rs1054190
    10799G/A  rs1054191
   NR1I3 5719C/T  rs2307424
    7738A/C  rs2307418
    7837T/G  rs4073054
   CYP3A5 6986A/G  rs776746
   CYP1A1 2455A/G  rs1048943
   CYP1A2 -163A/C  rs762551
   ABCG2 421C/A  rs2231142
    34G/A  rs2231137
    -15622C/T  *
    1143C/T  rs2622604
   ABCB1 3435C/T  rs1045642
    1236C/T  rs1128503
    2677G/T  rs2032582
Pharmacodynamic pathway PDGFRα 1580T/C  rs35597368
    -1171C/G  rs1800810
    -735G/A  rs1800813
    -573G/T  rs1800812
   VEGFR2 (=KDR) -604T/C  rs2071559
    -92G/A  rs1531289
    54T/C  rs7692791
    1191C/T  rs2305948
    1718T/A  rs1870377
   VEGFR3 (=FLT4) 1501A/G  rs307826
   RET 2251G/A  rs1799939
   FLT3 738T/C  rs1933437























































The hematological toxicities scored in this analysis were thrombocytopenia (40% any grade), 
leukopenia (59%, any grade). Non-hematological toxicities were primarily any toxicity higher 
than 2 (22%), mucosal inflammation (44%) and hand-foot syndrome (19%; Table 3). Dose 
reduction after cycle 1 to 3 was related to mucosal inflammation (P = .002) and any toxicity 
higher than grade 2 (P < .001)
Results 
Patients 
Nineteen out of 219 patients had to be excluded from analysis for several reasons including 
progressive disease (PD) during the first treatment cycle resulting in early death (n=4), 
 discontinuation of sunitinib in the first treatment cycle due to adverse events (hypertension 
grade 3, headache grade 3 and rash grade 3, respectively; n=3) and no acceptable genotyping 
success rate due to poor DNA quality (n=12). For toxicity analyses, a total of 200 patients were 
evaluable (Table 2). For the endpoint any toxicity higher than grade 2, the three patients who 
stopped therapy due to adverse events were included (n=203).
Table 2  Patient characteristics (N=203)  
Characteristic Value
Age (years) 
 Median (range) 60 (20-84)
Sex 
 Male 129 (63.5%)
 Female 74 (36.5%)
Body Surface Area (square meters) 
 Median (range) 1.93 (1.47-2.51)
ECOG performance status 
 0 81 (39.9%)
 1 90 (44.3%)
 2 17 (8.4%)
 3 8 (3.9%)
 Missing 7 (3.4%)
Ethnicity 
 Caucasian 190 (93.6%)
 Blacks 6 (3.0%)
 Asian 2 (1.0%)
 Latin-American 2 (1.0%)
 Middle East 3 (1.5%)
Tumor types  
 Renal cell carcinoma 152 (74.9%)
 Gastrointestinal stromal tumor 46 (22.7%)
 Other 5 (2.5%)
Previous medical treatments 
 Yes* 116 (57.1%)
 No 87 (42.9%)
First treatment regimen (N=116)* 
 Interferon-alpha (INF-α) 46 (39.7%)
 Imatinib 46 (39.7%)
 Sorafenib 5 (4.3%)
 Others 19 (16.4%)
Dose reduction after sunitinib cycle 1 – 3  
 Yes Renal cell carcinoma 58 (28.6%)
  GIST 14 (6.9%)
  Other tumor 1 (0.5%)
 No Renal cell carcinoma 94 (46.3%)
  GIST 32 (15.8%)
  Other tumor 4 (2.0%)
Baseline chemistry and hematology
Creatinine (μM) 
 Median (range) 96.0 (40-176)
Total bilirubin (μM) 
 Median (range) 7 (3-32)
Albumine (gram/L) 
 Median (range) 40 (23-52)
ALT (units/L) 
 Median (range) 18 (3-210)
AST (units/L) 
 Median (range)  24 (9-190)
Hemoglobin (mM) 
 Median (range) 7.6 (5.2-10.4)
Leukocytes (*10^9/L) 
 Median (range) 7.5 (3.6-56.5)
Thrombocytes (*10^9/L) 
 Median (range) 284.0 (92-864)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern Cooperative 






















































(P = .046), while the risk for this toxicity was 2.6-fold higher when 1 or 2 copies of TT in the 
ABCG2 haplotype were present (P = .016). For mucosal inflammation only CYP1A1 2455A/G 
was independently related; the G-allele (additive model) resulted in a 4.0-fold higher risk 
for mucosal inflammation (P = .021). The occurrence of hand-foot syndrome was related 
to the ABCB1 haplotype; the absence of copies of the TTT haplotype was protective and 
was related to a 2.6-fold lower risk to experience hand-foot syndrome as compared to 
patients with copies of the TTT haplotype (P=.035). The explained variance (R2) of the patient 
characteristics, without taking the polymorphisms into account, in the multivariate analyses 
was between the 2 to 10% of the total variance. After adding the selected polymorphisms 
the explained variance increased to 10 to 23% of the total variance.
Discussion
To the best of our knowledge, this is the first study exploring the relationship between 
drug-induced toxicity and genetic polymorphisms in genes encoding for enzymes, efflux 
transporters and targets involved in the pharmacokinetics and pharmacodynamics of 
sunitinib. 
Sunitinib is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP3A5. In addition, affinity 
of sunitinib for the ATP-binding cassette transporters ABCG2 and ABCB1 has also recently 
been reported.20 The transcription of CYP3A4 is regulated by members of the NR1I nuclear 
receptor subfamily.21 Metabolism through CYP1A1 and CYP1A2 is hypothesized since these 
enzymes appear to be involved in the metabolism of multiple tyrosine kinase inhibitors 
(eg, imatinib, erlotinib).22, 23 Both genes encoding the sunitinib targets, as well as genes 
encoding the enzymes (except for CYP3A4, in which no functional polymorphisms have 
been identified) and efflux transporters involved in sunitinib’s disposition and metabolism 
are highly polymorphic and may be related to the differential toxicity response in patients 
treated with sunitinib. 
Although the nature and incidence of adverse events related to sunitinib are currently 
well recognized and described, data regarding determinants of toxicity are still scarce.2, 
4, 5, 14, 24, 25  So far, only one study has described factors (low BSA, high age, female gender) 
that are associated with the development of severe toxicities, defined as dose reduction or 
permanent discontinuation of sunitinib therapy.9 That study, however, was limited to patient 
characteristics and no genetic determinants were investigated. In our study, these patient 
characteristics, and another (performance status), were included as covariates in the data 
analysis. We should emphasize, however, that the definition of the endpoint severe toxicity 
is different in both studies as well as the observed study period (whole sunitinib treatment 
period v first treatment cycle in our study). 
Pharmacogenetic risk factors for sunitinib-induced toxicity
The results of the multivariate logistic regression analysis for the selected endpoints throm-
bocytopenia, leukopenia, mucosal inflammation, hand-foot syndrome and any toxicity 
higher than grade 2 are summarized in Table 4. For thrombocytopenia, an increase in age 
(P = .030) and ECOG performance status (P = .050) were independently significant in the 
multivariate logistic model. The factors associated with development of leukopenia were: 
CYP1A1 2455A/G; the presence of the G allele in an additive model was related to a 6.2-fold 
increase in the risk for leukopenia during the first treatment cycle (P = .029); the presence 
of the FLT3 738C allele (dominant model) was related to a 2.8-fold reduction in the risk for 
leukopenia (P = .008); the absence of the NR1I3 CAG haplotype was related to a 1.7-fold 
increased risk for leukopenia (P = .041) and 4); one grade increase in ECOG performance 
status, implicating a worse clinical condition, was related to a 1.8-fold reduction in the risk of 
leukopenia (P = .016). The presence of the VEGFR-2 1191T-allele (additive model) was related 
to an increased risk of 2.4-fold for the development of any toxicity higher than grade 2 
Table 3  Number (No) of patients (%) according to the distribution of increased 
toxicity grades    
Toxicity No/Yes Grade No (%)
Thrombocytopenia (n=198) No  118 (59.0)
   Yes 1 58 (29.0)
    2 14 (7.0)
    3 7 (3.5)
    4 1 (0.5)
Leukopenia (n=198) No  81 (40.5)
   Yes 1 91 (45.5)
    2 22 (11.0)
    3 4 (2.0)
Any toxicity > 2 (n=203)  0, 1, 2 158 (77.8)
    3, 4 45 (22.2)
Mucosal inflammation (n=199) No  112 (56.0)
   Yes 1 57 (28.5)
    2 25 (12.5)
    3 5 (2.5)
Hand-foot syndrome (n=199) No  162 (81.0)
   Yes 1 27 (13.5)
    2 8 (4.0)










































































































































































































































































































































































































































   
   




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In our study, a large number of candidate polymorphic loci were evaluated and multiple 
analyses of each genetic polymorphism were performed. This introduces the potential 
problem of multiple testing which increases the risk to find false-positive relations. However, 
our study was designed to explore associations that should be confirmed in an independent 
group of patients. The presented odds ratios and CIs facilitate comparisons of replicate 
studies with our data. 
The ECOG performance status was not consistently related to the occurrence of toxicities in 
our study. The quantified performance status is multifactorial and is dependent on subjective 
interpretation of the physician. Moreover, in our study patients with poor performance status 
had relatively high baseline thrombocyte and leukocyte counts resulting in a small number 
of reported leukopenia and thrombocytopenia in this group in the first treatment cycle. 
Toxicities in the first treatment cycle of sunitinib were used as outcome measure. 
The rationale was that signs of clinical deterioration from disease progression in later cycles 
could be  misinterpreted and would interfere with the drug-induced toxicity outcome. We 
hypothesized that patients that suffer from relatively mild (grade 1 or 2) toxicities in the first 
treatment cycle were at risk for developing more severe toxicity during further treatment 
cycles because the two weeks of rest would not be sufficient for patients to recover to 
baseline conditions. This cumulative effect is underscored by measured blood cell counts 
and the observed dose reduction after cycle 1 to 3. Indeed, we found for leukocyte count and 
to a lesser extent also for thrombocyte count, that 91% and 73%, respectively, of the patients 
had not returned to baseline values (defined as > 90% of baseline counts) at cycle 2 day 1 
(data not shown). In addition, we found that mucosal inflammation and any toxicity higher 
than grade 2 were strongly related to a dose reduction after cycle 1 to 3, indicating that these 
toxicities are regarded as clinically relevant to the treating physicians. 
Together, the genetic, clinical and demographic determinants in this exploratory study 
explain between 10 and 23% of the total variance in toxicity response. Although it indicates 
that the major part of the variability is left unexplained, it also shows that pharmacogenetics 
may make a greater contribution to explaining variability in sunitinib toxicity as compared 
to the nongenetic determinants in our study. From this study we cannot conclude whether 
the genetic variants are prognostic or predictive markers, due to the absence of a placebo-
treated control group of patients. However in the future, pharmacogenetics may help to 
select patients which need a priori dose reduction to prevent toxicities. 
In conclusion, this study suggests a relationship between polymorphisms in the genes 
CYP1A1, ABCB1, ABCG2, NR1I3, VEGFR-2 and FLT3 and the development of sunitinib toxicity. 
The next step will be to validate our data with the aim to better understand the determinants 
of sunitinib toxicity.
To our knowledge, we report for the first time herein that the ABCB1 TTT haplotype was 
related to hand-foot syndrome. The TTT haplotype as well as the T genotype in 3435C/T and 
the T polymorphism in 1236C/T separately have been associated with higher exposures to 
drugs transported by ABCB1 due to a decreased expression of the ABCB1 transporter.26-31 
Also, for the other ABC-transporter investigated, ABCG2, the TT haplotype was related to 
the development of increased toxicity (eg, any toxicity > grade 2). This haplotype has been 
associated with increased erlotinib exposure, a tyrosine kinase inhibitor that uses metabolic 
and predisposition pathways similar to those of sunitinib.32 Thus, our results concerning 
ABCB1 and ABCG2 are in line with previously reported functional consequences of the studied 
genetic variants and might lead to an increased systemic exposure to sunitinib resulting in 
dose-limiting toxicities. Certainly, to confirm our findings, further studies that relate pharma-
cogenetics to pharmacokinetics and pharmacodynamics are required. 
Thus far, the extrahepatic CYP1A1 enzyme has not been described as being involved in the 
metabolism of sunitinib. For other receptor tyrosine kinase inhibitors, such as erlotinib, imatinib 
and gefitinib affinity for CYP1A1 has been demonstrated in in vitro studies.22, 23 Therefore, we 
also included genetic variants of CYP1A1 in the present study. The polymorphism studied in 
CYP1A1 resulting in an amino acid change of isoleucine 462 Valine was found to be related 
to the occurrence of mucosal inflammation and leukopenia. This suggests that CYP1A1 may 
also play a role in the metabolism of sunitinib in vivo. 
In addition, we investigated genetic polymorphisms in the NR1I3 gene, encoding the 
constitutive androstane receptor. This nuclear receptor plays an important role in the regulation 
of multiple drug detoxification genes, such as CYP3A4. The functionality of polymorphisms 
in NR1I3 is not yet fully elucidated, however we found a relationship between the absence of 
the CAG haplotype in this gene and an increased risk for leukopenia33. Obviously, it would be 
interesting to relate this polymorphism with sunitinib exposure levels in future studies.  
The VEGFR-2 1191CT and TT genotypes were found to be predictive for the development 
of coronary heart disease due to a lower binding efficiency of VEGF to the polymorphic 
VEGFR-2.34 In our study, these genotypes were related to the development of any toxicity 
higher than 2, which predominantly included fatigue, thrombocytopenia, and hypertension. 
The polymorphic receptor might therefore be involved in sunitinib-induced cardiac toxicity 
and the development of hypertension.   
The importance of the FLT3 receptor has been described in relation to the development of 
several subtypes of leukemia such as acute myeloid leukemia, acute lymphocytic leukemia, 
and chronic myeloid leukemia, in which FLT3 is frequently overexpressed and/or mutated.35, 
36 However, the association between FLT3 738T/C polymorphism and a reduction in the risk 
of leukopenia has not previously been described. Since sunitinib-induced leukopenia could 
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Purpose: To determine the effect of grapefruit juice, a potent intestinal cytochrome P450 
3A4 (CYP3A4) inhibitor, on steady-state sunitinib pharmacokinetics (PK).
Methods: Sunitinib PK were evaluated in cancer patients receiving sunitinib monotherapy 
in a “four weeks on - 2 weeks off” dose regimen. Serial blood samples for PK analysis of 
sunitinib were collected on two separate days. On both PK days patients received a single 
oral dose of 7.5 mg midazolam as a phenotypic probe for intestinal CYP3A4 activity. The 
first PK day was at steady-state sunitinib PK (between days 14-20), the second PK day was 
on day 28. On day 25, 26 and 27, 200 mL grapefruit juice was consumed three times a day. 
The effect of grapefruit juice on sunitinib exposure was assessed by comparing sunitinib 
pharmacokinetics on both PK days. 
Results: In 8 patients the effect of grapefruit juice on sunitinib exposure was evaluated. 
Concomitant use of grapefruit juice and sunitinib resulted in an 11% increase of the relative 
bioavailability of sunitinib (P < .05). The effect of grapefruit juice on CYP3A4 activity was 
confirmed by an approximate increase of 50% in mean midazolam exposure (AUC0-24hr) from 
122.1 ng*hr/mL to 182.0 ng*hr/mL (P = .034).
Conclusion: Grapefruit juice consumption results in a marginal increase in sunitinib 
exposure which was not considered clinically relevant. Therefore, the warning in the sunitinib 
drug label for concomitant use of grapefruit juice should be reconsidered.  
Introduction
Sunitinib malate (Sutent®; SU11248) is a multitarget tyrosine kinase inhibitor registered for 
the first line treatment of metastatic renal cell carcinoma (mRCC) and imatinib-resistant 
metastatic gastrointestinal stromal tumors (GIST).1-3 The approved dosing regimen for 
sunitinib is a “four weeks on – two weeks off” schedule.4 Sunitinib is absorbed from the 
gastrointestinal tract to an unknown extent. The intake of food does not affect the pharma-
cokinetics of sunitinib.5 Sunitinib is in vitro extensively protein bound, has a long half-life of 
∼50 hours and a large apparent volume of distribution of ∼2000 liters.3, 6 Cytochrome P450 
3A4 (CYP3A4) metabolizes sunitinib into an active metabolite, SU12662, which is further 
metabolized by CYP3A4 into inactive moieties.3, 7, 8 Sunitinib has not been described to be a 
substrate of any other metabolizing enzymes besides CYP3A4. It was identified in vitro as a 
moderate substrate of the ATP-binding cassette (ABC) drug transporters ABCG2 and ABCB1 
and showed no affinity for organic anion transporting polypeptides (OATPs). However, the 
clinical relevance of these transporters on the disposition in vivo needs to be addressed.9, 10
Co-administration of ketoconazol, a potent CYP3A4 inhibitor, resulted in a 51% increase of 
the combined area under the concentration time curve (AUC) of sunitinib and SU12662 
after a single dose of sunitinib in healthy volunteers.3 This observation was extrapolated to 
warnings for the potential effect of strong CYP3A4 inhibitors including grapefruit juice in the 
drug label of sunitinib8. 
Grapefruit juice contains a rich mixture of several hundred ingredients which may be 
responsible for the grapefruit juice – drug interaction effect.11-14 By administering the purified 
forms of the different compounds to human volunteers, the furanocoumarins (mostly 
bergamottin (BG) and 6’,7’-dihydroxybergamottin (DHB)) were confirmed to result in a 
significant CYP3A4 inhibiting effect.15-17 Grapefruit juice is an inhibitor of intestinal CYP3A4, 
with little effect on hepatic CYP3A4 activity.18 Grapefruit juice also appears to be an inhibitor 
of ABCB1 and possibly of OATP located in the intestines.17-20  
Recently, multiple oral anticancer therapies, mainly tyrosine kinase inhibitors, were introduced 
and since most of them are substrates of CYP3A4, their drug label contains a warning against 
the consumption of grapefruit juice. Sofar, only one study has determined the effect of 
grapefruit juice on an oral anticancer drug (etoposide).21 In this study an opposite effect 
of grapefruit juice was observed. Since more patients will be treated with oral anticancer 
therapy in the future, it is relevant to better understand and determine the clinical relevance 
of an effect of grapefruit juice on oral anticancer therapy exposure. Therefore, in this study 






















































Concentrations of BG and DHB were quantified in various batches of grapefruit juice 
from different brands using a validated high pressure liquid chromatography – ultraviolet 
detection (HPLC-UV) method. This assay was based on a previously published method 
with minor modifications.22 Briefly, the juice was homogenized by shaking. Grapefruit juice 
(0.5mL) was mixed with 10 µL internal standard fenprocoumon (100 µg/mL, in methanol) 
and 2 mL ethyl acetate. Calibration standards contained 0.2 – 4 µg/mL BG and 0.1 – 2 µg/mL 
DHB were prepared at the start of each analytical run. The standard stock solution contained 
BG and DHB (100 and 50 µg/mL in DMSO:methanol(1:3)). The residue from the organic 
phase was reconstituted with 100 µL of DMSO/acetonitril solution (1:3 v/v) and applied to a 
HPLC separation system (Unexas 2104, Knauer, Berlin, Germany). The compounds of interest 
were separated on a Hypersil ODS RP analytical column (4.6 x 100 mm, i.d 3 µm) using the 
following gradient [time scale (minutes - minutes)/ percentage of solvent A (water 2500/
phosphoric acid 1.25)/ percentage of solvent B (acetonitril)]: 0-7/70/30, 7-17 70/30 → 0/100, 
17-18/0/100, 18-19 0/100 → 70/30, 19-22/70/30. DHB, fenprocoumon and BG eluted at 10.9, 
12.8 and 16.5 minutes, respectively. Linearity was confirmed over the range of 0.2 – 24 µg/mL 
for BG and 0.1 – 12 µg/mL for DHB. The within day and between day precision and accuracy 
were < 15%.
Pharmacokinetic sampling 
Blood samples were collected on the first and second PK day of the study for assessing 
sunitinib and midazolam plasma concentrations.  Blood was collected in heparin-containing 
Methods
Patients
Patients eligible for study entry were treated with sunitinib at a dose level of 25 – 50 mg 
once daily in a “four weeks on – two weeks off” regimen. All patients were ≥ 18 years old, 
had a WHO performance status ≤ 2 and a life expectancy of at least 12 weeks.  Cytotoxic 
chemotherapy or radiation therapy within four weeks before entering the study protocol 
was not allowed. Concurrent use of substances known or likely to interfere with the pharma-
cokinetics of sunitinib and with CYP3A4 activity, such as ketoconazol, fluconazol, rifampicin 
and St. John’s wort, were not allowed within 14 days before study entry and during the 
study. All patients had adequate bone marrow, renal and hepatic functions as defined by 
hemoglobin ≥ 6.0 mmol/L, WBC ≥ 3.0 × 109/L, platelets ≥ 100 × 109/L, creatinine clearance 
≥ 60 mL/min and bilirubin ≤ 1.75 × the upper limit of institutional normal range. Prior to 
commencing the study, a sample size of 8 patients was determined as sufficient for a paired, 
two sided analysis to detect a difference of 25% in sunitinib exposure with a power (1-β) of 
0.8 (80%), and a two-sided significance level (α) of 0.05 (5%). The study was approved by the 
institutional ethics committee (Leiden University Medical Center, The Netherlands), and all 
patients gave written informed consent before entering the study. 
Study design
The study was designed to evaluate the effect of grapefruit juice on steady-state sunitinib 
pharmacokinetics.  All patients were treated with commercially available sunitinib malate 
hard capsule (Pfizer, Kent, United Kingdom) at an oral dose of 25 – 50 mg once daily in a 
“four weeks on followed by two weeks off” dose regimen. The study was performed during 
one sunitinib treatment cycle of six weeks.  Patients were admitted to the hospital on two 
separate PK days. The first PK day was at steady-state sunitinib PK (between day 14 - 20) 
and the second PK day was on day 28. On days 25, 26, and 27, the patients took 200 ml 
grapefruit juice of a preselected lot of commercially available grapefruit juice three times 
daily. On these three days, sunitinib was simultaneously used with the morning consumption 
of the grapefruit juice. On both PK days patients were given one midazolam 7.5 mg tablet 
(Roche, Woerden, The Netherlands) as a phenotypic probe to confirm the inhibitory effect of 
grapefruit juice on intestinal CYP3A4 activity (Fig. 1).   
Selection of a grapefruit juice batch 
Different batches of grapefruit juice show a considerable variability in BG (∼35 fold) and DHB 
(∼200 fold) concentration.22 Therefore selecting a batch with a sufficient amount of BG and 
DHB to induce a clinically relevant effect on CYP3A4 substrates was necessary before the 
interaction study was conducted.15   
GFJ consumption
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the likelihood ratio test. A decrease in ∆OFV of 3.84 (=P < .05) was considered statistical 
significant.  
A base model was developed to describe sunitinib pharmacokinetics, using sunitinib 
concentrations obtained on the first and second PK day. Next, a final model was developed 
by the introduction of a grapefruit juice effect on the relative bioavailability of sunitinib, 
resulting in an effect on the apparent clearance and apparent volume of distribution and 
thereby exposure to sunitinib, since it was hypothesized that grapefruit juice exerts its 
effect only by irreversible inhibition of intestinal CYP3A4 and possibly by inhibition of ABCB1 
(Fig. 2). The recovery half life of CYP3A4 activity after grapefruit juice consumption was set 
to 23 hours.25
The model was evaluated by goodness of fit plots, case deletion diagnostics and a numerical 
predictive check. Moreover, a log-likelihood profile was generated for the effect size of 
grapefruit juice to determine the confidence interval.
The effect of grapefruit juice on sunitinib bioavailability was evaluated for various scenarios: 
1) simultaneous intake of sunitinib and grapefruit juice, 2) sunitinib intake 7 hours, 3) 24 hours, 
4) 72 hours and 5) one week after the last grapefruit juice consumption.
tubes at the following time points: pre-dose, 10, 20, 40 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 
and 24 hours after simultaneous intake of sunitinib and midazolam.  Blood samples were 
centrifuged at 3,000 rpm for 10 minutes and plasma was stored at –80˚C until the day of 
analysis. 
Bioanalysis of sunitinib and midazolam
Sunitinib was measured using a validated liquid chromatographic-tandem mass spectrometric 
(LC-MS/MS) assay, which has been described earlier.23 The calibration curve of sunitinib is 
linear over the range of 0.2 – 500 ng/mL. The within day and between day precision and 
accuracy were < 8%. The LLQ of the sunitinib assay was 0.2 ng/mL. 
Midazolam was measured using a validated liquid chromatographic-tandem mass 
spectrometric (LC-MS/MS) assay. Briefly, 200 µl plasma was extracted by adding 500 µl of 
acetonitril containing midazolam D4 (4µg/L) as the internal standard, followed by vortex 
mixing and centrifugation at 13,000 rpm for 5 minutes at ambient temperature. The 
supernatant was collected and 10 µL was separated on an Atlantis T3 C18 analytical column 
(2.1 x 50 mm, i.d 3 µm) and eluted with the following gradient [flow rate (ml/min)/ time 
(minutes)/ percentage of solvent A (formic acid 0.1% in water)/ percentage of solvent B 
(formic acid 0.1% in acetonitril)]: 0.3/0.5/85/15/, 0.3/1/10/90, 0.3/4.3/10/90, 0.5/0.01/10/90, 
0.5/0.39/85/15, 0.5/3.3/85/15, 0.3/0.05/85/15, 0.3/0.05/85/15. The effluent was monitored with 
a Micromass Quattro LC triple-quadrupole mass-spectrometric detector (Waters, Milford, MA, 
USA) using the electrospray positive ionization mode. The calibration curve of midazolam 
was linear over the range of 1 – 100 ng/mL. The within day and between day precision and 
accuracy were < 5%. The LLQ of the midazolam assay was 0.3 ng/mL.
Pharmacokinetic analysis of midazolam
Midazolam plasma concentrations were analyzed by non-compartimental methods using 
WinNonlin (version 5.2.1) (Pharsight Corporation, Mountain View, CA, USA). The midazolam 
area under the concentration time curve (AUC0-24hr) was calculated and was compared 
between the first and second PK days. Statistical analysis included the two-tailed paired 
Student’s t-test, and P values < 0.05 were considered statistically significant. The statistical 
calculations were performed using SPSS 16.0 (SPSS Inc. headquarters, Chicago, Illinois, USA) 
Pharmacokinetic analysis of sunitinib 
Sunitinib plasma concentrations were evaluated by a population pharmacokinetic method 
using NONMEM (version VI, level 1.0) (Globomax, Hanover, MD, USA). The First-Order 
Conditional Estimation (FOCE) method of NONMEM with interaction (INTER) between the 
interindividual and residual random effects was used.24 Discrimination between hierarchical 
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respectively (P-value = .034). Thereby, midazolam exposure increased with ∼50% in the 
presence of grapefruit juice. These results confirm the inhibitory effect of grapefruit juice on 
intestinal CYP3A4 activity.
Pharmacokinetic analysis of sunitinib
A one-compartment model with linear elimination and first-order absorption adequately 
described the time profile of sunitinib concentrations. The data did not contain sufficient 
information to support a two-compartment model6. Inclusion of an absorption lag time 
significantly improved the base model of sunitinib. Between-subject variabilities of the 
absorption rate and clearance were large (60-70%). The base model of sunitinib is graphically 
presented in Figure 2 (left side). 
In the final model, CYP3A4 activity was depleted by each grapefruit juice consumption 
(9 in total) and the activity was restored with a half life of 23 hours (Fig. 3A).25 Inhibition of 
CYP3A4 activity resulted in an increase in the relative bioavailability of sunitinib (Fig. 3B). 
The individual predicted and measured sunitinib concentrations are depicted for all patients 
(Fig. 3C). Introduction of the grapefruit juice effect on the relative bioavailability of sunitinib 
significantly improved the model (∆OFV = -10.01, P < .05) and resulted in the final model 
(Fig. 2).
The estimated pharmacokinetic parameters in the final model are listed in Table 2. 
The derived parameters are calculated with the estimated pharmacokinetic parameters 
and represent the data when grapefruit juice and sunitinib are used simultaneously. Good-
ness-of-fit plots demonstrated that the final model adequately described the time profile 
of sunitinib concentrations. Case deletion diagnostics demonstrated that the estimated 
grapefruit juice effect was not highly dependent on the data from a single patient (range in 
relative F = 1.05 – 1.14). Moreover, suitability of the final model was confirmed by the results 
from a numerical predictive check.26 Out of 268 observed sunitinib concentrations, 21.6% 
were below the P25-P75 (interquartile) prediction interval, 57.1% were within the interval and 
21.3% was above the P25-P75 prediction interval.
Based on the final model it is determined that simultaneous intake of sunitinib and  grapefruit 
juice results in a decrease of intestinal CYP3A4 activity and a consequent increase of sunitinib 
exposure  of 11% (as a result of the increased relative bioavailability 1.11, 95%CI: 1.042-1.082). 
Since the intestinal CYP3A4 activity is restored with a half-life of 23 hours, the relative 
bio availability of sunitinib is also restored with a half-life of 23 hours. The different time 
interval evaluations resulted in the following estimates: when grapefruit juice is consumed 
7 hours before the sunitinib dose, the exposure is still increased by ∼8.9%, after 24 hours the 
effect is diminished to ∼5.3% and after 72 hours to ∼1.3%. If sunitinib therapy starts one week 
after the last grapefruit juice consumption the effect of grapefruit juice on the exposure to 
sunitinib is negligible (∼0.07%).  
Results
Patients
Eight patients were enrolled into the study. All were evaluable for PK analysis. Patient 
 characteristics are summarized in Table 1. No severe or unexpected side effects were 
observed during the three days of grapefruit juice co-administration or by midazolam 
co-administration on both PK days.
Selection of grapefruit juice
The concentration of BG and DHB was measured in 6 different lots of grapefruit juice. BG and 
DHB concentrations among the lots tested varied with ∼4.5 fold and ∼20 fold, respectively. 
The concentration of BG and DHB in the selected lot of grapefruit juice was 33.1 µmol/L and 
2.7 µmol/L, respectively, corresponding with 2.2 mg/200mL BG and 0.2 mg/200mL DHB. 
Due to the expiration date a second lot of the same brand was selected for the last two 
patients of the study. The concentrations in the second lot selected were 23.5 µmol/L BG 
and 5.7 µmol/L DHB, corresponding with 1.6 mg/200mL BG and 0.4 mg/200mL DHB. The 
concentration of BG in both lots was sufficient to induce a significant drug interaction.15 
Pharmacokinetic analysis of midazolam
Midazolam exposure (AUC0-24hr) increased after prior intake of grapefruit juice. The 
midazolam exposure expressed as AUC0-24hr (± standard error of the mean (SEM)) with 
and without grapefruit juice were 122.1 (± 32.9) ng*hr/mL and 182.0 (± 52.2) ng*hr/mL, 
Table I  Patient characteristics 
Characteristic Value
Number of patients 8
 Sex (female / male)  1/7
 Age, years* 54 (41 - 78)
Baseline serum renal and liver function parameters
 Creatinine, μM* 77 (56 - 122)
 Total bilirubin, μM* 9 (6 - 15)
 ALT, units/L*  39 (18 - 68)
Baseline bone marrow function parameters
 Hb, mM* 8.7 (7 - 9.4)
 WBC, x 109/L* 5.5 (3.5 - 38.2)
 Thrombocytes, x 109/L* 196 (149 - 318) 






















































This study shows that inhibition of the intestinal CYP3A4 activity by grapefruit juice results 
in a significant but not clinically relevant increase in the sunitinib exposure. The drug label 
of sunitinib includes the advice to avoid the consumption of grapefruit juice during sunitinib 
treatment. This warning is based upon an extrapolation of the effect of ketoconazol on sunitinib 
exposure after single dose administration. Our study is the first to directly investigate the effect 
of grapefruit juice on sunitinib exposure in cancer patients under steady-state conditions and 



































































Figure 3 Effect of grapefruit juice on sunitinib pharmacokinetics
A: Depletion of CYP3A4 activity by grapefruit juice consumption. B: Increase in relative bioavailability of sunitinib by 
grapefruit juice consumption. C: Individual predicted (lines) and measured (solid marks) sunitinib concentrations
Table 2  Estimated and derived sunitinib pharmacokinetic parameters in  
the final model  
Estimated Parameters  Estimate Standard Error of  Interindividual Standard Error
   Estimate (RSE%) variability of  IIV (RSE%)
    (IIV)(CV%)
  
Cl/F (L/hr) 50.5 28.5 67.9 42.7
Vd/F (L) 3210 7.8 nd nd
ka (hr-1) 0.468 29.1 63.9 42.9
Relative F  1.11 70 nd nd
Absorption lag time (hr) 0.487 7.3 nd nd
Proportional residual  16.3 22.9 nd nd
error (%) 
Derived Parameters* Sunitinib without  Sunitinib with 
  grapefruit juice  grapefruit juice
   when simultaneously taken
  
AUC0-24hr (ng*hr/mL) 1122  1245
 (277 – 2399)  (308 – 2663)
Cmax (ng/mL) 13.0  14.4
 (10.0 – 14.6)  (11.1 – 16.2)
t1/2 (hr)  53
  (12 – 107)
Tmax (hr)  8.2
  (2.8 – 12.4)
Abbreviations: RSE = relative standard error; Cl/F = apparent clearance; Vd/F = apparent volume of distribution; 
ka = absorption rate constant; F = bioavailability; nd = not determined; AUC0-24hr = area under the plasma 
concentration-time curve over the dose interval 0-24hr at steady-state pharmacokinetics; t1/2 = elimination 
half-life; Tmax = time to reach peak plasma concentration. Between-subject variability was assessed using 
exponential models. 





















































The half-life of sunitinib is long (∼50 hours). Steady-state sunitinib PK is therefore achieved 
within ∼ 8 days. After starting grapefruit juice consumption is takes ∼ 8 days to achieve 
new steady-state sunitinib PK. At the second PK day, after three days co-administration of 
grapefruit juice, a new steady-state was not reached yet. Since a large effect, and thereby 
potential toxicity, was hypothesized it was considered unethical to continue the co-admin-
istration until steady-state sunitinib PK was reached. Due to this study design the effect of 
grapefruit juice on sunitinib pharmacokinetics could only be estimated by a compartmental 
approach. The estimated apparent clearance and volume of distribution are similar to the 
described parameters of an earlier published compartmental approach.6 Conversely, a non-
compartimental approach was used for determining midazolam exposure after a single dose 
of 7.5mg. Since, only an exposure difference in midazolam was required to determine the 
effect of grapefruit juice, which could adequately be determined by a non-compartimental 
approach due to extensive sampling from start until undetectable levels of midazolam were 
measured.  
The lack of a clinically relevant effect of grapefruit juice on sunitinib exposure was not related 
to the batch of grapefruit juice that was used in this study. First, the grapefruit juice selected 
had a sufficient content of BG (2.2mg/ 1.6mg) to induce a significant effect on CYP3A4 
activity.15 Secondly, even after the recovery of a proportion of the intestinal CYP3A4 enzymes 
on the second PK day, a significant effect ∼50% was observed on the phenotypic drug 
midazolam, which is comparable to the effect of grapefruit juice on midazolam exposure 
explored in earlier interaction studies25, 40. No effect of sunitinib on midazolam exposure is 
expected since midazolam exposure is similar to earlier published data40, 42. The increase in 
midazolam exposure due to grapefruit juice co-administration confirms the significant effect 
that grapefruit juice has on intestinal CYP3A4 activity. Hence, the marginal effect observed 
on sunitinib bioavailability is likely to be the result of the limited efficiency of sunitinib 
metabolism by intestinal CYP3A4. The limited effect of grapefruit juice is in contrast with the 
large effect (51% increase) observed after the co-administration of ketoconazol.3 This could 
be the result of a change in enzymes that play a dominant role after prolonged exposure to 
the drug as was seen for imatinib in earlier studies.43 The interaction with ketoconazol was 
studied after a single dose, while the interaction with grapefruit juice was determined at 
steady-state sunitinib exposure. Another explanation could be that ketoconazol is a strong 
intestinal and hepatic CYP3A4 inhibitor while grapefruit juice is only capable of inhibiting 
intestinal CYP3A4. 
In conclusion, grapefruit juice only marginally increases the sunitinib exposure which is not 
regarded clinically relevant. Therefore, the warning in the drug label for the concomitantly 
use of grapefruit juice should be reconsidered.
Moreover, this is the second study investigating an interaction of grapefruit juice with oral 
anticancer therapy and both studies show an irrelevant effect of grapefruit juice which 
contrasts the warning in the drug label21. All eight registered tyrosine kinase inhibitors are 
substrates of CYP3A4 and therefore include the warning for consuming grapefruit juice in 
their drug label. This is the first study that shows a clinically irrelevant effect of grapefruit 
juice on one of the tyrosine kinase inhibitors, sunitinib, which could also be relevant for the 
other TKIs. 
Grapefruit juice is a potent inhibitor of intestinal CYP3A4 with little effect on the activity of 
hepatic CYP3A4. The affinity for only intestinal CYP3A4 was concluded from the significant 
effect grapefruit juice has on the exposure to CYP3A4 substrates (e.g. simvastatin, felodipine, 
triazolam) after oral administration, while the effect was only limited after intravenous admin-
istration of these drugs.15, 27-29 Grapefruit juice is also an inhibitor of the drug transporters 
ABCB1, OATP1A2 and OATP2B1, which could contribute to the effect of grapefruit juice on the 
exposure of co-administered drugs.13, 30-35 
Midazolam is extensively metabolized by CYP3A4 with less affinity for CYP3A5, and is not 
transported by ABCB1, ABCG2 and OATPs36-39.  In previous studies, grapefruit juice showed 
a pronounced effect on the exposure of orally administered midazolam25, 29, 40. In this study, 
midazolam was co-administrated on both PK days as a phenotypic probe to confirm the 
decreased activity of intestinal CYP3A4 by the selected batch of grapefruit juice.
The patients in our study consumed grapefruit juice three times a day for three days (25, 
26, and 27) at steady-state. On the last sunitinib treatment day (day 28) in the six week 
treatment cycle, the sunitinib PK was determined and compared to the data obtained 
without the exposure to grapefruit juice. The effect of grapefruit juice was estimated on 
the relative bioavailability of sunitinib, since grapefruit juice is a potent intestinal CYP3A4 
inhibitor and therefore, only an effect on the sunitinib uptake is expected rather than on 
sunitinib clearance, volume of distribution, absorption rate constant and lag time. Indeed 
the concomitant use of grapefruit juice results in a significant increase of 11% in sunitinib 
exposure. However, since the reported interpatient variability in sunitinib clearance is large 
∼ 40% the effect of grapefruit juice on sunitinib exposure is negligible and should not be 
regarded as clinically relevant.6 Moreover, the marginal 11% increase in sunitinib exposure 
is unlikely to result in a different toxicity profile or treatment efficacy, although data on the 
drug exposure – treatment outcome and toxicity response relation are not available yet. 
Grapefruit juice irreversibly inhibits CYP3A4 and it therefore takes time to restore CYP3A4 
functionality since new enzymes needs to be formed.  The recovery half-life of CYP3A4 
activity after consuming grapefruit juice was set to 23 hours according to the recovery 
study of Greenblatt et al.14 The recovery half-life was confirmed by several interaction studies 
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Context: The effects of mitotane on pharmacokinetics of co-administered drugs are 
unknown. The aim of the present study was to describe the effects of mitotane on the 
 pharmacokinetics of the phenotypic probe midazolam and of sunitinib. 
Patient and Methods: Sunitinib and midazolam pharmacokinetics were evaluated in 
9 patients during sunitinib therapy. Two of these patients had adrenocortical carcinoma 
(ACC) and were treated with mitotane. Serial blood samples for pharmacokinetic analysis 
of midazolam, 1-hydroxy-midazolam and sunitinib were collected at steady-state sunitinib 
 pharmacokinetics (between days 14-20). To assess CYP3A4 activity the patients received 
a single dose of oral midazolam 7.5mg concomitantly with sunitinib at the day of PK 
assessment. 
Results: Both mitotane treated patients showed highly induced CYP3A4 activity reflected by 
decreased midazolam exposure compared to the other 7 patients (mean AUC0-12hr ± SD = 7.8 
± 2.6 µg*hr/L vs. 139.6 ± 59.7 µg*hr/L, resp), increased 1-hydroxy-midazolam exposure (mean 
AUC0-12hr ± SD = 341.8 ± 69.6 µg*hr/L vs. 35.2 ± 11.5 µg*hr/L, resp) and a decreased sunitinib 
exposure (mean AUC0-24hr ± SD= 268 ± 0.3 µg*hr/L vs 1344 ± 358 µg*hr/L, resp).
Conclusions: Mitotane is associated with a strong inducing effect on CYP3A4 activity 
which will result in clinically relevant interactions since many drugs are metabolized by this 
enzyme.
Introduction
Mitotane (o,p’-DDD) is used to treat patients with adrenocortical carcinoma (ACC)1, 2. Careful 
monitoring of serum drug levels is important, because mitotane has a narrow therapeutic 
window, Mitotane levels > 14 mg/L are required for the therapeutic effects, whereas serum 
drug levels >20mg/L correlate with considerable side-effects especially neurologic toxicity3. 
Since mitotane accumulates in adipose tissue, the plasma elimination half-life is extremely 
long (18-159 days). Consequently, it can take months to reach steady-state pharmacokinetics 
and, conversely, it takes also months to observe a decrease in plasma levels after discontinu-
ation of mitotane3. Unfortunately, many patients show progressive disease despite treatment 
with mitotane. Therefore, more effective additional treatment modalities are warranted, 
including polychemotherapy.
Surprisingly, there is hardly any information available on the metabolic pathways of mitotane, 
nor on the potential influence of mitotane on the metabolism of co-administered drugs. 
However, organochlorine insecticides, to which mitotane is chemically closely related, induce 
microsomal liver enzymes4. In accordance, a case report described an interaction between 
mitotane and the anticoagulant warfarin which resulted in increased warfarin requirements, 
suggesting induction of metabolizing enzymes by mitotane5. 
In the present report the pharmacokinetic effects of mitotane on cytochrome P450 (CYP) 
3A4 activity is described using the phenotypic probe midazolam6. Midazolam is extensively 
metabolized by CYP3A4 and to a lesser extent by CYP3A57. It is used as a phenotypic probe 
to determine the activity of CYP3A47 . In addition, we describe the effect of mitotane on the 
exposure to a relatively new oral anticancer drug sunitinib. Sunitinib is also metabolized by 
CYP3A4 to an equally active metabolite SU12662, which is further metabolized to inactive 
moieties by CYP3A48. These studies were performed in 9 patients with different malignan-
cies who participated in a sunitinib pharmacokinetic study designed to determine the rela-
tion between CYP3A4 activity and sunitinib exposure. Two of these patients showed a very 
different pharmacokinetic profile. Both patients were treated with mitotane for ACC.    
Patients and Methods 
Patients
Nine patients were included in the pharmacokinetic study. Two patients (1 male; 46 years old, 
72kg, Eastern Cooperative Oncology Group (ECOG) performance status = 1 and 1 female; 
42 years old, 65kg, ECOG performance status = 1) with metastatic ACC showed progressive 
disease despite mitotane therapy and were treated with sunitinib as an experimental therapy. 









































during mitotane treatment the patient continued this therapy since it was hypothesized that 
some cells might still be sensitive to mitotane. The patient was treated with sunitinib for 
three months (2 treatment cycles of 6 weeks) and stopped since no response to sunitinib was 
observed. In January 2008, the patient volunteered in the pharmacokinetic study.  
Patient 2, a 44 year old woman, was diagnosed in June 2005 with ACC in her right adrenal 
gland with two hepatic metastases with a total tumor radius of ~ 6.3 inches. The adrenal 
gland was extirpated and in addition a segmental resection of the liver was performed. In 
September 2006 there was recurrence of the tumor. Mitotane therapy started in June 2005 
and continued until August 2007. After failed standard systemic anti-tumour therapies she 
started with sunitinib as an experimental therapy in October 2007 and was treated with 
 sunitinib for three months (2 treatment cycles) and stopped since no response to sunitinib 
therapy was observed. In October 2007, the patient volunteered in the pharmacokinetic 
study.  
Pharmacokinetic data
Mitotane has an extremely long elimination half life (18-159 days) and therefore an effect 
of mitotane on co-administered drugs could still be present although mitotane therapy 
stopped several months before (patient 2). Indeed, the mitotane serum concentrations were 
8.1 mg/L in patient 1 and 4.9 mg/L in patient 2. Both mitotane exposed patients showed 
highly induced CYP3A4 activity resulting in decreased sunitinib, and midazolam exposure 
(including increased 1-hydroxy-midazolam exposure) (Fig. 1). 
The two mitotane treated patients showed markedly reduced sunitinib exposure (AUC0-24hr) 
compared to the other 7 patients (mean AUC0-24hr ± SD= 268 ± 0.3 µg*hr/L versus 1344 ± 
358 µg*hr/L, respectively, Fig. 1A) as well as compared to sunitinib exposure levels reported 
in literature (mean AUC0-24hr ± SD  = 965 ± 367 µg*hr/L11 and 1296 ± 358 µg*hr/L12). 
In addition, mitotane treatment was associated with strikingly reduced midazolam exposure 
(AUC0-12hr) compared to the exposure measured in the other patients (mean AUC0-12hr ± 
SD = 7.8 ± 2.6 µg*hr/L versus 139.6 ± 59.7 µg*hr/L, respectively, Fig. 1B). Examples of dose 
normalized (7.5 mg) midazolam exposure levels reported in literature are: (AUC0-12hr ± SD) 
116 ± 57.4 µg*hr/L13 and (AUC0-∞ ± SE) 120.6 ± 15.7 µg*hr/L14. Midazolam is metabolized by 
CYP3A4 into 1-hydroxy-midazolam and to a lesser extent into 4-hydroxy-midazolam. Both 
patients treated with mitotane showed highly elevated 1-hydroxy-midazolam exposure 
levels (AUC0-12hr) compared to the other patients in the sunitinib pharmacokinetic study 
(mean AUC0-12hr ± SD = 341.8 ± 69.6 µg*hr/L versus 35.2 ± 11.5 µg*hr/L, respectively, Fig. 1C), 
indicative of increased CYP3A4 activity.
cell carcinoma, 1 prostate carcinoma, 1 chordoma and 1 osteosarcoma; median (range) age 
= 60 (41 – 77); weight = 82kg (68 – 98); ECOG performance status = 1 (0 – 1)) used sunitinib 
without mitotane therapy. The study was approved by the institutional ethics committee 
(Leiden University Medical Center, The Netherlands), and all patients gave written informed 
consent before entering the study.
Study design
All patients were treated with sunitinib 37.5 – 50 mg once daily in a “four weeks on – two 
weeks off” dosing schedule. Pharmacokinetic assessment of midazolam and sunitinib at 
steady-state was performed between days 14 - 20. A single dose of midazolam 7.5 mg was 
administered concomitantly with the regular dose of sunitinib. Blood samples were collected 
pre-dose, and 0, 10, 20, 40 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hours after midazolam and 
sunitinib administration. 
Measurement
The mitotane concentrations in both patients were measured by gas chromatographic – 
electron capture detection assay9. Sunitinib concentrations were quantified by liquid chro-
matographic tandem mass spectrometric (LC/MS/MS) assay10. Midazolam and 1-hydroxy-
midazolam levels were determined by LC/MS/MS assay.
  
Pharmacokinetic analysis
Sunitinib, midazolam and 1-hydroxy-midazolam plasma exposure was assessed by non-
compartimental methods using WinNonlin (version 5.2.1) (Pharsight Corporation, Mountain 
View, CA, USA). Midazolam and 1-hydroxy-midazolam exposure (AUC0-12hr) was assessed 
over 12 hours since midazolam and 1-hydroxy-midazolam have a short half-life (1.0-3.5 hr 
and 0.8-1.0 hr, respectively), and therefore the elimination was nearly completed at 12 hour 
post-dose. Sunitinib exposure (AUC0-24hr) was assessed over 24 hours. The mitotane concen-
trations of both mitotane users were determined in the pre-dose blood sample.
Results
Clinical characteristics of patients with ACC
Patient 1, a 44 year old man, was diagnosed in March 2007 with ACC in his right adrenal gland 
of 3.5 inches. The primary tumor was extirpated. However, in May 2007 there was local and 
distal recurrence of ACC. Mitotane therapy was started in May 2007. After failed standard 
systemic anti-tumour therapies he started with sunitinib as an experimental therapy in 










































Mitotane treatment was associated with induced metabolism of midazolam as well as of 
sunitinib in these 2 patients. Since midazolam is mainly metabolized by CYP3A4 with little 
affinity for CYP3A5, ABCB1 and ABCG2 our observation supposedly is the result of a strong 
inducing effect of mitotane on CYP3A4 activity7, 15, 16.This observation is clinically relevant, since 
many drugs are metabolized through CYP3A4 e.g. simvastatin, clarithromycin, cyclosporine 
etc17. Consequently, co-administration of mitotane is likely to result in drug-drug interactions, 
as observed with midazolam and sunitinib. This inducing effect of mitotane on CYP3A4 is 
extremely potent even in comparison with the CYP3A4 inducing effects of rifampicin. The 
CYP3A4 inducing effect of mitotane in our study (17.8-fold decrease in midazolam exposure) 
is much stronger than the effect described for rifampicin on midazolam exposure (8.0-fold 
decrease in midazolam exposure)18. 
In conclusion, in this pharmacokinetic study we observed a very strong CYP3A4 inducing 
effect of mitotane which led to a significant drug-drug interaction with sunitinib even after 
2 month of cessation of mitotane therapy. This CYP3A4 inducing effect of mitotane will also 
affect the pharmacokinetics of other drugs which are metabolized by CYP3A4 and can thus 
cause considerable drug-drug interactions. We can not exclude additional effects of mito-
tane on other metabolizing enzymes. Therefore, physicians who treat ACC patients with mi-
totane should be aware of these potential drug interactions which can result in inadvertent 




































































Figure 1  Individual plasma concentrations of  A) sunitinib, B) midazolam and  
C) 1-hydroxy-midazolam.
  The 2 black curves represent the mitotane treated patients, the gray curves 
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Purpose: Furanocoumarins in grapefruit juice are potent cytochrome P450 3A4 (CYP3A4) 
inhibitors, however it appears that this only effects intestinal CYP3A4. The reason for an 
absent effect on hepatic CYP3A4 is yet unknown and we hypothesize that this might be the 
result of limited absorption of these substrates after oral administration.   
Therefore, the absorption of bergamottin (BG) and 6’,7’-dihydroxybergamottin (DHB) was 
studied in healthy volunteers after drinking grapefruit juice. Additionally, the concentration 
of BG and DHB in different brands and lots of grapefruit juice was analyzed.    
Patients and Methods: Six Caucasian healthy volunteers consumed 3 times 400 mL 
(equal to a BG and DHB dose of 3 x 2.45 mg and 3 x 3.22 mg respectively) grapefruit juice at 
t= 0, 3 and 6 hour. The serum concentrations of BG and DHB were determined at t= 1, 7 and 
8 hour using a validated HPLC-UV method.
Results: BG and DHB levels were undetectable in all volunteers both after single and after 
multiple dosing, indicating that these inhibitors can only act via the intestinal and not via the 
hepatic CYP3A4. The variability of BG and DHB concentrations between the different brands 
and lots of grapefruit juice is substantial. However, the variability within one lot is small. 
Conclusion: Since the furanocoumarins BG and DHB are not absorbed after a single or 
multiple consumptions of grapefruit juice, they are intestinal CYP3A4 inhibitors rather than 
hepatic CYP3A4 inhibitors. The large variability in concentration BG and DHB between 
different brands and lots of grapefruit juice necessitates quantification of these ingredients 
for selecting grapefruit juice for interaction studies. 
Introduction
In 1991 the first report was published describing the potential interaction between grapefruit 
juice and felodipine1. Grapefruit juice resulted in an increased felodipine plasma concentration, 
which led to a decrease in blood pressure. In the following years the prominent role of the 
metabolic enzyme cytochrome P450 3A4 (CYP3A4) underlying this drug interaction became 
clear. The effect of grapefruit juice on CYP3A4 appears to be the result of a irreversible 
inactivation of this enzyme2, 3. The pronounced effect of grapefruit juice on the oral availability 
of multiple drugs that are substrates of CYP3A4, has since the first serendipitous observation, 
been described thoroughly in many studies4-10. Additionally, an inhibitory effect of grapefruit 
juice on the ATP binding pocket B1 transporter (P-glycoprotein) and on the organic anion 
transporting polypeptide 1A2 (OATP1A2) and OATP2B1 was postulated8, 11-15. 
In contrast to orally administered drugs, grapefruit juice appears to have only a little effect 
on intravenously administered drugs16-19. Grapefruit juice acts by inhibiting intestinal CYP3A4 
activity during uptake of the drug from the intestinal lumen to the systemic circulation and it 
is thought that hepatic CYP3A4 is largely unaffected, but this has never been studied in detail. 
Possible explanations for this divergent effect of grapefruit juice on intestinal and hepatic 
CYP3A4 could be poor absorption of the CYP3A4 inhibiting ingredients or dilution of these 
substances to concentrations below their effective enzyme inhibitory concentrations20.
Grapefruit juice is a complex and rich mixture of several hundred ingredients. Much effort 
has been invested to identify the chemical substance responsible for the inhibiting effect 
on CYP3A4. The flavonoids; naringin, naringenin, quercetin, kaempferol, and the furano-
coumarins; bergamottin, 6’,7’-dihydroxybergamottin and its dimers bergapten, bergaptol, 
6’,7’-epoxybergamottin have been suggested to contribute to the grapefruit juice – drug 
interactions2, 12, 20, 21. The administration of the purified forms of these different compounds to 
human volunteers, pointed into the direction of the furanocoumarins as being the group of 
substances most responsible for the CYP3A4 inhibiting effect10, 22, 23. The most abundant fura-
nocoumarins present in grapefruit juice are bergamottin (BG) and 6’,7’-dihydroxybergamottin 
(DHB). A complicating factor is that among grapefruit juices brands the concentrations of 
these furanocoumarins exhibit substantial variability, potentially resulting in a more or less 
pronounced effect on CYP3A424. To find an explanation for the pronounced effect of BG and 
DHB on the intestinal but absent effect on the hepatic CYP3A4 enzyme, we investigated 
whether BG and DHB are absorbed after drinking grapefruit juice with a predetermined dose 
of BG and DHB. Additionally, BG and DHB were quantified in different brands and batches of 





































































26 – 40) consumed 3 times 400 mL of a preselected grapefruit juice batch at 0, 3 and 6 hour. 
To determine serum concentrations of BG and DHB, blood samples were collected at 1, 7 
and 8 hour. Blood samples were centrifuged at 4,000 rpm for 5 min and serum was divided 
into two tubes and stored at –20˚C until the day of analysis. The study was approved by the 
institutional ethics committee (Leiden University Medical Center, Leiden, The Netherlands). 
Analysis of bergamottin and 6’, 7’-dihydroxybergamottin in serum
The analytical method used to determine BG and DHB in serum is identical to the method 
used to determine BG and DHB in juice. Sample preparation was moderately adjusted; 0.5mL 
serum, 0.5mL phosphate buffer pH 3.0, 0.5M, 10 µL internal standard (10 µL/mL in methanol) 
and 4mL ethyl acetate were mixed and processed similar to the method described for 
grapefruit juice. Calibration standards contained 0.02 – 0.4 µg/mL BG and 0.01 – 0.2 µg/mL 
DHB were prepared at the start of each analytical run. The standard stock solution contained 
BG and DHB (10 and 5 µg/mL in DMSO:methanol(1:3)). Linearity was confirmed over the range 
of 0.04 – 1.60 µg/mL for BG and 0.02 – 0.80 µg/mL for DHB. The within day and between day 
precision and accuracy were within 15%. Stability was studied over a period of 30 days at 
four conditions; room temperature, refrigerated, frozen and after 3 freeze-thaw cycles and 
accuracy and precision remained within 15%. The LLQ levels for BG and DHB were 0.04 µg/
mL and 0.02 µg/mL, respectively. The LLQ easily met the criteria of accuracy and precision of 
< 20% and the BG and DHB response at the LLQ was at least 5 times the blank response25.  
Results
Bergamottin and 6’,7’-dihydroxybergamottin concentration in grapefruit juice
The BG and DHB concentrations as determined in different brands and lots of grapefruit 
juice are summarized in Table 1 and showed considerable variability. Moreover, the variation 
in BG and DHB concentrations within one lot (analyzed in three packets) was relatively small 
(< 10%). For the performance of the study in healthy volunteers Brand B2 was selected.
Amount of grapefruit juice consumed by healthy volunteers
We aimed to investigate the absorption of a BG dose in the range of at least 1.7-2 mg BG 
from the intestines, which is a dose capable of inducing a significant effect on felodipine 
exposure10. To administer a sufficient amount of BG in our experiment 400mL (= 2.45 mg BG) 
of grapefruit juice was administered. 
Serum bergamottin and 6’, 7’-dihydroxybergamottin concentration
The serum concentrations BG and DHB after a single dose and after multiple doses of 400mL 
grapefruit juice were not detectable (< 0.04 µg/mL BG and <0.02 µg/mL DHB =LLQ).  
Material and methods
BG and DHB in grapefruit juice
Materials
Five different brands and different lots of a single brand of commercially available grapefruit 
juices were obtained from local grocery stores in The Netherlands. BG and DHB were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). The internal standard fenprocoumon was 
kindly supplied by F. Hoffmann-La Roche (Basel, Switzerland).  
Analysis of bergamottin and 6’, 7’-dihydroxybergamottin in grapefruit juice
The concentrations BG and DHB were determined using a validated high pressure liquid 
chromatography – ultraviolet detection (HPLC-UV) method. The used assay is based on a 
previously published method with minor modifications24. Briefly, the juice was homogenized 
by shaking. Grapefruit juice (0.5mL) was mixed with 10 µL internal standard (100 µg/mL, in 
methanol) and 2 mL ethyl acetate. Calibration standards contained 0.2 – 4 µg/mL BG and 
0.1 – 2 µg/mL DHB were prepared at the start of each analytical run. The standard stock 
solution contained BG and DHB (100 and 50 µg/mL in DMSO:methanol(1:3)). The extraction 
was performed by shaking for 30 minutes and separation by centrifugation; 4,000 rpm for 
3 minutes. The organic phase was collected and evaporated (40°C; N2). The residue was 
reconstituted with 100 µL of DMSO/acetonitril solution (1:3 v/v). A volume of 30 µL of each 
sample was applied to a HPLC separation system (Unexas 2104, Knauer, Berlin, Germany). The 
compounds of interest were separated on a Hypersil ODS RP analytical column (4.6 x 100 
mm, i.d 3 µm) and eluted over 22 minutes with a flow rate of 1 mL/min and the following 
gradient [time scale (minutes - minutes)/ percentage of solvent A (water 2500/phosphoric 
acid 1.25)/ percentage of solvent B (acetonitril)]: 0-7/70/30, 7-17 70/30 → 0/100, 17-18/0/100, 
18-19 0/100 → 70/30, 19-22/70/30. The effluent was monitored with a diode array detector 
(Dionex, UVD340U, Germering, Germany). The UV absorption profile was monitored between 
210 – 350 nm. DHB, fenprocoumon and BG eluted at 10.9, 12.8 and 16.5 minutes, respectively. 
Linearity was confirmed over the range of 0.2 – 24 µg/mL for BG and 0.1 – 12 µg/mL for DHB. 
The within day and between day precision and accuracy were within 15%. 
Study in healthy volunteers
Study design
The study was designed to evaluate the absorption of BG and DHB from the gastrointestinal 
tract after consuming volumes of grapefruit juice concordant to the volumes described to 





































































of an irreversible inactivation of the intestinal and not hepatic CYP3A4 enzyme but the 
reason for this divergent effect is yet unclear20. Our study shows for the first time that the 
furanocoumarins BG and DHB are not absorbed after single or multiple consumptions of 
grapefruit juice which could explain their inhibiting effects on CYP3A4 located in the gastro-
intestinal tract but the absent effect on the same enzymes located in the liver. In addition, a 
large variability in furanocoumarin concentrations was observed in different brands and in 
different lots of one brand of grapefruit juice. 
Besides inhibition of intestinal CYP3A4, grapefruit juice also inhibits the transporters ABCB1, 
OATP1A2 and OATP2B1 and this may additionally contribute to the effect that grapefruit 
juice has on the exposure of co-administered drugs8, 11-15, 26. Our results also implicate that 
interaction of BG and DHB with these transporters located outside the intestinal wall, such as 
in the kidney, will be limited16, 17. 
We investigated the absorption of BG and DHB after a single dose but also after multiple 
dosing since one may argue that BG and DHB is only absorbed after saturation of CYP3A4 
e.g. after the first dose. Indeed, one study has reported an effect of grapefruit juice on the 
elimination half life of midazolam and the production of 14CO2 after intravenous erythromycin 
administration and therefore an effect on hepatic CYP3A4 activity after consuming double 
strength grapefruit juice 240 mL tid for three days27. In contrast, an effect of grapefruit juice 
on hepatic CYP3A4 activity studied with other compounds (lovastatin and simvastatin) was 
not observed with similar amounts of double strength grapefruit juice28, 29.  In all three studies 
the concentration of BG and DHB in the juices was not quantified. Contrastingly, in the our 
study for the first time the quantity of BG and DHB administered was measured and related 
to the amount of BG and DHB absorbed. Double quantities of grapefruit juice (400mL) were 
used to simulate the double strength used in the described studies, which is approximately 
double the amount normally used in interaction studies10, 16, 27, 30. Additionally, 1.7mg and 
2mg bergamottin causes a significant drug interaction with felodipine. The 400mL used in 
this study equalizes 2.45mg BG and 3.22mg DHB. Repeated doses were administered with 
short time intervals (3hours) to saturate the intestinal CYP3A4 and prevent the formation 
of new CYP3A4 (CYP3A4 t½ ≅ 7 – 23hours)4, 5. The sampling times, 1 hour after de first dose 
and 1 and 2 hours after the third dose of grapefruit juice, were selected based on the time 
to maximal BG concentration after consumption of BG capsules; ∼1 hour10. However, also 
after multiple dosing non-detectable serum levels of BG and DHB were found. The lower 
limit of quantification of the validated HPLC-UV method was 0.02 µg/mL for BG and 0.04 µg/
mL for DHB, which makes the method suitable for detecting clinically relevant BG and DHB 
concentrations. Indeed, BG and DHB were able to inhibit  CYP3A4 mediated testosterone 
hydroxylation by 50% and 87.5% at 0.17 – 0.04 µg/mL and 0.15 – 0.04 µg/mL in in vitro 
experiments, respectively20. Serum BG and DHB levels below the lower limit of quantitation 
of the assay are therefore very unlikely to result in any clinical effect on hepatic CYP3A4. 
Discussion
In this study the absorption of the two major furanocoumarins in grapefruit juice, capable of 
inhibiting CYP3A4, was investigated in order to clarify their effect on intestinal and hepatic 
CYP3A4 activity. Indeed, the effect of grapefruit juice on CYP3A4 is thought to be the result 
Table 1  BG and DHB concentration in different batches grapefruit juice 
Product Bergamottin (mg/L) 6’,7’-dihydroxybergamottin (mg/L)
Brand A lot 1 11.9 2.0
Brand A lot 2 8.0 2.1
Brand A lot 3 8.4 2.4
Brand B lot 1 10.0 7.5
Brand B lot 2 6.1 8.1
Brand C 2.6 1.0
Brand D 5.5 1.1
Brand E 4.3 0.4
Healthy volunteer 
Standard 4 





































































These results indicate that these grapefruit juice compounds are not or only in a very limited 
amount absorbed after oral consumption and therefore only result in a local effect on the 
transporters and enzymes in the intestinal wall. 
Our study confirms earlier findings regarding high variability of furanocoumarins concen-
trations in different brands and lots of grapefruit juices24. The concentrations BG and DHB 
measured in grapefruit juices are in the same range as earlier reported. The variability was 
postulated to be the result of the kind of grapefruit used (white, pink or red) and the storage 
conditions of the juices24. 
 The variable concentrations in the different juices have important implications both clinically 
and experimentally. Drug-interactions with grapefruit juice could be strongly influenced by 
the juice that is used since higher concentrations of BG and DHB would logically result in a 
more pronounced inhibition of intestinal CYP3A4. Therefore, in pharmacological interaction 
studies a standardized quantity of BG and DHB should be administered in order to 
interpret the results and make the comparison with other studies possible. An international 
standardized quantity of 2mg BG could be used since this amount has demonstrated to 
result in a significant drug interaction in humans10. DHB has always demonstrated to exhibit 
a greater potency as BG in vitro, however the magnitude of the difference varied from ∼2 
- >20-fold20. An international standardized quantity of 1mg DHB could therefore be safely 
suggested for interaction studies.
In the current study we have focused on the most abundant furanocoumarins, BG and DHB 
and therefore we can not totally exclude an effect of other active compounds in grapefruit 
juice on hepatic CYP3A4 activity. However, interaction studies with the purified form of the 
different compounds of grapefruit juice make the furanocoumarins the group that most 
likely results in an inhibitory effect of CYP3A410, 22, 23. Theoretically, by the design of our study 
we can not exclude the absorption of BG and DHB across the intestinal wall followed by an 
extremely high extraction ratio for these components, which could result in undetectable 
levels of BG and DHB in serum due to a complete first pass effect. However this theoretical 
large effect of BG and DHB on hepatic enzymes has not been confirmed in interaction 
studies so far. 
In conclusion, BG and DHB are not absorbed in clinically relevant amounts after oral 
administration of grapefruit juice. This explains why grapefruit juice has an effect on orally 
administered CYP3A4 substrates whereas it has no effect on CYP3A4 substrates when 
administered intravenously. The observation that the contents of BG and DHB are highly 
variable among different brands and lots of grapefruit juices has important consequences 
for both the interpretation of clinical grapefruit juice – drug interactions and the design of 
interaction studies. 
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Tyrosine kinases regulate cellular proliferation, survival, differentiation, function, and motility1. 
In the 1980s the first aberrant protein (BCR-ABL) leading to uncontrolled tyrosine kinase 
activity was discovered2. This fusion protein was the product of the minute chromosome, 
later known as the Philadelphia chromosome, discovered in chronic myelogenous leukemia 
(CML) by Nowell and Hungerford in 19603. Since the discovery of BCR-ABL, several tyrosine 
kinases have been associated with development of cancer. For example, human epithelial 
growth factor (HER2) is expressed in ∼25% of all breast cancers4, BCR-ABL is expressed in ∼90% 
of Philadelphia chromosome positive CML5 and cKIT is expressed in ∼85% of gastrointestinal 
stromal tumors (GIST)6. The tyrosine kinases are deregulated as a result of protein fusion, 
mutations or increased/aberrant expression of a receptor tyrosine kinase, its ligand, or both1. 
Because tyrosine kinases appear to be important in cancer biology they were interesting 
proteins for targeted anticancer therapy. Since 2001, eight tyrosine kinase inhibitors (TKIs) are 
approved for the treatment of specific malignancies. In this thesis the clinical pharmacology 
of two TKIs, imatinib and sunitinib, were studied and described. Imatinib is the first licensed 
TKI and is approved for the treatment of Philadelphia chromosome positive (Ph+) CML and 
for cKIT positive unresectable and/or metastatic malignant GIST7-9. The second drug studied, 
sunitinib, is approved for the treatment of  GISTs after failure of imatinib therapy as well as for 
the treatment of advanced and/or metastatic renal cell carcinoma (mRCC)10-12. 
Pharmacokinetic aspects 
TKIs appear to have very similar pharmacokinetic profiles (chapter 2). However many 
 pharmacokinetic aspects remain to be studied because most of these drugs received 
accelerated approval before completing all intended studies, since they are used for serious 
life-threatening diseases with poor treatment options available. For example, imatinib 
was introduced onto the marked for CML after one phase I and three phase II trials7, 13-16. 
The applicant committed e.g. to provide complete follow-up safety and efficacy, to 
conduct a dose finding study in children, to study imatinib pharmacokinetics in patients 
with liver impairment and to study the influence of cytochrome P450 (CYP) 3A4 inducers on 
imatinib exposure after drug approval17, 18. Sunitinib was also approved under accelerated 
approval regulations for the treatment of mRCC with the commitment to provide additional 
information on e.g. the efficacy and safety after complete follow-up, provide additional 
information on the adverse effect ‘left-ventricular ejection fraction’, provide an analysis on 































Interpatient variability in drug exposure
The interpatient variability in drug exposure is large, ∼40% for both imatinib and sunitinib, 
similar to the reported variability of all TKIs18, 26-29. The study of van Glabbeke et al. demonstrated 
that imatinib related toxicities are highly dose dependent and thus associated with imatinib 
exposure30. On the other hand, lower trough levels of imatinib appeared to be associated with 
a decreased efficacy to imatinib therapy31, 32.  Although little data is available on the relation 
between sunitinib exposure and toxicity or efficacy, a similar relationship is hypothesized. 
Sunitinib dose escalation results in a proportional increase in sunitinib trough levels. 
At increasing dose levels more dose limiting toxicities were observed33. An association 
between sunitinib trough levels and treatment response has not been published yet. The large 
interpatient variability can result in either unintended toxicity response as well as in decreased 
therapeutic response. Hence identification of factors affecting the pharmacokinetic profile of 
TKIs could aid in predicting and adjusting the individual doses to prevent toxic response or 
therapeutic failure22. In the population pharmacokinetic approach of Widmer et al. multiple 
variables that might explain for the large interpatient variability of imatinib such as age, body 
weight, gender, disease and α-1 acid glycoprotein were explored. Only α-1 acid glycoprotein 
explained a substantial part of the interpatient pharmacokinetic variability28. For sunitinib, only 
recently, a study has been described in which variables were explored that could explain for 
the large interpatient variability in pharmacokinetics. Body weight, gender, race, elevated ECOG 
performance status, and tumor type explained a substantial part of the interpatient variability 
in the apparent clearance; body weight and gender explained a part of the interpatient 
variability in the volume of distribution. However, the major part of the interpatient variability 
in sunitinib pharmacokinetics remains unexplained34. Besides the patient characteristics and 
the physiological parameters, also the activity of both the enzymes and transporters might be 
of great influence on the large interpatient variability. Both imatinib and sunitinib are substrates 
of ABCB1 and ABCG219, 21. The genes encoding these transporters are highly polymorphic which 
could significantly influence drug absorption35. Additionally, functional polymorphisms in 
enzymes can decrease or increase the metabolic capacity. Genotyping as well as phenotyping 
of enzymes and transporters might help us to explain a large part of the interpatient variability. 
Several studies have investigated the effect of transporter polymorphisms on imatinib 
exposure. ABCB1 1236T>A, ABCB1 2677T>A and ABCG2 421C>A polymorphisms appear to effect 
imatinib trough levels36-38. Similarly the CYP2D6*4 polymorphism results in an increase in 
imatinib exposure22. For sunitinib no studies are available associating genetic polymorphisms 
in transporters or enzymes and drug exposure. However, an effect of polymorphisms in 
enzymes and transporters is hypothesized since sunitinib is also a substrate for CYP3A4, ABCB1 
and ABCG2 and exploring such associations seems interesting to investigate. In chapter 7 
the relation between sunitinib-induced toxicity and polymorphisms in genes encoding 
of sunitinib in liver impaired patientsi. After drug approval, case reports and investigator 
driven interactions and drug disposition studies are published that provide additional 
insight in involvement of enzymes and drug transporters important in drug disposition. For 
instance the influence of the adenosine-5’-triphosphate (ATP) binding-cassette (ABC) drug 
transporters B1 and G2 on imatinib and sunitinib disposition was discovered after approval of 
the drug by independent researchers19-21. The clinical relevance of the affinity and inhibition 
capacity of sunitinib and imatinib for these transporters needs to be further addressed in 
additional research. 
The clinical relevance of the principal metabolic pathways is typically investigated in healthy 
volunteers after a single dose of the drug of interest in pharmacological studies before 
drug approval. However, the clinical relevance of these apparently important enzymes at 
steady-state pharmacokinetics is usually unknown. In chapter 3 an absent effect of ritonavir, 
a potent CYP3A4 inhibitor, was observed on steady-state imatinib pharmacokinetics while 
CYP3A4 is claimed to be the dominant metabolic route of imatinib. For imatinib some extra 
studies have been dedicated to the effect of the  less dominant enzymes22-24. CYP1A2 is one of 
these minor enzymes in imatinib metabolism. However an absent effect of CYP1A2 induction, 
by cigarette smoking, on imatinib pharmacokinetics was observed in the study described in 
chapter 4. Still many metabolic pathways in imatinib metabolism need to be explored and 
additional research is required to better define important enzymes at steady-state imatinib 
pharmacokinetics in cancer patients. Additionally, the uptake of imatinib from the rectum 
was measured and described in chapter 5. It appears that imatinib is moderately absorbed 
from the rectum and this route of administration could be considered when oral intake is 
impossible. 
Only little information on the metabolism of sunitinib is available25, 26. Since the TKIs appear to 
have a very similar pharmacokinetics profile many pathways known for other TKIs could be 
of interest for sunitinib. Additionally, the effect of sunitinib on drug disposition of co-admin-
istered drugs has not been investigated in cancer patients at steady-state pharmacokinetics. 
Therefore, the effect of sunitinib on midazolam exposure and the effect of grapefruit juice on 
sunitinib exposure have been studied at steady-state sunitinib pharmacokinetics in cancer 
patients. Sunitinib appears to have an inducing effect on CYP3A4 activity (chapter 6) which 
needs confirmation. Coincidently, a very potent inducing effect on CYP3A4 by mitotane was 
observed, resulting in decreased sunitinib and midazolam exposure (chapter 9). Grapefruit 
juice increases the relative bioavailability of sunitinib to a clinically non-relevant extent 
(chapter 8), and therefore no scientific evidence was found for the warning in the sunitinib 
label regarding grapefruit juice consumption. 
































Besides the specific tyrosine kinase related resistance, it is thought that exposure levels (phar-
macokinetics) also may play a role in the initial or secondary resistance. Recently, a correlation 
was observed between clinical effect in CML (defined as major molecular response and 
complete cytogenetic response) and a minimal trough level of imatinib, indicating that 
inadequate drug exposure levels could also result in initial or secondary imatinib resistance31. 
A minimal exposure to imatinib and sunitinib is also suggested for the effective treatment 
of GIST and mRCC, although studies supporting this hypothesis have not been performed 
yet.  Several possible mechanisms have been described resulting in an inadequate drug 
exposure; i) increased levels of the acute phase binding protein (α acid glycoprotein (AAG)) 
resulting in a reduced free fraction of the drug28, 44, ii) increased functionality of the highly 
polymorphic efflux transporters ABCB1 and ABCG221, 35-37, iii) upregulated drug clearance by 
increased activity of metabolizing enzymes22, 40. Additionally, the exposure to the drug can 
decrease over time due to increased drug clearance27.  
Future research perspectives
In the recent years important progress has been made in unraveling the pathophysiology of 
cancer. With this gaining insight, targeted therapies, that can specifically inhibit deregulated 
cellular processes important for maintenance of the malignancies, have been and are being 
developed. Ultimately, this may lead to an approach of cancer as being a chronic disease 
instead of a life threatening disease. A major challenge to address in the treatment of chronic 
cancerous disease is how to circumvent antitumor drug resistance. 
With the better characterization of tumor biology and the somatic mutations resulting in 
tumor progression, the disease could be treated on a more individualized and targeted basis. 
For example, GIST tumors harboring specific mutations in the cKIT receptor that respond 
better to either imatinib or sunitinib might better be treated based upon somatic tumor char-
acteristics rather that the first line, “one size fits all” approach. Drug development of anticancer 
drugs for tumor subtypes harboring specific somatic mutations rather than for anatomic or 
histological tumor subtypes may lead to more effective therapies and less tumor resistance. 
However, this approach may be in conflict with the study design of pharmaceutical industry 
at this moment in which antitumor drugs are developed for large groups of patients and it 
is therefore questionable whether we can expect this somatic mutation driven approach 
from industry studies. For GIST tumors the role of cKIT mutations for imatinib and sunitinib 
sensitivity are thoroughly investigated and better understood. However, for mRCC and many 
other tumors these investigations for tumor subtype specific drug sensitivity should be 
performed in the nearby future.
Additionally, genotypic features in drug targets, enzymes and transporters might predispose 
metabolizing enzymes, drug transporters, targets are described. Polymorphisms in the genes 
CYP1A1, ABCB1, ABCG2, NR1I3, VEGFR-2 and FLT3 appear to be associated with the development of 
sunitinib-induced toxicity. Both imatinib and sunitinib are extensively metabolized by CYP3A418, 
26. CYP3A4 is also highly polymorphic; however clinically significant polymorphisms are very 
uncommon and therefore only a limited role for CYP3A4 pharmacogenetics is predicted39. 
A CYP3A4 phenotypic approach to predict the systemic exposure to imatinib and sunitinib 
might instead very well explain the large interpatient variability in pharmacokinetics40. 
In chapter 6 the relation between CYP3A4 activity, determined by midazolam exposure, and 
sunitinib were investigated and a good relation between the activity of CYP3A4 and sunitinib 
exposure as well as with sunitinib trough levels was found.
Mechanisms of resistance
Resistance to imatinib and sunitinib therapy can be subdivided into two separate mechanisms: 
tyrosine kinase reactivation in the presence of a TKI by for example gene amplification or 
point mutations or the development of resistance which is independent of the tyrosine 
kinase activity41. 
Point mutations in the tyrosine kinase are the most common reason for the development of 
TKI resistance. Indeed, for imatinib resistance, various secondary mutations in BCR-ABL have 
been characterized. Mutations in the adenosine triphosphate (ATP) binding loop (P-loop) of 
BCR-ABL are frequently observed and associated with a poor response42.  Most GISTs harbor 
(primary) mutant c-KIT (∼80%) or platelet-derived growth factor receptor α (∼5-7%). ∼14% 
of the GISTs exhibit primary resistance to imatinib, additionally another 40-50% develop 
resistance within 2 years of therapy43. GIST responsiveness to imatinib varies for the different 
primary c-KIT genotype; exon 11- mutant GISTs are more sensitive than exon 9-mutant or 
wild-type GISTs. In contrast, progression free and overall survival on sunitinib therapy were 
significantly longer for primary c-KIT exon 9 mutations and the wild type genotype compared 
to exon 11 mutations. Secondary point mutations are common in GISTs that show secondary 
resistance but not in those that exhibit primary resistance. Secondary point mutations are 
usually located in the drug/ATP binding pocket of the receptor (exon 13 and 14) or in the 
activation loop (exon 17). In patients that exhibit resistance to imatinib because of secondary 
point mutations the progression free and overall survival for sunitinib were longer for patients 
who had secondary c-KIT exon 13 or 14 mutations than those with secondary c-KIT exon 17 
or 18 mutations. Secondary mutations in the activation loop (exon 17 and 18) are insensitive 
to imatinib and sunitinib therapy43. Associations between primary and secondary mutations 
in tyrosine kinases, important in renal cell carcinoma, and response to sunitinib therapy have 































drug concentrations and disease response during phase II and III trials could help us in indi-
vidualizing treatment aimed at preventing therapeutic failure and toxicities. The TKIs are 
generally administered in a daily regimen and thereby suppress tumor growth continuously. 
Interesting parallels between the therapy with TKIs and antiretroviral therapy (used in HIV 
infections) which also encounters resistance can be drawn. The interindividual variability is 
large for all TKIs and determinants for this large variability are at least partly unknown. The 
“fixed dose for all tumors approach” that is applied will not result in the aimed exposure level 
or the aimed trough level in all patients due to the large interpatient variability. Therefore 
therapeutic drug monitoring (TDM) could become important in the treatment of cancer 
for this group of drugs. Initially, it needs to be established which PK parameter associates 
best with therapeutic response. Limiting sampling makes TDM more feasible. Therefore 
after establishing the most suitable PK parameter effort should be invested in determining 
the minimal amount of samples needed to obtain the parameter. For sunitinib for example 
we have investigated that trough levels correspond well with exposure levels, which makes 
trough level monitoring suitable for both concentration threshold as well as exposure 
determination. The monitoring just after starting therapy is required to adjust the dose 
until the aimed drug concentration is reached. However, since the drug concentration can 
decrease over time, repeatedly monitoring would be required. For most TKIs the correct 
PK parameter that relates to therapeutic response needs to be identified and additionally a 
limiting sampling approach needs to be defined.  
Although a promising group of new drugs have been discovered and are used in the 
treatment of malignancies still great profit can be achieved by a better understanding of 
important pharmacogenetic and pharmacokinetic features of these drugs which could 
result in a more individualized approach with less toxicity and more efficacy. 
for development of side effects to antitumor therapy. The drug targets are not solely 
expressed on tumor tissues but also on “healthy” cells responsible for physiological processes 
in our body. Affinity differences, due to genetic alteration, of the drug for the targets could 
result in a more or less pronounced effect on normal cells and thereby results in toxicity. 
By better characterization of factors that result in toxicity, therapies can be selected that 
have a favorable toxicity profile which will result in a better adherence to and acceptance 
of the therapy and less required dose adjustments. Dose adjustments due to toxicity could 
be harmful since subtherapeutic exposure levels for an adequate antitumor response might 
be generated. Also polymorphisms in genes encoding enzymes and transporters important 
for drug metabolism and disposition can lead to toxicity or inefficacy as a result of higher or 
lower exposure levels. 
Enzymes and transporters claimed to be important at time of drug approval are typically 
identified in in vitro studies and confirmed in single dose interaction studies in healthy 
volunteers. The warnings for co-administered drugs and food in the drug label are based 
upon extrapolations from these single dose interactions studies. Since TKIs are administered 
on a daily basis and some appear to be substrates as well as inhibitors of their own metabolic 
and disposition pathway, the enzymes and transporters that are important at steady-state 
pharmacokinetics in cancer patients could be very different from those identified just 
after starting therapy as we have demonstrated in several studies described in this thesis. 
Therefore, pharmacological studies at steady-state pharmacokinetics using phenotypic 
probes should be done to identify the enzymes and transporters that are important in drug 
metabolism and disposition. This will result in better scientifically based warnings in the drug 
label for drugs and food that should not be co-administered. This may ultimately result in 
more reliable medication surveillance by physicians and pharmacists resulting in less sub- 
and supratherapeutic exposure levels in patients treated with these drugs. 
For all TKIs, except for imatinib in CML treatment, minimal exposure levels or minimal trough 
levels required for a therapeutic response are unknown. A complicating factor is that different 
tumors (depending on different TKs) and tumor subtypes (with different somatic mutations) 
will require different concentration levels due to sensitivity differences. Inadequate drug 
concentrations could result in either tumor progression or drug related toxicities. I would like 
to hypothesize that subtherapeutic concentrations results in the selection of less sensitive 
cells which, by generating secondary mutations, results in drug resistance. Based on data 
from dose limiting toxicity studies (phase I trails), initially a fixed dose is used for the treatment 
with TKIs, regardless of the sensitivity of the tumor or the individual drug concentration. Only 
during phase I studies pharmacokinetics data are collected while the therapeutic response 
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Every year approximately 3.2 million Europeans are diagnosed with cancer and with ∼1.7 
million deaths from cancer per year it is the second most common cause of deathi. In the 
Netherlands approximately 83 thousand persons are diagnosed with cancer each year and 
the mortality incidence is around 40 thousand persons a yearii. Although, multiple anticancer 
therapies have been developed in the recent years, the quest for novel therapies which 
harbors better efficacy and less toxicity is still an important topic.
In the 1980s a group of possibly interesting proteins, tyrosine kinases, in cancer biology were 
discovered. Tyrosine kinases (TKs) are enzymes that catalyze the transfer of phosphate from 
adenosine triphosphate (ATP) to other cellular proteins and thereby regulate several crucial 
processes regarding survival, proliferation and motility of cells. The activity of TKs is normally 
under tight control. However, in multiple cancers TKs appear to be deregulated which make 
them interesting targets for anticancer therapy. In 2001 the first tyrosine kinase inhibitor (TKI), 
imatinib, was registered for the treatment of BCR-Abl positive chronic myelogenous leukemia 
(CML). Since the introduction of imatinib, seven other TKIs have been registered and more 
TKIs will be introduced in the near future. Although these TKIs were initially introduced 
as the “magic bullets” that would be highly tumor-cell specific and thus highly antitumor 
effective with only minor toxicity towards normal cells, limitations were soon encountered. 
The development of resistance and the occasionally observed toxicities constitute the major 
challenge in the treatment with TKIs.
A better understanding of the pharmacokinetics of TKIs might help us to prevent sub- 
or supratherapeutic exposure to these drugs. Additionally, a better understanding of 
polymorphisms in the pharmacokinetic and pharmacodynamics pathways of the TKIs might 
also help us to prevent toxicities and to optimize tumor response by individualizing the dose 
and choice of antitumor therapy. This thesis focuses on the pharmacokinetics of imatinib and 
sunitinib in cancer patients and on the use of different tools, phenotyping and pharmacog-
enotyping, to optimize and individualize TKI therapy.  
TKIs represent a relatively new and fast growing group of anticancer drugs developed as oral 
formulations which are administered in cancer patients in a daily regimen. Most of the current 
knowledge of the pharmacokinetic behavior of the TKIs is derived from in vitro experiments, 
animal studies, drug-drug interaction studies and mass balance studies in healthy volunteers 
with a single dose of the aimed TKI. However, since this group of drugs is administered 
in a daily schedule, other enzymes and drug transporters might become important at 
steady-state pharmacokinetics, which could result in adjusted warnings for co-administered 









exposure after rectal administration appeared to be approximately 40% of the exposure 
reached after oral administration. Therefore, rectal administration could be considered in 
situations were oral intake of the tablets is impossible. 
Clinical pharmacology of sunitinib
Sunitinib is a multitargeted tyrosine kinase inhibitor, known to inhibit vascular endothelial 
growth factor receptors (VEGFRs) 1, 2, and 3, platelet-derived growth factor receptor (PDGFR) 
α and β, KIT, Fms-like tyrosine kinase 3 receptor (FLT3), and the receptor encoded by the ret 
proto-oncogene (RET). The drug is approved for the first line treatment of metastatic renal 
cell carcinoma (mRCC) and imatinib resistant metastatic GIST. The toxicity profile of sunitinib 
is pronounced and includes e.g.: fatigue, mucosal inflammation, cardiotoxicity and myelo-
suppression. Approximately 30% of the patients treated with sunitinib need a dose reduction 
or interruption due to adverse events making toxicity a limiting factor in the successful 
treatment with this drug. In the following chapters several approaches have been explored 
with the aim to individualize sunitinib therapy and thereby reduce toxicity. Additionally, the 
effect of CYP3A4 inhibition on sunitinib exposure as well as the effect of sunitinib on CYP3A4 
activity is studied in drug-interaction studies.  
In chapter 6 the possible use of the noninvasive CYP3A4 phenotypic probe, midazolam, to 
predict sunitinib exposure was explored. Additionally the relation between sunitinib plasma 
trough levels and sunitinib exposure was determined since monitoring sunitinib trough 
levels provide a more feasible and assessable approach to study exposure-effect and -toxicity 
relations. Moreover, the effect of sunitinib on CYP3A4 activity was evaluated.  Since sunitinib 
is solely metabolized by CYP3A4, the activity of CYP3A4 might explain the large and yet 
unexplained interpatient variability (∼40%) in sunitinib clearance. The activity of CYP3A4 can 
be determined by the phenotypic probe midazolam which is also mainly metabolized by 
CYP3A4 without exerting influence on the activity of this enzyme. It appears that midazolam 
exposure relates well to sunitinib exposure as well as sunitinib trough levels and explains 
a large part of the interpatient variability in sunitinib clearance. Also a strong relation was 
found between sunitinib trough levels and sunitinib exposure which legitimates the use of 
sunitinib trough levels instead of the multiple sampling approaches to determine exposure-
effect and –toxicity relationships. Additionally, sunitinib appears to be a mild CYP3A4 inducer 
however this observation needs confirmation. 
Both genes encoding the sunitinib targets (VEGFR1, -2 and -3, PDGFR-α and PDGFR-β, KIT, 
FLT3, and RET), as well as genes encoding the enzymes and efflux transporters involved in 
sunitinib’s disposition and metabolism are highly polymorphic and may be related to the 
differential toxicity response in patients treated with sunitinib. The identification of genetic 
pharmacokinetic aspects; absorption, distribution, metabolism, excretion (ADME), drug 
transporters and drug-drug interactions of the eight registered TKIs: imatinib, gefitinib, 
erlotinib, sorafenib, sunitinib, dasatinib, lapatinib and nilotinib. Additionally, the similarities 
and differences between these apparently related TKIs are summarized.
Clinical pharmacology of imatinib
Imatinib is predominantly metabolized by the enzyme cytochrome P450 3A4 (CYP3A4) 
and is therefore prone to drug interactions with co-administered drugs, food, and herbal 
supplements. The warnings for CYP3A4 inducers or inhibitors are based on drug interaction 
studies with a single-dose of imatinib.  However, it is unknown if similar drug interactions 
occur at steady-state imatinib pharmacokinetics.  Therefore, the effect of ritonavir, a potent 
CYP3A4 inhibitor, on steady-state imatinib in cancer patients was investigated (chapter 
3).  Surprisingly, imatinib appears to be insensitive to potent CYP3A4 inhibition by ritonavir 
at steady-state. Since imatinib is a CYP3A4 inhibitor itself it is hypothesized that the drug 
relies on alternate elimination pathways after prolonged exposure due to autoinhibition of 
CYP3A4. For drugs with complex elimination pathways, such as imatinib, interaction studies 
that are performed after a single dose may not provide us with correct information applicable 
for clinical practice. Therefore, it is preferred to perform interaction studies at steady state 
 pharmacokinetics which better represents the clinical situation since other enzymes, that 
only play a secondary role in in vitro experiments, could play a dominant role at steady-
state. 
Possible interesting cytochrome enzymes for imatinib metabolism are: CYP1A1, CYP1A2, 
CYP2C9, CYP2C19, and CYP2D6. CYP1A2 is induced by cigarette smoking and therefore 
smokers might be exposed to lower blood concentrations of imatinib than non smokers. 
In chapter 4 the effect of smoking on imatinib pharmacokinetics, safety, and efficacy 
was investigated. The results of this study did not reveal a dominant role for CYP1A2 in 
imatinib metabolism since smoking did not alter the pharmacokinetics and thereby the 
exposure to imatinib. Interestingly, smoking was related to an increased risk for grade ≥ 2 
anemia and fatigue and additionally showed a shorter overall survival and a shorter time 
to progression on treatment with imatinib. However, these last two observations warrants 
further confirmation. 
Coincidently, one of the patients who volunteered in the imatinib pharmacokinetic study 
was admitted to the hospital a year later with tumor-related intra-abdominal obstructions 
and diffuse intra-abdominal bleedings. Due to gastro-intestinal obstruction the patient was 
unable to take the imatinib tablets orally; therefore the tablets were administered rectally. 







different brands and lots of grapefruit juice necessitates quantification of these ingredients in 
order to make the interpretation of the results and comparison between different interaction 
studies possible. 
In the final chapter the results of this thesis are discussed and possible future directions 
are outlined. Future developed antitumor treatments will more specifically interact with the 
underlying mechanism responsible for deregulation of cellular growth control in tumor cells. 
With a better understanding of tumor biology, a more individualized approach will probably 
be reached resulting in the application of targeted drugs developed to inhibit specific tumor 
subtypes. Individualization will also result in the selection of the right individual patients that 
profit most an endurable toxicity profile.  Additionally, monitoring the exposure to the drugs 
and adjusting the individual dose based on the exposure level measured will contribute 
to the optimization of antitumor response and limitation of drug related toxicities. Much 
effort will be needed to determine the exposure-effect and exposure-toxicity relation for 
the different tumor subtypes and patients. The use of predictive biomarkers and therapeutic 




markers related to toxicity outcomes in the pharmacokinetic and pharmacodynamic pathways 
of sunitinib are described in chapter 7. The selected toxicity outcomes;  thrombocytopenia, 
leucopenia, mucosal inflammation, hand-foot syndrome and any toxicity > grade 2, were 
based on the results of a published placebo controlled study. We selected toxicities that 
appear to be causally related to sunitinib treatment. Thrombocytopenia was not associated 
with any of the genetic polymorphisms studied. Polymorphisms in FLT3, NR1I3 and CYP1A1 
were related to leucopenia. The same polymorphism in CYP1A1 was related to mucosal 
inflammation. Hand-foot syndrome appeared to be related to a polymorphism in ABCB1. 
Finally any toxicity > grade 2 was associated with polymorphisms in VEGFR2 and ABCG2. 
The polymorphisms identified in this study should be regarded as hypothesis generating 
and need to be confirmed in an independent group of patients. 
Since CYP3A4 appears to be the most important enzyme in the metabolism of sunitinib the 
drug label warns for multiple drugs and food substrates known to interfere with the activity 
of this enzyme. However, most of these warnings are not based on study results but rather 
are extrapolations of the observed interaction with model drugs such as rifampicin (CYP3A4 
inducer) and ketoconazol (CYP3A4 inhibitor). Grapefruit juice is a potent CYP3A4 inhibitor 
of the enzymes located in the intestines. The effect of grapefruit juice on the bioavailability 
of sunitinib has not been studied yet. Nevertheless, the drug label of sunitinib advises 
patients to avoid the consumption of this juice. In chapter 8 the effect of grapefruit juice 
on steady-state sunitinib exposure was evaluated. The co-administration of grapefruit juice 
with sunitinib resulted in an 11% elevation of sunitinib bioavailability which is not regarded 
as clinically relevant.
Two patients in the sunitinib pharmacokinetic study described in chapter 8 showed aberrant 
pharmacokinetics of sunitinib and midazolam, the latter being used as a CYP3A4 phenotypic 
probe (chapter 9). Both patients were also treated with mitotane which appeared to be a 
very potent CYP3A4 inhibitor.
As described before, grapefruit juice is a potent inhibitor of intestinal CYP3A4 enzymes. 
However it has no effect on the same CYP3A4 enzymes located in the liver. An explanation 
for this unexpected effect is not found yet. A possible explanation could be that the active 
ingredients in grapefruit juice are not absorbed across the intestinal wall. 
Chapter 10 describes the absorption of two active ingredients in grapefruit juice in 
healthy volunteers after consuming large quantities of the juice: bergamottin (BG) and 
 6’,7’-dihydroxybergamottin (DHB), which are held responsible for CYP3A4 inhibition. 
Additionally the amount of BG and DHB in different brands and lots of grapefruit juice was 
quantified. The two ingredients, BG and DHB, were undetectable both after single and 
multiple consumptions of grapefruit juice. Therefore, the lack of substantial absorption of BG 
and DHB probably explains why grapefruit juice has an inhibitory effect on intestinal CYP3A4 
























Kanker is een veelvoorkomende aandoening en vormt de op één na meest voorkomende 
doodsoorzaak in Europa evenals in Nederland. Ongeveer de helft van de patiënten met kanker 
overlijdt en medicamenteuze behandelingen zijn, uitzonderingen daargelaten, over het 
algemeen maar beperkt effectief en weinig specifiek. De vraag naar betere therapeutische 
mogelijkheden die gerichter de tumorcellen bestrijden en minder schadelijke effecten op 
gezond weefsel laten zien is daarom van groot belang. In de tachtiger jaren werd een groep 
eiwitten ontdekt, tyrosine kinasen, die mogelijk een cruciale rol vervullen in het ontstaan van 
kanker. Tyrosine kinasen (TKs) zijn enzymen die middels fosfaatoverdracht op andere eiwitten 
binnen de cel verschillende cruciale processen activeren en coördineren, waaronder de 
overleving en deling van cellen. De activiteit van deze TKs is normaliter streng gereguleerd. 
Echter bij verschillende vormen van kanker is vastgesteld dat de nauwe regulatie van deze TKs 
niet meer goed functioneert. Hiermee werden ze een geschikt aangrijpingspunt voor nieuw 
te ontwikkelen antikanker therapie. In 2001 werd de eerste TK remmer, imatinib, op de genees-
middelenmarkt toegelaten. Het geneesmiddel werd geregistreerd voor twee types kanker die 
sterk afhankelijk bleken te zijn van een ontregelde TK activiteit. Na de toelating van imatinib 
zijn nog zeven andere TK remmers toegelaten voor verschillende tumoren. 
Deze nieuwe groep TK remmers werden initieel gezien als het universele antwoord op de 
behandeling van kanker. Echter de beperkingen van deze geneesmiddelen zijn inmiddels 
ook duidelijk. Resistentie tegen TK remmers vormt een groot probleem en ook bijwerkingen 
(toxiciteit) blijken een grote belemmering in de behandeling te vormen. Een beter begrip 
over hoe het menselijke lichaam omgaat met deze TK remmers, de farmacokinetiek van deze 
geneesmiddelen, kan ons helpen bij het goed doseren van de TK remmers bij patiënten 
die behandeld worden met deze geneesmiddelen. Hiermee kan een te hoge blootstelling 
(geneesmiddelspiegel) worden voorkomen, waardoor het risico op toxiciteit afneemt alsmede 
een te lage blootstelling waardoor het geneesmiddel niet effectief is. Aanvullend kunnen 
genetische veranderingen (o.a. polymorfismen), die coderen voor de enzymen, de genees-
middelen pompen (transporters) en de TKs voor een afwijkende reactie van de patient en of 
tumor op het geneesmiddel zorgen. Een beter inzicht op de invloed van deze polymorfismen 
kan dus ook resulteren in een betere individuele afstemming van de therapie. Het doel van het 
in dit proefschrift beschreven onderzoek was meer kennis te vergaren over de farmacokine-
tiek van imatinib en sunitinib in patiënten met kanker. Ook zijn verschillende mogelijkheden 
onderzocht om de therapie beter op de individuele patiënt af te stemmen en daarmee over- 
en onderdoseringen te voorkomen. 
TK remmers vormen een relatieve nieuwe en snel groeiende groep geneesmiddelen. 
Het zijn geneesmiddelen die dagelijks, oraal moeten worden ingenomen in tegenstelling tot 
de meeste tot dusver gebruikte antikanker therapieën die vooral intraveneus worden gegeven. 
















tumorgroei. Deze patiënte kon niets oraal innemen, waardoor besloten werd imatinib 
tabletten rectaal te geven. Resultaten van dit n = 1 onderzoek zijn beschreven in 
hoofdstuk 5. De opname van imatinib uit het rectum resulteert in ongeveer 40% 
blootstelling van de blootstelling waargenomen na orale inname. Rectale toediening kan 
daarom overwogen worden in noodsituaties waarbij uiteraard gecorrigeerd moet worden 
voor de gereduceerde opname. 
Klinische farmacologie van sunitinib 
Sunitinib is een TK remmer die meerdere TKs remt. Sunitinib vertoont een uitgesproken 
toxiciteitprofiel. Bijwerkingen die veelvuldig gerapporteerd worden zijn o.a.: vermoeidheid, 
slijmvliesontstekingen, cardiale afwijkingen en beenmergonderdrukking. Ongeveer 30% van 
de mensen die behandeld worden met sunitinib heeft een dosisreductie of –onderbreking 
nodig ten gevolge van bijwerkingen op het geneesmiddel. In dit proefschrift zijn meerdere 
benaderingen bekeken met tot doel de sunitinib bijwerkingen te verminderen. Tevens is 
gekeken naar de farmacokinetiek van sunitinib na chronische blootstelling in patiënten met 
kanker. 
In hoofdstuk 6 is een onderzoek beschreven dat de relatie bestudeert tussen CYP3A4 
activiteit en sunitinib blootstelling. Tevens is gekeken naar de relatie tussen de sunitinib 
dalspiegels en de totale blootstelling aan sunitinib. Aanvullend is de invloed van sunitinib 
op de CYP3A4 activiteit bestudeerd. Sunitinib wordt voor zover bekend alleen via CYP3A4 
omgezet. De variatie in sunitinib blootstelling tussen patiënten is groot ∼40%. Het is goed 
voorstelbaar dat de activiteit van CYP3A4 sterk bepalend is voor de sunitinib blootstelling en 
een groot deel van de variatie tussen de patiënten verklaart. Het geneesmiddel midazolam 
wordt vaak gebruikt om de activiteit van CYP3A4 te bepalen omdat midazolam alleen via 
CYP3A4 gemetaboliseerd wordt en zelf geen invloed heeft op de activiteit van dit enzym. 
Uit ons onderzoek blijkt dat de midazolam blootstelling goed is gerelateerd aan de sunitinib 
blootstelling en aan de sunitinib dalspiegels. Midazolam blootstelling lijkt hiermee een groot 
gedeelte van de variatie tussen de patiënten te kunnen verklaren. Sunitinib dalspiegel en 
sunitinib blootstelling zijn sterk gecorreleerd waardoor in vervolgonderzoek de sunitinib 
dalspiegel in plaats van de vele male intensievere volledige sutent blootstellingbepaling kan 
worden gebruikt om de relatie tussen sunitinib blootstelling met effectiviteit en toxiciteit 
vast te stellen en eventueel dosisaanpassingen te doen. Sunitinib lijkt een stimulerend effect 
te hebben op de CYP3A4 activiteit deze bevinding moet echter bevestigd worden in een 
grotere groep patiënten. 
De relatie tussen sunitinib toxiciteit en genetische veranderingen (polymorfismen) die 
coderen voor zowel enzymen, geneesmiddel pompen als de aangrijpingspunten voor 
(regeerbuis / celonderzoek) experimenten, dierexperimenteel onder zoek, genees middel inter-
actiestudies en blootstellingstudies in gezonde vrijwilligers na de inname van een eenmalige 
dosis van het beoogde geneesmiddel. Echter de farmaco kinetiek van een geneesmiddel kan 
behoorlijk veranderen als het dagelijks wordt ingenomen (continue blootstelling) en het zijn 
eigen chemische omzetting (metabolisme) mogelijk remt of stimuleert. In hoofdstuk 2 wordt 
een overzicht gegeven wat tot dusver bekend is over de farmacokinetiek; opname, verdeling, 
metabolisme en uitscheiding alsmede het transport en de geneesmiddelinteracties van de 
acht tot dusver geregistreerde TK remmers: imatinib, gefitinib, erlotinib, sorafenib, sunitinib, 
dasatinib, lapatinib en nilotinib. Tevens wordt ingegaan op overeenkomsten en verschillen 
tussen deze geneesmiddelen die allen tot dezelfde familie behoren. 
Klinische farmacologie van imatinib
Imatinib wordt vooral gemetaboliseerd door een enzym genaamd cytochroom P450 3A4 
(CYP3A4). Dit enzym is betrokken bij het metabolisme van veel geneesmiddelen en wordt 
tevens door veel geneesmiddelen geremd of gestimuleerd (geinduceerd). Imatinib is daarom 
gevoelig voor geneesmiddelinteracties. De bijsluiter van imatinib waarschuwt dan ook voor 
het gebruik van remmers of inductoren (stimulatoren) van dit enzym aangezien dat de 
imatinib blootstelling kan beïnvloeden. In hoofdstuk 3 hebben we onderzocht of bij continue 
blootstelling aan imatinib remming van CYP3A4 invloed heeft op deze blootstelling. Hiertoe is 
ritonavir, een krachtige CYP3A4 remmer, toegevoegd aan de behandeling met imatinib, nadat 
imatinib al geruime tijd gebruikt werd. Imatinib bleek in dit onderzoek ongevoelig voor de 
gelijktijdige toediening van een krachtige remmer van CYP3A4. Imatinib blijkt zelf ook in staat 
CYP3A4 te remmen. Het is daarom mogelijk dat imatinib na langere blootstelling zijn eigen 
metabolisme via CYP3A4 remt en omgezet wordt door enzymen die aanvankelijk minder 
belangrijk leken in in vitro experimenten. Enzymen die in staat zijn imatinib te metaboliseren 
zijn: CYP1A1, CYP1A2, CYP2C9, CYP2C19 en CYP2D6. In een volgend onderzoek, beschreven in 
hoofdstuk 4, is gekeken naar de invloed van CYP1A2 stimulatie op de imatinib blootstelling. 
Het is bekend dat het roken van sigaretten het enzym CYP1A2 stimuleert. Als CYP1A2 een 
belangrijk enzym vormt in de omzetting van imatinib zou roken resulteren in een lagere 
imatinib blootstelling vergeleken met niet-rokers. Dit effect hebben we echter niet kunnen 
waarnemen. Rokers kregen wel vaker anemie (bloedarmoede) en waren vaker vermoeid dan 
niet rokers. Tevens lieten rokers een kortere overleving en een kortere tijd tot tumorgroei op 
imatinib therapie zien. Deze laatste bevindingen moeten beschouwd worden als hypothese 
genererend en dienen bevestigd en verklaard te worden in aanvullend onderzoek. 
Ongeveer een jaar na deelname aan het imatinib farmacokinetiek onderzoek, beschreven 
















De overeenkomst tussen de patiënten bleek het gebruik aan mitotaan te zijn. Mitotaan is 
een geneesmiddel wat als sinds 1959 gebruikt wordt bij de behandeling van bijnierschors-
carcinoom. Er is echter vrijwel niets bekend over de omzetting van mitotaan en over het 
effect wat mitotaan heeft op de activiteit van verschillende enzymen en daarmee op de 
blootstelling van andere geneesmiddelen. Mitotaan blijkt zich te gedragen als een krachtige 
CYP3A4 inductor wat veel consequenties heeft voor geneesmiddelen die naast mitotaan 
worden gebruikt (hoofdstuk 9). 
In hoofdstuk 10 wordt de absorptie van bergamottin (BG) en 6’,7’-dihydroxybergamottin 
(DHB) bestudeerd in gezonde vrijwilligers. BG en DHB worden gezien als de verbindingen in 
grapefruitsap die verantwoordelijk zijn voor het remmen van het CYP3A4 enzym in de darm. 
Ook is onderzocht of in verschillende merken en in de verschillende charges van hetzelfde 
merk grapefruitsap de concentraties BG en DHB veel uiteen lopen. Beide verbindingen 
konden na ruime consumptie van het sap niet worden teruggevonden in het bloed van 
de vrijwilligers. Een beperkte absorptie van BG en DHB door de darm is daarom mogelijk 
de verklaring voor het krachtige effect van grapefruitsap op de darmenzymen maar niet 
op de enzymen in de lever. Bovendien blijkt de concentratie BG en DHB erg te variëren 
tussen de verschillende merken en charges grapefruitsap. Dit maakt het noodzakelijk om de 
hoeveelheid BG en DHB voor interactieonderzoeken te standaardiseren zodat vergelijking 
tussen en interpretatie van de resultaten van de studies met grapefruitsap mogelijk wordt. 
In het laatste hoofdstuk worden de resultaten van het uitgevoerde farmacologische 
onderzoek naar imatinib en sunitinib in perspectief geplaatst. Ook worden toekomstige 
ideeën belicht die voorvloeien uit het bescheven onderzoek. 
Waarschijnlijk zullen tumoren door een beter inzicht in de mechanismen die ten grondslag 
liggen aan het ontstaan ervan anders behandeld gaan worden. Het uitgangspunt van de 
behandeling zal dan niet zozeer gestuurd worden door het orgaan waarin de tumor zich 
ontwikkeld maar meer door het eiwit / de eiwitten die voor de ontregelde groei van cellen 
zorgen. Hierdoor wordt de keuze voor behandeling meer per individu dan per patiënten 
groep bepaald waarbij de therapie wordt afgestemd op het type ontregeling, de gevoeligheid 
en het genetisch profiel van de tumor. Daarnaast zal ook gestreefd worden naar de meest 
ideale blootstelling aan het geneesmiddel waarbij effectiviteit zonder onnodige toxiciteit 
wordt bereikt. Met de introductie van deze nieuwe groep geneesmiddelen die door 
continue blootstelling de groei van de tumor onderdrukken zal in de komende jaren veel tijd 
besteed gaan worden aan het vaststellen van de relatie tussen geneesmiddelblootstelling 
- tumoreffect en –bijwerkingen. De rol van ‘therapeutic drug monitoring’ zal hiermee een 
belangrijke positie gaan innemen bij de behandeling van tumoren zoals dat nu al het geval 
is voor menig ander ziektebeeld. 
sunitinib is beschreven in hoofdstuk 7. Trombocytopenie (bloedplaatjes tekort), leukopenie 
(witte bloedcellen tekort), slijmvliesontsteking, hand-voet syndroom (rode en pijnlijke 
handen en voeten) en matig ernstige bijwerkingen in het algemeen (toxiciteit > graad 2) 
zijn als eindpunten genomen. Deze bijwerkingen zijn geselecteerd op basis van een studie 
waarin de toxiciteit in een placebo groep vergeleken werd met de toxiciteit in een sunitinib 
behandelde groep. Als de bijwerking veel voorkwam in de sunitinib behandelde groep en 
niet in de placebo groep dan werd een causaal verband verondersteld tussen het sunitinib 
gebruik en het optreden van de bijwerking. Aanvullend hebben we een selectie gemaakt op 
basis van objectiviteit en klinische relevantie. Trombocytopenie bleek niet gerelateerd aan 
een polymorfisme. Leukopenie kon geassocieerd worden met een polymorfisme in FLT3, 
NR1I3 en CYP1A1. Hetzelfde polymorfisme in CYP1A1 was gerelateerd aan het optreden van 
slijmvliesontstekingen. Hand-voet syndroom bleek gerelateerd aan ABCB1 polymorfismen 
en toxiciteit > graad 2 bleek geassocieerd met een polymorfisme in ABCG2. De functiona-
liteit van enkele polymorfismen die gevonden zijn zouden de bijwerkingen goed kunnen 
verklaren. Van enkele andere polymorfismen is de functionaliteit nog niet opgehelderd. Deze 
studie moet gezien worden als een exploratief onderzoek waarin gezocht is naar genetische 
veranderingen die mogelijk gerelateerd zijn aan bijwerkingen. De relatie tussen de genen 
die wij gevonden hebben en de bijwerkingen die optreden moet in een onafhankelijk 
onderzoek bevestigd worden. 
CYP3A4 speelt bij de omzetting van sunitinib een cruciale rol. Ook in de bijsluiter van 
sunitinib wordt gewaarschuwd voor de combinatie van sunitinib met sterke remmers en 
inductoren van CYP3A4. De geneesmiddelen waarvoor gewaarschuwd worden zijn niet 
allemaal in combinatie met sunitinib onderzocht. Er zijn parallellen getrokken tussen het 
onderzoek wat is uitgevoerd met een model remmer (ketoconazol) en inductor (rifampicine) 
van CYP3A4 en andere geneesmiddelen waarbij een vergelijkbaar effect bekend is. Zo is ook 
grapefruitsap opgenomen in de lijst met middelen die niet gecombineerd mogen worden 
met sunitinib. Grapefruitsap is een krachtige remmer van de CYP3A4 enzymen die in de 
darm aanwezig zijn. Het heeft echter geen invloed op de CYP3A4 enzymen in de lever. 
Voor sunitinib is het niet bekend hoeveel procent van de dosis van het geneesmiddel in de 
bloedcirculatie wordt opgenomen (wat de biologische beschikbaarheid is). De invloed van 
de CYP3A4 activiteit in de darm op de sunitinib blootstelling is hierom lastig te voorspellen. 
In hoofdstuk 8 is een onderzoek beschreven waarin de invloed van grapefruitsap op de 
sunitinib blootstelling wordt onderzocht. Gelijktijdige consumptie van grapefruitsap met 
sunitinib inname resulteert in een 10% hogere sunitinib blootstelling wat niet als klinisch 
relevant wordt beschouwd aangezien de variatie tussen patiënten in sunitinib blootstelling 
al ∼40% is. 
Het viel op dat twee patiënten die behandeld werden met sunitinib een erg afwijkende 
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